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Life is short,
The art long,
Opportunity fleeting,
Experiment treacherous,
Judgment difficult.
- Hippocrates
Aphorisms, sec. I, I
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BRIEF ABSTRACT
Aryl hydrocarbon receptor (ARR) expression and activity was characterized in
the teleost hepatoma cell line, PLHC-l. This work was carried out in order to gain
insights into mechanisms of halogenated aromatic hydrocarbon (HAR) toxicity. The
results improve our ability to characterize the risks posed by HAR exposure as well as
further demonstrate the application of cultured cells to questions of ARR function.
Cell proliferation, the cell cycle, and DNA sequences for an ARR2 and ~-actin
were all characterized in PLHC-l. Serum withdrawal of early-passage cells reduced AHR
expression and consequently TCDD-induced induction of cytochrome P450lA (CYFIA),
which is mediated by the ARR.
Serum in cell culture medium was found to reduce bioavailability of ARR
agonists and significantly alter relative potencies ofCYPIA induction, raising the
possibility of artificial differences in measured potencies among cell types and
laboratories. A quantitative pharmacological approach was used to show that both ARR
binding affinity and intrinsic efficacy ofligands contribute to observed CYFIA induction
potencies. These data also demonstrate the existence of "spare receptors" in this system.
Non-additive effects oflow-efficacy ligands call into question the utility of the "toxic
equivalency factor" approach currently used for HAR risk assessment.
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COMPLETE ABSTRACT
The teleost hepatoma cell line, PLHC-I, was further characterized and used to
explore mechanisms of toxicity ofhalogenated aromatic hydrocarbons (HAH) and
function of the aryl hydrocarbon receptor (AHR). This work proceeded along two
principle avenues: I) investigation of interactions among AHR signaling and pathways
involved in cell cycle and cell proliferation, and 2) determination of factors contributing
to measured response potencies of AHR ligands. These two lines converged to allow use
of a quantitative stimulus-response model to correlate a decline in AHR expression with
changes in response.
The doubling time, lengths of cell cycle stages, and ability of several cell cycle
inhibitors to synchronize populations were determined. The prototypical AHR agonist
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) was found to inhibit PLHC-I proliferation
in a time- and dose-dependent manner in one sub-clone, but not in several others,
suggesting heterogeneity exists within the cell line. Identification of partial sequences for
an AHR2 and ~-actin were obtained and used to measure AHR mRNA expression. Use
of this technique and ligand binding assays demonstrated no change in AHR mRNA or
protein levels throughout the cell cycle.
The effect of serum in cell culture medium on the bioavailability of AHR agonists
was determined in PLHC-I cells. The EC50 for AHR-mediated induction of cytochrome
P450lA (CYP1A) activity by TCDD was increased 20-fold when 10% calf serum was
present in the medium as compared to treatment in serum-free medium. The apparent
difference in potencies was a result of decreased bioavailability in the presence of serum,
effectively reducing the concentration ofTCDD within the cells. Induction ofCYP1A
protein and activity in response to treatment with each ofthree coplanar polychlorinated
biphenyls (PCB congeners 77, 126, and 169) was similarly affected by serum. Relative
potencies (calculated as EC50TCDD I EC50pCB) for CYP1A activity induction by the three
PCBs were significantly higher in the absence of serum.
In order to build quantitative stimulus-response model for the AHR, binding
affinities and CYPIA induction potencies were measured in PLHC-I cells for ten
halogenated aromatic hydrocarbons (HAH). From these data, an operational model of
AHR action was used to determine intrinsic efficacies of these ligands. TCDD,2,3,7,8-
tetrachlorodibenzofuran (TCDF), and non-ortho-substituted PCB congeners 77,81, 126
and 169 behaved as full agonists and displayed high intrinsic efficacy. In contrast, the
mono- and di-ortho substituted PCBs bound to the AHR but displayed lower or no
intrinsic efficacy. PCB 156 was a full agonist, but with an intrinsic efficacy 10- to 50-
fold lower than non-ortho-substituted PCBs. PCB 118 was a very weak partial agonist.
PCBs 105 and 128 were shown to be competitive antagonists in this system. In co-
treatments, both PCB 156 (a low intrinsic-efficacy agonist) and PCB 128 (a competitive
antagonist) inhibited the induction ofCYP1A by TCDD. The stimulus-response model
also demonstrates the existence of"spare" receptors in this system. These data show that
the insensitivity ofPLHC-1 cells to ortho-substituted PCBs is due to both reduced
affinity and reduced intrinsic efficacy as compared to non-ortho-subsituted PCBs.
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The ability of changes in serum used in cell culture medium to alter expression of
the AHR and subsequent induction ofCYPlA in PLHC-l teleost hepatoma cells was
tested. Growth in serum-free medium for two days led to a loss of CYPIA inducibility
by TCDD. In contrast, growth in medium with 10% delipidated calf serum increased the
inducibility of both CYPIA protein and enzymatic activity, relative to controls grown
with 10% complete calf serum. Measurement of induction of CYPIA in cells grown in
serum-free medium for 1 and 2 days demonstrated a progressive loss of inducibility.
This loss of response was correlated to a time-dependent loss of AHR protein, as
measured by specific binding of 3H-TCDD. Using an operational model for AHR action
in PLHC-l, the measured reduction in AHR could be shown to account for the changes in
induction ofCYPlA. Expression of AHRprotein was unaffected by growth in 10%
delipidated serum. These phenotypes were found in only a limited subset ofPLHC-l,
and only in early-passage cells. Comparison of early- and late-passage cells revealed a 2-
fold greater rate of proliferation in the latter, suggesting a growth advantage is coincident
with loss of controls on expression of AHR. These results provide a quantitative link
between changes in receptor expression and a downstream response, pointing the way for
future studies of effects on sensitivity to toxic responses in vitro and in vivo.
Taken together, this work further establishes the PLHC-l cell line as a piscine
model of AHR research. Fundamental molecular processes of AHR function have been
explored using models ofreceptor pharmacology. The knowledge gained from these
models has been applied not only to specific questions ofHAH toxicity in fish, but also
to general studies ofHAH risk assessment across the vertebrate subphylum. Extension
and continued use of this approach will strengthen the connections among our
understanding of AHR activity and HAH toxicity from the level of the molecule to the
environment.
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Understanding mechanisms and risks of halogenated aromatic hydrocarbon
(HAH) toxicity is a continuing goal for human and environmental health. Study of
various model organisms and cell systems has proven fruitful in moving toward that goal.
The aryl hydrocarbon receptor (Ab receptor, AHR) has been identified as a cellular factor
governing the action of many of these compounds, and provides an essential link in the
pathway from exposure to response. Quantitative models of AHR action are being
developed to provide guidance in HAH risk assessment. Despite these successes, there
are substantial deficiencies in our understanding ofthe mechanisms of toxicity and the
predictive power of our models.
BACKGROUND
HAH Toxicity
Halogenated aromatic hydrocarbons are persistent environmental contaminants.
This class of chemicals includes polychlorinated biphenyls (PCBs), halogenated
dibenzodioxins, and halogenated dibenzofurans (Figure 1). These compounds have
mostly anthropogenic origins and enter the aquatic environment through wastewater and
runoff from terrestrial sources. They are toxic to several groups of organisms, including
mammals (reviewed in Vanden Heuvel and Lucier 1993), fish (Peaka1l1975), and marine
invertebrates (Wassermann et al. 1979). In addition, they are very hydrophobic and
accumulate in sediments (Kalmaz and Kalmaz 1979) as well as lipid-rich animal tissues
(Ernst et al. 1976).
The hydrophobicity ofHAH makes trophic transfer the most common method of
uptake, although water- and airborne exposure take place (WHO 1976). Partitioning of
HAH to lipid-rich tissues leads to slow excretion and bioaccumulation, and
biomagnification through successive trophic levels results. High level consumers, such
as fish and marine mammals, can carry burdens of these compounds that greatly exceed
their concentration in the environment (Wassermann et al. 1979). In addition, slow
excretion can lead to toxic effects after the original source of exposure has been removed.
19
3,3',4,4'-tetrachlorobiphenyl (PCB 77)
PCB
3 2 ortho meta
4\ ) < )para
5 6
CI
CI CI
CI
Chlorinated
Dibenzo-p-dioxin
ClyY0TlYCI
CI~O~CI
2,3,7,8-tetrachlorodibenzo-p-dioxin
Chlorinated
Dibenzofuran
CI
CI
CI
CI
2,3,7,8-tetrachlorodibenzofuran
Figure 1. Representative HAH structures.
Toxicity ofHAH has been characterized best with PCBs and 2,3,7,8-
tetrachlorodibenzo~p-dioxin (TCDD). Toxic effects include mortality, liver enlargement
and damage, reduced weight gain, carcinogenesis, teratogenesis, and immunosuppression
(Wassermann et al. 1979; Poland and Knutson 1982). In mammals, TCDD has also been
implicated in chloracne, gastric and urinary tract lesions, and lymphoid involution
(Poland et al. 1982). Both lethal and sublethal toxic effects ofHAH have been noted in
aquatic and marine organisms including phytoplankton, zooplankton, fish, and marine
mammals (Wassermann et al. 1979). Reduced growth rate, vascular defects, thymic
involution, fin necrosis, and damage to liver parenchymal cells are among the sublethal
effects noted following exposure of fish to TCDD (Spitsbergen et al. 1988).
Several sub-lethal responses to HAH have been characterized as potential
biomarkers of sensitivity, exposure and effect (Huggett 1992). Induction of cytochrome
P450 lA (CYPIA) isoforms is commonly used due to its sensitivity, ease of
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measurement by enzyme activity or immunoassay, and well-established link to the AHR,
which mediates RAH toxicity (see below). CYPIA induction is also important
toxicologically, because it metabolizes many AHR ligands, and in the process can create
toxic products, such as reactive polynuclear aromatic hydrocarbon (PAH) metabolites
(reviewed in Schenkman and Greim 1992) or reactive oxygen (Schlezinger et al. 1999).
Due to the number and severity ofRAH toxic effects, elucidating their
mechanism(s) of toxicity is a priority for toxicologists. Furthermore, the health risk to
humans and wildlife associated with exposure to these compounds has made them the
target of governmental regulatory measures designed to limit production at the sources
and remediate contamination at the most polluted sites. Several methods for determining
maximum safe levels of exposure have been proposed and implemented (reviewed in
Kociba 1991), leading to an increased need for a thorough, quantitative understanding of
the fundamental mechanisms to choose among these competing methods.
The most striking example of a quantitative difference in RAH toxicity is in the
wide range of potencies for the different compounds (Safe 1990), known as structure-
activity relationships (SAR). Lethal potencies in a single species can range over 5 orders
of magnitude, from !lg/kg doses of TCDD killing half a test population (LD50) to >10
mg/kg LD50s for some ortho-substituted PCBs (van den Berg et al. 1998). PCBs with
two ortho substitutions generally are not toxic. The relative toxic potencies for
compounds used in this work are shown in Table l.
The knowledge that these compounds have a shared mechanism oftoxicity
involving a receptor protein has led to the proposal that the toxicity of complex mixtures
can be considered as a whole, rather than for each compound individually. This has been
labeled the toxic, or TCDD, equivalency factor (TEF) concept (Safe 1987). Originally
proposed as a quantitative method to relate in vitro bioassay data to expected in vivo
effects, the practice has grown to incorporate methods for correlating concentrations of
individual compounds with the toxic potential of the entire mixture. The toxic equivalent
of a mixture is determined by multiplying the concentration of each compound by its
toxicity relative to TCDD (i.e. the values in Table 1), and then summing these individual
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equivalents to find the potential toxicity of the mixture. This approach assumes that the
toxicity of individual compounds is additive, which is not always true (see below).
Table I reveals another feature of the relationship between compound structure
and potency: ortho-substituted PCBs are less toxic than non-ortho substituted PCBs in
fish, and are less potent than in mammals. This is a phenomenon that was first described
by studying CYPIA induction in vivo (Gooch et al. 1989) and subsequently confirmed by
embryotoxicity and in vitro bioassay experiments (Walker and Peterson 1991; Zabel et al.
1995; Hahn and Chandran 1996a; Clemons et al. 1998). The underlying mechanism for
this difference in potencies is unclear.
Studies ofHAH toxic potency have also sought to explain observed differences
among species and strains. For example, there is a >2500-fold difference between the
LD50s for TCDD in the highly-sensitive guinea pig and the comparatively insensitive
hamster (Kociba and Schwetz 1982), and a 5-fold difference in LD50 between the "Ah-
responsive" C57BL/6 and "Ah-non-responsive" DBN2 strains of mice (poland et al.
1982). Furthermore, potencies for sub-lethal effects are typically greater than acute
lethality, but the magnitude of this difference varies among species and endpoints
(reviewed in Hahn 1998b). Such differences must be explained before inter-species
extrapolation ofpotencies can be accurately performed.
The desire to promote risk-assessment, regulation, remediation, and prevention
based on a detailed understanding of the mechanism of action has been a driving force in
the study ofHAH toxicity and, consequently Ah receptor signal transduction, since its
inception.
AhReceptor
Experiments led by Nebert (Neber! et al. 1972) and Poland (1974) in the early
1970s revealed differences in CYPIA-catalyzed aryl hydrocarbon hydroxylase (AHH)
inducibility by PAHs and TCDD between two strains of inbred mice. Work in these
laboratories and others over the next decade revealed that this difference was due to a
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Table 1. Names and relative toxic potencies of selected HAH (relative potencies
following van den Berg et al. 1998).
Relative toxic potency
Short name Full name Mammals Fish
TCDD 2,3,7,8-tetrachlorodibenzo-p-dioxin 1 1
TCDF 2,3,7,8-tetrachlorodibenzofuran 0.1 0.05
Non-ortho PCBs
PCB 77 3,3' ,4,4' -tetrachlorobiphenyl 0.0001 0.0001
PCB 81 3,4,4' ,5- tetrachlorobiphenyl 0.0001 0.0005
PCB 126 3,3' ,4,4' ,5-pentach10robiphenyl 0.1 0.005
PCB 169 3,3' ,4,4',5,5' -hexach10robiphenyl 0.01 0.00005
Mono-ortho PCBs
PCB 105 2,3,3' ,4,4' - pentachlorobipheny1 0.0001 <0.000005
PCB 118 2,3' ,4,4' ,5- pentachlorobiphenyl 0.0001 <0.000005
PCB 156 2,3,3' ,4,4' ,5- hexachlorobiphenyl 0.0005 <0.000005
Di-ortho PCB
PCB 128 2,2' ,3,3' ,4,4' - hexachlorobiphenyl 0 0
single autosomal dominant gene (Nebert et al. 1972), and Poland (1975) postulated the
existence of an "induction receptor".
Synthesis of a high-affinity radioligand allowed for biochemical characterization
of a cytoso1ic receptor responsible for PAH and HAH binding, and this receptor was later
linked to the genetic studies (Poland et al. 1976; Okey et al. 1979). The gene locus was
named ah (later changed to AHR) for aryl hydrocarbon, and the receptor came to be
called the aryl hydrocarbon receptor (Ah receptor or AHR). The binding affinities of
several compounds to the AHR matched their relative potencies in eliciting toxicity,
suggesting that their primary mechanism oftoxicity involves this receptor (reviewed in
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Huff et al. 1994). More recently, it has been shown that AHR-deficient mice are resistant
to TCDD toxicity (Fernandez-Salguero et al. 1996).
Purification of the receptor (Bradfield et al. 1991) led to N-tenninal amino acid
sequence, which was used to clone the corresponding eDNA from mice (Burbach et al.
1992; Ema et al. 1992). Work with cell lines deficient in AHH inducibility had led to the
cloning of another protein required for AHR function, the Ah receptor nuclear
translocator (ARNT), the year before (Hoffman et al. 1991). These events have led to a
rapid increase in our understanding of AHR signal transduction, confinning and
extending earlier work (Hankinson 1993).
Signaling Pathway
The AHR exists in the cytoplasm complexed with two 90 kD heat shock proteins
(HSP90; Perdew 1988) and an immunophilin-like protein (Carver and Bradfield 1997;
Ma and Whitlock 1997; Meyer et al. 1998). Ah receptor ligands are hydrophobic and
diffuse through the cell membrane. Equilibrium dissociation constants (KD) for purified
receptor and its high-affinity ligands are on the picomolar order ofmagnitude, but
impurities in preparation usually lead to measured KD in the nanomolar range (Bradfield
and Poland 1988b). HSP90 is necessary for ligand binding (Whitelaw et al. 1995), and
the protein complex translocates to the nucleus and dissociates after ligand has been
bound (Figure 2). The process ofligand binding, translocation, complex dissociation,
and ARNT dimerization often is referred to as transfonnation.
Following nuclear translocation, the AHR dimerizes with ARNT (Hoffman et al.
1991; Figure 3). Despite its name, ARNT does not appear to be necessary for nuclear
translocation, as ligand-induced nuclear translocation still takes place in ARNT deficient
mouse cell lines (Pollenz et al. 1994). However, ARNT does appear to facilitate for
dissociation ofHSP90 (McGuire et al. 1994). In addition, ARNT is a dimerization
partner for other PAS proteins (see below), and competition for ARNT may limit AHR
activity (Gradin et al. 1996; Chan et al. 1999) and contribute to HAH toxicity.
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Figure 2. The Ah receptor signaling pathway. Numbered events are: 1) entry of ligand
into the cell, 2) binding of ligand to the receptor, 3) transformation of the receptor to an
active form and nuclear translocation, 4) dimerization with ARNT and binding to XREs,
5) recruitment of transcriptional cofactors and stimulation of gene transcription, and 6)
translation of the protein.
The AHR-ARNT dimer binds to DNA sequences called xeniobiotic, dioxin, or
AHR responsive elements (here referred to as XREs; Jones et al. 1986; Denison et al.
1988). The consensus sequence for these sites is 5'TNGCGTG3' (Dolwick et al. 1993;
Lusska et al. 1993). An additional, 100 kD protein appears to be involved in the DNA-
bound complex (Elferink et al. 1990; Swanson et al. 1993). A carboxy-terminal domain
25
is required for transcriptional activation (see below), likely by mediating interactions with
transcriptional co-activators and the basal transcription machinery.
More than a dozen genes respond to AHR ligands, typically by transcriptional
induction (Hankinson 1995, Table 2). Induction ofmRNA, protein, and enzyme activity
from one of these genes, CYPIAl, is the best characterized, and is used as a diagnostic
for AHR signaling.
Structure and Expression Patterns
Functionally significant domains of the AHR have been identified using sequence
homology, deletion analysis, receptor chimeras, and site-directed mutagenesis. These
domains are shown in Figure 3. The AHR is a member of the basic helix-loop-helix
(bHLH) superfamily of transcription factors as well as the emerging PAS family of
proteins (named for ARNT and Per and Sim, two Drosophila genes). The bHLH domain
is important for dimerization and DNA binding (Reisz-Porszasz et al. 1994). The PAS
domain includes two 50 amino acid repeats, labeled PAS A and PAS B. This domain is
involved in dimerization as well (Reisz-Porszasz et al. 1994). In addition, the PAS B
repeat is within the overlapping sites for HSP90 and ligand binding. A C-te=inal
glutamine rich domain is necessary for transcriptional activation (Whitelaw et al. 1994).
The bHLH, PAS, and transcriptional activation domains are present in ARNT and
perfo= the same functions, with the exceptions ofHSP90 and ligand binding.
The AHR and ARNT have been found in most mammalian tissues examined to
date (reviewed in Schmidt and Bradfield 1996). With some exceptions, they demonstrate
coordinate levels of expression. In mice, AHR and ARNT are expressed by gestational
day 10-11, and their levels in various tissues change throughout gestation (Abbott et al.
1995a; Abbott and Probst 1995b). The highest levels of expression were seen in tissues
undergoing a high degree of differentiation and proliferation.
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Table 2. Gene products regulated by ligands of the AHR; after Hankinson (1995), with
additions. t).: increase or decrease in level or rate; ND: not determined
AHR and/or ARNT mRNA
Gene product dependence level Transcription rate Reference
CYFIAI Yes T T (Israel and J.P.
Whitlock 1984)
CYPIA2 Yes t t (Pasco et al. 1993)
CYPlBl Yes t t (Sutter et al. 1991)
NQOl Yes t t (Favreau and
Pickett 1991)
GST-Ya Yes t t (Ruslunore and
Pickett 1990)
Ugt 1*06 Yes t ND (Sutter et al. 1991)
PAI-2 ND t t (Sutter et al. 1991)
TGF-~2 ND t t (Gaido et al. 1992)
c-fos No t ND (Puga et al. 1992;
Hoffer et al. 1996)
FosB No t ND (Hoffer et al.
1996)
Jun-B No t ND (Puga et al. 1992;
Hoffer et al. 1996)
c-Jun Yes t ND (Puga et al. 1992;
Hoffer et al. 1996)
Jun-D Yes t ND (Puga et al. 1992;
Hoffer et al. 1996)
ALAS Yes ND ND (Poland and
Glover 1973)
ALDH3 Yes t t (Vasiliou et al.
1993)
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Figure 3. Functional domains of mouse AHR and ARNT; after Hankinson (1995).
Radioligand binding (Lorenzen and Okey 1990), photoaffinity labeling (Hahn et
al. 1994), and RT-PCR cloning (Hahn and Karchner 1995; Hahn et al. 1997; Tanguay et
al. 1998, Karchner et a11999) have been used to identify AHR homologues in fish
(reviewed in Hahn 1998a). The photoaffinity labeling study found no evidence of AHR
in any invertebrate species examined, although a specific binding protein was identified
in two out of three cartilaginous fishes and all of the bony fishes studied. Subsequently,
AHR homologues have been cloned from C. elegans (Powell-Coffman et al. 1998),
Drosophila (Duncan et al. 1998), and primitive vertebrates (Hahn et al. 1997). The C.
elegans and lamprey AHRs do not bind TCDD (Powell-Coffman et al. 1998; Karchner et
al unpublished). Thus, while AHR homologues occur throughout much of the animal
kingdom, the HAH binding function appears to have emerged early in vertebrate
evolution.
Two AHR forms occur in the killifish Fundulus heteroclitus, smooth dogfish
(AHR1 and AHR2; Hahn et al. 1997) and rainbow trout (AHR2a and AHR2~; Abnet et
al. 1999). Phylogenetic analyses indicate that a duplication event early in vertebrate
evolution may have led to the two dogfish and Fundulus forms, suggesting that multiple
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fonns may exist in other vertebrate species. The two trout fonns are both more closely
related to Fundulus AHR2 than AHR1, and are likely the result of a more recent
duplication in the salmonid lineage. Both AHR fonns in Fundulus and rainbow trout are
capable of binding ligand.
Ah Receptor Signaling Cross-Talk
Cell Cycle
The cell cycle is divided into four stages: Gl (gap 1), S (DNA synthesis), G2 (gap
2), and M (mitosis). Transitions from one stage to the next are controlled by the cyclins
and the kinases with which they dimerize. Work in yeast, Xenopus, and sea urchin
models has uncovered many of the activities and interactions of these proteins (reviewed
in Murray and Hunt 1994). Cyclins regulate the activity of their partner kinases, and
several such dimers have been identified that act at different stages of the cell cycle.
Such activity is necessary for the cell to continue through stopping points in the
cell cycle tenned "checkpoints." Checkpoints can serve to ensure sufficient cell size or
appropriate environmental conditions before the cell continues, or they can stop the cell
cycle when damage occurs. Proteins that act to limit cell proliferation, and typically are
involved in checkpoint regulation, are products of tumor suppressor genes (Hinds and
Weinberg 1994). Many tumor suppressors have been identified, and mutations in their
genes lead to increased incidence of cancer.
The gene product of one such suppressor, the retinoblastoma gene (RB), is
intimately involved with the Gl---+S checkpoint. The RB gene product (pRB) is also a
site of action of other tumor suppressors, including p16, p21, and p53. pRB binds and
inhibits both the transcription factor E2F and the tyrosine kinase c-abl, inhibiting
progression from Gl to S. Phosphorylation ofpRB by the cdk4/cyclin D complex causes
dissociation of the pRB/E2F dimers and entry into S phase.
Study of these cell cycle controls has been aided by the ability to obtain cells
enriched in one stage of the cell cycle through various chemical and physical means.
Chemical cell cycle inhibitors offer many options for point of cycle synchronization.
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Mimosine blocks cells in late GI; aphidicolin, thymidine and hydroxyurea inhibit DNA
synthesis, blocking in S; and nocodazole stops mitosis at metaphase (reviewed in Krek
and DeCaprio 1995). Removal of the blocking agent by addition of fresh cell culture
medium allows cells to resume progression through the cycle in syuchrony. Synchronous
populations obtained by these methods are extremely useful for study of cycle-dependent
processes. The population gradually becomes more asynchronous with each successive
cycle, so this technique is less useful for long-term studies.
AHR Ligands and Cell Cycle / Cell Proliferation
Evidence for an effect of AHR ligands on the cell cycle and cell proliferation has
come from a number of sources. Histopathology of tissues from various TCDD treated
mammalian species show some general similarities (reviewed in Poland et al. 1982).
Epithelial tissues are usually hype!plastic, while lymphoid tissues show hypoplasia or
atrophy. Liver and cardiovascular lesions are also frequently observed. Gierthyand
Crane (Gierthy and Crane 1984) first described an inhibition of proliferation by TCDD in
cultured epithelial cells (contrast with hype!plasia in vivo). This effect has since been
extended to MCF-7 breast cancer cells (Gierthy et al. 1993), rat H4IIE hepatoma cells
(Gottlicher et al. 1990), rat livers (Fox et al. 1993) and primary rat hepatocytes (Hushka
and Greenlee 1995).
Growth inhibition by TCDD in rat cells is due to an AHR-dependent delay in
Gl-.-+S progression (Wiebel et al. 1991; Weiss et al. 1996). This evidence is supported
by a lengthened GI stage in AHR-deficient HEPA-I (mouse hepatoma) cells (Ma and
Whitlock 1996). Transfection of an AHR-expressing vector restored the wild type Gl
length, as well as several other characteristics. It is expected that the delay in GI-.-+S
progression is due to interactions between the AHR and control ofthe GliS checkpoint,
which was detailed above. A clue to the mechanism has come with the finding that the
AHR associates with the retinoblastoma gene product, and that this association shows
preference for the ligand-bound AHR (Ge and Elferink 1998).
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Growth inhibition by TCDD has not been observed in all studies. Inhibition of
proliferation of murine Swiss 3T3 cells was observed after treatment with BaP, but not
TCDD (Vaziri and Faller 1997). Stimulation of proliferation by TCDD has been
observed in other cell culture experiments (Dickins et al. 1981; Busser and Lutz 1987;
Wolfle et al. 1988; Lucier et al. 1991; Schrenk et al. 1992), and evidence suggests that
proliferative effects are dependent on cell type and culture conditions.
While investigating the effect of actin microfilament and microtubule disrupters
on CYP1A1 induction, SchOller et al. (1994) found that prolonged (20-24 hour) exposure
to nocodazole inhibited CYP1A1 induction. However, this inhibition was due to cells
being arrested in G2 or mitosis rather than disruption of the microtubule network. The
AHR in these cells still binds TCDD, but it does not bind DNA as efficiently (Scholler et
al. 1994). Other agents that block cells in G2 or M had similar effects. The cells
resumed cycling once the nocodazole had been washed out, and CYP1Al induction was
restored coincident with progression to Gl (J. J. Reiners, Jr., personal communication).
These results taken together raise the possibility that AHR is involved in
regulation of the cell cycle and that cell cycle progression can in tum affect AHR
function. This tentative hypothesis clearly requires demonstration of the effects noted
above in other systems as well as a more complete understanding of the mechanisms
involved. It is possible that the AHR originally evolved to perform functions distinct
from ligand binding and transcriptional regulation, and now has a multiple functions in
later vertebrates. Such dual roles have recently come to light for several proteins
involved in regulation ofproliferation (Jacks and Weinberg 1998).
AHR and Phosphorylation
Effects ofTCDD on cell proliferation may occur by modulating protein
phosphorylation. TCDD stimulates tyrosine phosphorylation in mouse hepatocytes (Ma
and Babish 1993). Similar effects have been observed in rainbow trout (Newsted and
Giesy 1993). Phosphorylation is rapid and occurs in nucleus-free extracts, indicating that
de novo protein synthesis is not required (Enan and Matsumura 1994; Enan and
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Matsumura 1995). The kinase src may mediate these effects (Enan and Matsumura
1996). These discoveries have led to speculation regarding a second pathway of AHR
action distinct from transcriptional regulation (Matsumura 1994).
Phosphorylation of AHR and ARNT appears to be necessary for transcriptional
regulation by their heterodimer. Tetradecanoyl phorbol acetate, which downregulates
protein kinase C (PKC) at high concentrations, inhibits CYPIAI induction by AHR
ligands (Carrier et al. 1992; Okino et al. 1992), as do the inhibitor calphostin C and
various phosphatases. Phosphatase treatment in vitro revealed that ARNT
phosphorylation appears to be necessary for dimerization, while AHR phosphorylation is
necessary for XRE binding (Berghard et al. 1993). Pre-activation ofPKC enhances
CYPlAl induction by AHR ligands, and inhibition ofPKC by staurosporine abolishes
CYPlAl induction (Chen and Tukey 1996). The AHR can be transformed in isolated
cytosol in the presence of PKC inhibitors, suggesting that phosphorylation precedes
ligand binding (Schafer et al. 1993).
AHR transformation also can modulate PKC activity. Treatment of cultured
aortic smooth muscle cells with BaP or TCDD results in an initial decrease in PKC
activity, followed by a marked increase (Weber et al. 1994). This effect is cell cycle
dependent. Cells synchronized by serum starvation showed decreased levels and
activities ofPKC isoforms u, ~2, and & in Gl, followed by increases in ~2 and & after
entry into S phase (Weber et al. 1997). Whether or not PKC activity affects AHR activity
in these cells has yet to be determined, but it is possible that the two proteins are involved
in a feedback loop of mutual regulation.
Murine fibroblasts grown in the absence of serum have been demonstrated to
down regulate AhR expression (Vaziri et al. 1996). Expression could be induced by
addition of growth factors whose receptors signal via tyrosine phosphorylation or by
ectopic expression of v-src, a constitutively active form of a protein downstream in the
signaling pathway from some of those receptors. Experiments using a cell-cycle blocker
showed that lack of AhR expression was not due simply to cell cycle arrest but rather was
linked to tyrosine phosphorylation.
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Interactions between the AHR and other cell receptors have been characterized.
In several studies decreased epidermal growth factor (EGF) binding by EGF receptor has
been noted after treatment with TCDD (e.g. Sewall et al. 1993). Effects ofTCDD on the
estrogen (Wang et al. 1993) and progesterone receptors (Harper et al. 1994) also have
been noted. Several cytokines have been implicated in modUlation of AHR gene
regulation (Abdel-Razzak et al. 1993).
Receptor Pharmacology
The actions of many therapeutic and toxic agents are mediated by receptors,
cellular sites with relatively great affinity for the agent (or ligand) and an ability to
produce a response following interaction with the ligand. Since the concept of specific
receptors for different drugs and toxins was formulated early in the 20th century,
characterization and quantification of these interactions and responses have been
continuing activities for pharmacologists and toxicologists. The AHR can be expected to
conform to many, ifnot all, of the general aspects ofreceptor pharmacology as they are
currently understood.
Clark (1937), first applied a mathematical model to the interaction between a drug
and its receptor, borrowing an hyperbolic relationship from physical chemistry used to
describe adsorption of small molecules to activated charcoal:
[AR]
[R T ]
[A] (1)
where [A], [RT] and [AR] are the concentration of ligand, receptor, and the ligand-
receptor complex, respectively, and KD is the equilibrium dissociation constant. This
equation is still the one commonly used to describe binding of a single molecule to a
single receptor.
As measurements ofresponse to ligands followed, it became obvious that
response was not always simply proportional to the number ofoccupied receptors. Some
ligands bound to the receptor, but produced no response, while some were less effective
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at producing a response once bound. Ariens (1954) introduced the concept of "intrinsic
activity" and defined response as:
Em
a[AR]
= [R T ]
ax [A]
[A]+KD
(2)
where Ea and Em are the response at ligand concentration [A] and the maximal response,
and a is the intrinsic activity, which has a value between 0 and 1 for each ligand. Each
ligand thus has two properties defining its interaction with the receptor, the affinity,
governed by KD, and the activity, a. Compounds with a=l were termed full agonists,
a=O antagonists, and O<a<l dualists, or partial agonists.
Later Stephenson (1956) would replace a with a function e "efficacy" which did
not assume a linear relationship between receptor occupation and response. Furchgott
(1966) further revised this model to account for differences in receptor concentration by
defining the "intrinsic efficacy" as the ability of a ligand to convert its receptor to a form
capable ofproducing response. Intrinsic efficacy is therefore theoretically a property of
the ligand and receptor, and is independent of tissue-specific effects, such as receptor
concentration and coupling of the receptor to downstream events.
Stephenson's efficacy function was given definition by Black and Leff (1983),
who upon study of several receptor systems proposed that response is often an hyperbolic
function of receptor occupancy:
= ---0-[A_R-=--]_
K E +[AR]
(3)
where KE is the concentration ofligand-receptor complex producing a half-maximal
response. Combining equations 1 and 3 yields:
(4)
which was termed the "operational model" of receptor action. The utility of this model
lies in the ability to calculate KE once KD, RT, and dose-response data have been
determined. KE also is a mathematical concept with a definite biological counterpart,
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rather than a nebnlous fitting parameter. The drawback to this approach is that KE
incorporates both ligand-specific and tissue-specific properties affecting efficacy.
These concepts have been introduced because they are important relationships
that underlie the actions of receptors in general, and should apply to the AHR in
particular. The concepts of affinity, intrinsic efficacy, and tissue coupling can be
explored for their contributions to observed differences in HAH potency among
compounds, species, strains, tissues, and endpoints. These principles have been
underdeveloped in the field of AHR research beyond the measurement of binding
affinities for a wide range of compounds. In particular, variations in intrinsic efficacies
among HAH will lead to non-additive interactions in mixtures, and thereby create
difficulties in applying the TEF concept.
RATIONALE
This research was conducted to further establish the Poeciliopsis lucida
hepatocellular carcinoma (PLHC-l) cell line as a piscine model in AHR research and
then use that model to address outstanding issues of HAH toxicity and AHR function.
Chapter 2 describes the development and use of several techniques for the study of AHR
function and interaction with the cell cycle. Chapter 3 explores the critical issue of
conditions affecting exposure to and uptake ofHAH in cultured-cell bioassays. Chapter
4 demonstrates the utility of a quantitative pharmacological approach to addressing
mechanistic questions in AHR signal transduction. Chapter 5 reveals how models of
receptor action can be used to predict the effects of perturbations to the signaling
pathway.
A model piscine cell system is valuable to the field of AHR research for several
reasons. First, the utility of cultured cells for rapid acquisition of data and exquisite
control of experimental conditions has been demonstrated in mammalian systems. This
is an obvious concept, but one slower to take hold in environmental biology. Second,
fish are economically and agriculturally important organisms that are impacted by AHR-
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mediated toxicity in freshwater and coastal ecosystems. Understanding the mechanisms
of toxicity and impacts of these compounds on fish populations have been recognized as
significant issues by the international ecotoxicology community. Third, interspecies
extrapolation is a technique commonly used to estimate the risk HAH pose to humans.
Measuring effects in a broad range of organisms increases the data available for
extrapolation and thereby improves human risk assessment. Last, fish are the earliest-
evolving animals known to express an AHR capable of binding HAH. Studying the
structural and functional changes that led to this binding capability and subsequent
response is necessary to understand the AHR's changing function(s). Furthermore,
comparing the shared and distinct features of AHR signal transduction across a range of
species will yield clues to the inceptive and current "endogenous" functions ofthis
protein.
Given this need for a piscine cell model, the PLHC-I cell line has many qualities
to recommend it. These cells are ofhepatocellular origin, facilitating comparison with
liver responses in vivo and well-established cell models such as the mouse HEPA and rat
H4IIE hepatocellular lines. In addition, PLHC-I are derived from a fish that is adapted to
warm environments, with maximum proliferation of the cells observed at 30°C. The
importance of this fact as regards ease of culture and increased rate ofproliferation (and
thus supply of cells for experiments) when compared to other piscine cell lines cannot be
overemphasized. Finally, when this work was initiated several important aspects ofAHR
function in PLHC-I had already been established. The cells express an AHR capable of
binding ligand and inducing CYPIA in response (Hahn et al. 1993). Methods for assay
ofCYPlA protein and catalytic activity had been worked out (Bruschweiler et al. 1996a;
Hahn et al. 1996b). All these factors combined to make the PLHC-l cell line the obvious
choice for further study.
Despite the preexisting base of knowledge, a substantial gap existed between the
detail in which AHR function had been described in mammalian cell systems and PLHC-
1 cells. Some of this work (largely presented in Chapter 2 and Appendix B) was carried
out to narrow that gap, but the focus ofthis thesis is to demonstrate the utility ofthis
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system for addressing unanswered questions regarding aspects of AHR signal
transduction. To that end, the novel pharmacological approach developed in Chapter 4
was used to address the mechanism of reduced toxicity of ortho-substituted PCBs in fish.
The resulting quantitative model is used to suggest a mechanism for the reduced CYPIA
induction presented in Chapter 5. Similarly, the findings in Chapter 3 will apply
individually to any cultured cell system used to study HAH, but have perhaps the greatest
impact on analysis of results among multiple systems.
The hopeful result of research in this field, as in any, is to move from a
descriptive to a predictive mode of study, or from experiment to theory. Chapters 4 and 5
and Appendices C and D represent some of the first steps in that direction for AHR
research. The ability to predict an outcome before the experiment is performed, rather
than attempt to explain it afterward, is the hallmark of a maturing field. Doubtless, these
early models will soon be regarded as crude and overly simplistic, but it is exciting to be
a part of the effort to develop them nonetheless.
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ABSTRACT
Aryl hydrocarbon receptor ligands have been implicated in altered cell
proliferation in many tissues in vivo and cell types in vitro. The mechanisms underlying
these effects have not been explored in non-mammalian systems. This work establishes
techniques for identifying and characterizing possible interactions between cell
proliferation, the cell cycle, and AHR signal transduction in the piscine cell line PLHC-I.
The doubling time of these cells was determined to be 22 hours, with cell cycle stage
lengths of 13,3, and 6 hours for GI, S and G2/M, respectively. A minimum seeding
density of 1.2x I05 cells per cm2 in medium with 10% calf serum and O.3x I05 cells per
cm2 in 10% fetal bovine serum was found to be required for subsequent proliferation. Of
several cell cycle inhibitors tested, aphidicolin and nocodazole were the only ones
effective for obtaining synchronous cell populations. Fluorescence activated cell sorting
was used to identify cells responding to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on
the basis of induced cytochrome P450lA protein or enzymatic activity. TCDD was
found to inhibit PLHC-I proliferation in a time- and dose-dependent manner in one sub-
clone, but not in several others. Partial sequences for AHR and f)-actin were obtained
and used to design specific primers for RT-PCR measurement of AHR mRNA content.
This technique was used with synchronous PLHC-I cells to show that AHR expression
does not vary during the cell cycle, and these results were confirmed at the level ofAHR
protein expression by measurement of specific binding of 3H-TCDD. Taken together
these results indicate that PLHC-I are amenable to analysis of AHR-cell cycle
interactions, but that heterogeneity of sub-clones may limit their usefulness for
investigating AHR-mediated changes in proliferation.
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INTRODUCTION
Altered cell proliferation is a hallmark of the toxicity of2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) and related halogenated aromatic hydrocarbons
(HAH). Carcinogenesis, epithelial proliferation, immunosupression, and teratogenesis
are some of the known effects ofthese compounds (Poland et al. 1982). The toxic effects
ofHAH are mediated by the aryl hydrocarbon receptor (AHR), and mechanism(s) of
altered proliferation are expected to involve the AHR. However, the pathway(s) linking
AHR signaling and cell proliferation are not well understood.
Inhibition of proliferation in response to HAH treatment has been observed in
vitro in a wide range of cell types, including epithelial cells (Gierthy et al. 1984), MCF-7
breast cancer cells (Gierthy et al. 1993), rat H4IIE hepatoma cells (Gottlicher et al. 1990),
rat livers (Fox et al. 1993) and primary rat hepatocytes (Hushka et al. 1995). However,
stimulation ofproliferation by TCDD has been observed in other experiments (Dickins et
al. 1981; Busser et al. 1987; Wolfle et al. 1988; Lucier et al. 1991; Schrenk et al. 1992),
and evidence suggests that proliferative effects are dependent on cell type, time in culture
and culture conditions.
Work in rodent hepatoma cells has provided the first clues of a mechanism for
inhibition ofproliferation by linking AHR signaling and the cell cycle. Inhibition by
TCDD in rat cells is due to an AHR-dependent delay in G1~S progression (Wiebe1 et al.
1991; Weiss et al. 1996), and a lengthened G1 stage has been observed in AHR-deficient
HEPA-1 mouse hepatoma cells (Ma et al. 1996). The retinoblastoma gene product,
which is involved in the G1/S checkpoint, interacts with the AHR (Ge et al. 1998), and it
has been hypothesized that the delay in G1~S progression is connected to this
interaction.
Studies to date have focused on mammalian systems, but proliferative
abnormalities have been noted in vivo in TCDD-treated fish (Spitsbergen et al. 1988).
Effects of TCDD on cell proliferation have not been examined in cultured fish cells. A
recent rise in use of cultured fish cells for a wide variety of in vitro toxicity studies (Baksi
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and Frazier 1990; Babich and Borenfreund 1991a; Bois and Lee 1991; Pesonen and
Andersson 1997; Segner 1998), has made these systems available for use in studies of
interactions between AHR signaling and cell proliferation. By extending knowledge of
such effects beyond the mammalian class, the shared and distinct features among taxa can
be used to build hypotheses of AHR evolution and function in cell proliferation.
The PLHC-I cell line, derived from a 7,12-dimethylbenz(a)anthracene induced
hepatocellular carcinoma ofPoeciliopsis lucida (Hightower and Renfro 1988), was
chosen for this study. These cells have been used for investigations of cytotoxicity
(Babich et al. 1991b; Ryan and Hightower 1994; Bruschweiler et al. 1995; Huuskonen et
al. 1998a; Fent and Batscher 2000) and effects of AHR ligands (Bruschweiler et al.
I996a; Bruschweiler et al. 1996b; Celander et al. 1996; Celander et al. 1997; Villeneuve
et al. 1997; Huuskonen et al. 1998b; Huuskonen et al. 1998c; Smeets et al. 1999;
Huuskonen et al. 2000). PLHC-I cells show induction of CYPIA (an AHR-mediated
response) in response to AHR agonists (Hahn et al. 1993; Hahn et al. 1996a; Hahn et al.
1996b; Hestermann et al. in press). These properties together with their relatively rapid
proliferation led to the use ofPLHC-l cells here.
This study had the dual objectives of I) characterizing proliferation and cell cycle
in PLHC-l cells and 2) developing techniques to study interactions between AHR
signaling and cell proliferation. Cell cycle synchronization, flow cytometric analysis of
induction ofCYPIA protein and activity, the effect of TCDD on proliferation, and
analysis of AHR mRNA and protein content were all performed in these cells. The
results provide a basis for future studies of links between proliferation and AHR signal
transduction in fish cells.
41
MATERIALS AND METHODS
Chemicals and solutions
The 2,3,7,8-tetrachloro[I,6}Hldibenzo-p-dioxin ([3H1TCDD, purity 2 97%,
specific activity 27 Ci/mmol) was obtained from Chemsyn Science Laboratories (Lenexa,
KS). TCDD and 2,3,7,8-tetrachlorodibenzofuran (TCDF) were obtained from Ultra
Scientific (Kingston, RI). Oregon-Green conjugated goat anti-mouse IgG and
methoxyfluorescein methyl ester (MFME) were from Molecular Probes (Eugene, OR).
Restriction enzymes were from Promega (Madison, WI). All other reagents were
obtained from Sigma (St. Louis, MO).
Saline GM is 0.8% NaCl, 0.11 % glucose, 0.04% KCI, 0.039% Na2HP04, 0.015%
KH2P04, 0.5 rnM EDTA. Phosphate-buffered saline (PBS) is 0.8% NaCI, 0.115%
Na2HP04, 0.02% KCI, 0.02% KH2P04, pH 7.4. Stock solutions ofaphidicolin,
nocodazole, TCDF and TCDD were prepared in dimethyl sulfoxide (DMSO) at 1000x
the desired final concentration. Mimosine, thymidine and hydroxyurea were diluted in
PBS. Concentrations of [3H1TCDD solutions were verified by liquid scintillation
counting (LSC) on a Beckman LS5000TD.
Growth and Treatment ofCells
PLHC-1 cells (Hightower et al. 1988), clone HC-16, were grown at 30DC in
minimum essential medium (MEM) containing Earle's salts, nonessential amino acids, L-
glutamine and 10% calf serum, as described previously (Hahn et al. 1993). Cells were
seeded and treated in 25 cm2 flasks in 6 ml medium. Unless noted otherwise, seeding
density was 1.5x106/ml (2.4x105/cm2). None of the chemical treatments used reduced
cell viability, as determined by Trypan Blue exclusion.
Treatment of cells for synchronization with hydroxyurea, mimosine, nocodazole,
and thymidine were performed as described (Krek et al. 1995). For all but nocodazole,
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PLHC-1 cells were treated with the indicated concentration of chemical for 24 hours,
rinsed with prewarmed medium, given fresh medium, and sampled at subsequent
intervals for DNA content analysis. Treatment with aphidicolin was by a method
specifically for monolayer cultures (Sourlingas and Sekeri-Pataryas 1996), and both
single- and double-block methods were employed. For double-block synchronization,
cells were treated for 24 hours, rinsed and given fresh medium for 8-12 hours, and then
treated again with aphidicolin for 16 hours. Nocodazole treatment was performed after a
16 hour pre-treatment with either thymidine or aphidicolin.
Cell Cycle Analysis
DNA staining for cell cycle analysis using propidium iodide (PI) was performed
as described (Crissman and Hirons 1994). Cells were trypsinized, pelleted, and
resuspended in one volume ice-cold saline GM. The suspension was gently vortexed
during dropwise addition of three volumes ice-cold 95% ethanol. Using cold reagents
and gradual addition of ethanol reduced clumping of cells. Fixed cells were stored at 4°C
until one day before analysis, and then were pelleted and resuspended in equal volumes
30 fig/ml PI and 100 fig/ml Rnase A, both in PBS. Stained cells were stored overnight at
4°C, and protected from light until analysis. Flow cytometry was performed on a Becton
Dickinson FacScan instrument at the MIT Cell Sorting Facility or a FacsCalibur at
WHOI. Data from ten thousand ungated events were collected for each analysis.
Modeling of cell cycle stages was performed using ModFit software (Verity).
Coefficients of variation were typically 3-5%.
Analysis ofCYP1A Protein and Activity
Cells were analyzed for CYPIA protein or activity 24 hours after TCDD or
DMSO treatment. CYPIA protein was measured by the method of Stauber et al (1995).
Cells were trypsinized, pelleted, resuspended in 0.4% formalin, and incubated overnight
at room temperature. Formalin-fixed cells were incubated in 0.05% Triton-X for 15
minutes on ice and then washed twice in 0.1 % BSA in PBS. Cells were then incubated
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with 250 [11 mouse anti-scup CYFIA monoclonal antibody 1-12-3 (Park et al. 1986) or
non-specific mouse IgG (both 1 [1g/ml in PBS) for 15 minutes on ice and washed in goat
serum and then twice in 0.1 % BSA. They were then incubated in 250 [11 Oregon-Green
conjugated goat anti-mouse IgG (1 [1g/ml in PBS) for 15 minutes on ice and washed
twice in 0.1 % BSA. Finally, the cells were resuspended in PBS and stored at 4°C in the
dark until analysis.
CYPIA activity was measured as O-demethylation ofMFME by a variation of a
previosly established protocol (Miller and Whitlock 1981). Cells were trypsinized and
resuspended to 106/ml in MFME in PBS for 20 minutes prior to analysis of fluorescein
production by flow cytometry. The suspension was protected from light until analysis.
AHR Quantification by TCDD Binding
Specific binding of eH1TCDD in PLHC-l cells was measured by a modification
of the whole-cell filtration assay ofDold and Greenlee (1990). Cells were treated with I
nM eH1TCDD in the presence or absence of200 nM unlabeled TCDF and inCUbated 2
hours at 30°C. This time was determined to be sufficient to achieve a steady state of
bound radioligand (Appendix B). Cell densities were equal among treatments in order to
minimize protein concentration effects on binding (Bradfield et al. 1988a). Following the
incubation, tubes were vortexed briefly to assure even distribution of cells, and a 0.1 ml
aliquot was removed to determine final eH1TCDD concentration. Three, 0.45 ml aliquots
of cell suspension from each tube were then collected under vacuum on prewetted 25 mm
Whatman GFIF filters. Filters were then washed three times with 2.5 ml acetone that had
been precooled to -80°C. The number ofwashes was determined empirically as that
necessary to remove the free eH1TCDD remaining on the filters (Appendix B).
Replicates were processed in batches of twelve on a Millipore 1225 filter manifold.
Radioactivity remaining on the filter was quantified by LSC. Cell protein was measured
on separate aliquots by the bincinchinoic acid method of Smith (1985), using BSA as the
standard and MEM as the blank.
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Cloning ofAHR and fJ-aetin eDNA Fragments
TCDD- and DMSO-treated cells were trypsinized, pelleted and resuspended in I
ml RNA STAT-60 (Tel-Test, Friendswood, TX). RNA extraction continued according to
the manufacturer's instructions. Poly(Af mRNA was isolated using mini-oligo(dT)-
cellulose spin columns (5 Prime -7 3 Prime, Boulder, CO). Reverse transcription
coupled-PCR was performed using the Gene-AMP RNA-PCR kit (Perkin-Elmer) and a
GeneAmp 2400 thermocycler. Reverse transcription was primed with random hexamers,
and primer sets Q£lBI and AlIBI (Table I) were used to amplify AHR, and FI/RI ~­
actin. All primers were at I [J.M. PCR conditions were: 95°C, 1:45; 35 cycles of (95°,
0:15,50°,0:30; 72°,1:00); 72°, 7:00.
Products of expected size were cloned into pGEM-T Easy (Promega). Twelve
AHR clones were digested using 2 separate restriction enzymes, Pst I and Sac I, and the
sizes of the resulting fragments were compared to those predicted from previously
obtained sequence for a PLHC-I AHR2 (D. Franks and M. Hahn, unpublished results).
Two AHR and two ~-actin clones were sequenced by the University of Maine sequencing
facility (Orono, ME).
Measurement ofAHR mRNA by RT-PCR
Cells were treated in 25 cm2 flasks, and total RNA was isolated as detailed above.
cDNA was synthesized from 2 [J.g of total RNA using OmniscripFM Reverse
Transcriptase (Qiagen, Valencia, CAl and random hexamers. One fifth of the reaction
volume (equivalent to cDNA from 400 ng ofRNA) was used for each PCR reaction.
Specific primers used to amplify PLHC-I AHR and ~-actin are shown in Table I.
Primers were designed to cross mRNA splice sites (as predicted by alignment of the
PLHC cDNA and Fundulus heteroelitus genomic AHR2 sequences) to eliminate
amplification of AHR genomic DNA. The AHR and ~-actin primers have nearly
identical melting temperatures and amplify products of similar size, facilitating RT-PCR
under the same conditions. PCR was performed using Amplitaq Gold (Perkin-Elmer)
with: 95°C, 10:00; 34 cycles of (95°, 0: 15, 60°, 0:30); 72°, 7:00. The number of cycles
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used was within the range of exponential amplification for both AHR and f)-actin
products.
PCR products were separated by agarose gel electrophoresis and stained by
soaking the gel in 1 J.1g/ml ethidium bromide for 30 minutes. Quantification ofbands was
performed with a Multi1mage™ analysis system (Alpha Innotech, San Leandro, CA).
Integrated densities of AHR bands were normalized to integrated density of f)-actin bands
from the same samples, and these values were then normalized to those in untreated cells.
Table 1. PCR primer sequences.
Primer name Sequence (5' -'3> 3')
Degenerate
Primers
Al
Qf
D1
FI
RI
Specific Primers
AHRF
AHRR
ActinF
ActinR
ARGCICTSAAYGGITT
AACCCITCIAAGMGlCAYMG
CATICCRCTYTCICCIGTYTT
ACAACGGYTCSGGYATGTGC
GAAGCAYTTGCGRTGWACRAT
CAATCCCCTCAGATGCAGACCTCTCC
ATAACCCAGGATTATCTTCCCCCTGC
CCATTGGCAACGAGAGGTTCCGTTGC
CTCATCGTACTCCTGCTTGCTGATCC
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RESULTS
PLHC-l Growth Characteristics
The proliferative rate for the PLHC-I cells was measured by counting cells at
increasing intervals following seeding in 25 cm2 flasks (Figure I). Cells were in lag
phase until 24 hours after seeding, and then proliferation proceeded exponentially for 30
hours before reaching a stationary plateau. A fit through the exponential growth stage
predicts a population doubling time of 22 hours.
The short period of exponential growth was likely due to high seeding density
(2Ax 105 cells/cm2). At this density, the cells are -75% confluent after attachment.
Previous evidence suggested that PLHC-I do not proliferate at low densities (Hahn and
Woodward, unpublished results). The minimum seeding density was determined in the
standard medium (MEM + 10% calf serum; Figure 2A) and in MEM + 10% fetal bovine
serum (Figure 2B). In 10% calf serum, PLHC-I proliferated at initial densities greater
than or equal to 1.2xl05 cells/cm2, although proliferation was much slower below
2Ax 105 cells/cm2 In contrast, 10% FBS supported proliferation at densities as low as
3x104 cells/cm2 , although the lag phase was prolonged at lower densities.
Cell Cycle Analysis and Synchronization
Several flasks of PLHC-I at different times in the log phase of growth were
analyzed for DNA content by flow cytometry (an example is shown in Figure 3A). The
percentages of cells in GI, S, and G2/M were determined, and these percentages were
assumed to equal the fraction oftime spent in each stage by an average cell. Multiplying
by the doubling time yields estimates of 13,3, and 6 hours for GI, S, and G2/M,
respectively. These lengths have been confirmed by sampling parasynchronous (nearly
synchronous) cells at increasing intervals after removal of aphidicolin. Attempts to label
cells with bromodeoxyuridine in order to measure lengths of cycle stages more precisely
were unsuccessful.
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Figure 1. Proliferation in PLHC-l cells. Cells were seeded in 25 cm2 flasks at 2Ax 105
cells/cm2 and subsequently counted at the indicated times using a hemacytometer. The
best fit through the exponential growth phase is shown and predicts a population
doubling time of 22 hours.
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Figure 2. Determination of the minimum seeding density. Cells were seeded at the
densities indicated in the legend and subsequently counted. (A) Cells cultured in MEM
supplemented with 10% calf serum. (B) Cells cultured in MEM with 10% fetal bovine
serum.
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Date acquired: 26-Apr-96
File: 26APR96.014
Source: SAMPLE 10
Case: PATIENT 10
Analysis type: Manual analysis
Prep: FreshJFrozen
DIPLOID: 100.00 %
Dip GO-G1: 60.32 % at 45.07
Dip G2-M: 27.60 % at 86.02
Dip S: 12.08 % G2IG1: 1.91
Dip %CV: 7.48
Total S~Phase: 12.08 %
Extra Pop: %
Debris: 1.76 0/"
Aggregates: 32.39 °/0
Modeled Events: 12823
ReS: 4.932
250 Diploid B.A. D.: 9.55 %
Figure 3. FlDw cytometric analysis of DNA content in PLHC-l. Cells were fixed in
ethanol and stained with PI as indicated in the Methods. (A) Exponentially growing cells
were used to determine the fraction of cells in each stage of the cycle. (B) Cells treated
with 5 flM aphidicolin 8 hours after removal ofthe agent. The arrow indicates the
population of cells with twice the expected DNA content.
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Table 2. Synchronization ofPLHC-l by chemical treatment.
"None" indicates no significant enrichment of a single cycle stage.
Agent Concentration(s) tested Maximum synchrony
Aphidicolin 1.5 to 15 J.lM (0.5-5 J.lg/ml) 80%
Hydroxyurea lmM None
Mimosine O.2mM None
Nocodazole 500 ng/mL 75%
Thymidine 2mM None
Several chemical treatments were tested for their ability to block cell cycle
progression ofPLHC-l (Table 2). Only aphidicolin and nocodazole treatment resulted in
populations enriched in one stage ofthe cycle. Treatment with aphidicolin consistently
resulted in a population of cells with twice the expected DNA content (4n in G1, 8n in
G2; Figure 3B), and this population persisted until the first mitosis following aphidicolin
removal. Maximum synchrony with nocodazole was achieved using a pre-treatment with
aphidicolin and shaking off mitotic cells following nocodazole treatment. Cell yields
using this technique were substantially lower than with aphidicolin, and did not permit
exponential growth following reattachment. This problem was also encountered when
using fluorescence-activated cell sorting (FACS) with the vital DNA stain Hoechst 33342
to obtain a synchronous population (not shown).
A higher degree of synchrony was attained with greater cell densities (Figure 4).
This is consistent with faster proliferation at these densities, since slower cell-cycle
progression would lead to fewer cells accumulating in S phase during a 24-hour
aphidicolin treatment.
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Figure 4. Density-dependence of synchronization efficiency. Cells were fixed at the
indicated times following removal of 5 flM aphidicolin. Analysis of cell cycle was
performed as in Figure 3A. Seeding densities were (A) 3.6x105 cells/cm2, (B) 2.4x105
cells/cm2 and (C) 1.6x 105 cells/cm2
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Figure 5. Flow cytometric analysis of CYPIA expression. Cells were treated with 2 nM
TCDD or 0.1 % DMSO for 24 hours. (A) Cells were trypsinized and resuspended in the
indicated concentration ofMFME for 20 minutes prior to measurement of fluorescein
fluorescence. (B) Cells were fixed and prepared for immunofluorescence as detailed in
the Methods. TCDD-treated cells incubated with a non-specific primary antibody are
included as a controL
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Single-Cell CYP1A Analysis
CYPlA expression was determined in individual cells in two ways: by
immunostaining of fixed cells and measurement ofMFME O-demethylation activity in
viable cells (Figure 5). Both techniques are capable of distinguishing populations of cells
treated with CYPlA inducers from uninduced controls; however, there was overlap
between the signal determined for the two populations. The induced and control peaks
were resolved better using MFME metabolism.
MFME concentrations between 50 and 500 nM produced the best results.
Concentrations lower than 50 nM resulted in a high degree of overlap between control
and induced populations, and concentrations higher than 500 nM produced too much
background fluorescence for the cytometer to distinguish individual events (i.e. cells).
The 20-minute incubation time used was determined by a time course of fluorescein
production. Fluorescence values shown for the induced population persisted for at least
one hour, which facilitated counting and sorting of cells.
Imrnunodetection of CYP1A protein produced populations with a high degree of
overlap (Fig. 5B). However, antibody concentrations and wash conditions were not
optimized, so better resolution may be possible.
TCDD Treatment and Proliferation
The effect of TCDD on proliferation ofPLHC-l cells is shown in Figure 6. Cells
were treated with 2 nM TCDD or 0.1 % DMSO one day after seeding and counted at
subsequent intervals (Fig. 6A). The onset ofproliferation was delayed between two and
five days in TCDD treated cells, but by seven days post-treatment cell counts were equal
to those in control cells. The dose-response relationship for this effect after two days
indicates a significant decline in cell numbers at TCDD concentrations in excess of 0.06
nM (Fig. 6B). This delay in proliferation was consistently measured through several
passages in this sub-clone of cells, but not in any of several subsequent ones.
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Figure 6. Effect of TCDD on PLHC·1 proliferation. Cells were seeded at 2.4x 105
cells/cm2, treated 24 hours later with the indicated concentrations ofTCDD and counted
at subsequent times. Points are means ± SE of three replicates. * indicates significantly
fewer cells in TCDD treatment. (A) Time course ofproliferation. (B) Dose-response
relationship. Cells were counted two days after treatment. The 0.01 nM TCDD point
indicates treatment with DMSO alone.
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Sequencing and Expression ofAHR2 in PLHC-l
An AHR was cloned from PLHC-I cells by harvesting RNA, isolating mRNA,
and using RT-PCR with degenerate primers to amplify a portion of the gene. An AHR2
fragment had already been isolated from these cells (D. Franks et ai, unpublished results),
but expression of an AHRI remained a possibility. Because AHRI expression is very
low in fish liver, but possibly inducible by AHR agonists (W. Powell, S. Karchner, and
M. Hahn, unpublished results), RNA was isolated from TCDD- and DMSO-treated cells.
The primer set Qf/Bl (which amplify both AHRI and AHR2 in Fundulus heteroclitus)
amplified a product of the expected size (-1000 bp; the -600 bp product has been seen in
other systems, and is not AHR), while Al/B 1 did not (Figure 7A). Degenerate f)-actin
primers also successfully amplified a band of expected size. These products were cloned,
and several AHR clones were chosen for further analysis. Six clones from DMSO-
treated and 12 from TCDD-treated cells were digested with restriction enzymes that had
only one recognition site in the previously determined partial AHR2 sequence. All but
one ofthe clones produced restriction products of the expected size (not shown), and that
clone as well as one other AHR and two actin clones were sequenced. The two AHR
clones had nearly identical sequences (one contained a base change in the restriction site),
and agreed with the sequence previously obtained (Figure 7B). The actin products were
also nearly identical, and showed high identity (95.3% nucleotide identity) with Fundulus
heteroclitus f)-actin (Figure 7C). These sequences were used to generate specific PCR
primers for use in semi-quantitative RT-PCR (Table 1, Figure 7B&C).
Expression of the PLHC-l AHR was measured in synchronized cells. After
release from aphidicolin block, cells progressed from G1 into S and G2 phases (Figure
SA). RT-PCR amplification of AHR and actin revealed no effect of cell cycle
progression on expression of AHR mRNA (Figure 8B). Likewise, specific binding of
TCDD by the AHR was not significantly altered (Figure 8C).
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AACCCGTCGAAGAGGCATCGGGATCGGCTGAATGGGGAGCTGGACCGCTTGATGGAGCTGCTGCCTTTCCCTGATGAG
N P S K R H R D R LNG E LOR L MEL L P F P D E
80 90 100 110 120 130 140 150
GTTCGCTCCAGCTTGGACAAGCTCTCTGTCCTGCGCCTGAGCGTGGGATACCTCAGGGTCAAGAGCTACTTTAAAACT
V R S S L 0 K L S V L R L S V G Y L R V K S Y F K T
160 170 180 190 200 210 220 230
TCCATGAAGAATGGTAATGGCAGCCGGGTGCCTCTGGGGGTCAACGGGCAGAACATGGACTCTACTGGTTTCTCTGAA
S M K N G N G S R V P L G V N G Q N M D S T G F S E
240 250 260 270 280 290 300 310
GGAGAGCTGCTGCTGCAGGCGCTGAACGGCTTTGTGTTGGTGGTGACATCTGAAGGAATGGTGTTTTACACCTCCCCT
GEL L L Q A LNG F V L V V T S E G M V F Y T S P
320 330 340 350 360 370 380 390
ACCATCAAAGACTACTTGGGCTTCCATCAGTCAGACGTGGTCCACCAGAGTGTGTTTGAGCTCATCCACACTGACGAC
T I K D Y L G F H Q S D V V H Q S V F ELI H T D D
400 410 420 430 440 450 460
CGAGCCATGTTCAGACAGCAGCTCCACTTTGCCTTAAACCCTCCTCCAATCCCCTCAGATGCAGACCTCTCCCAGAAC
RAM F R Q Q L H F A L N P P PIP S DAD L S Q N
480 490 500 510 520 530 540
TGTGAAAATGCAGTGATGTACAACCCAGAGCAGCTCCCCCCTGACAACTCCTCCTTCCTGGAGAGGAGCTTTTTCTGT
C E N A V M Y N P E Q L P P D N S S F L E R S F F C
550 560 570 580 590 600 610 620
CGCTTCCGATGTCTTTTGGACAACTCCTCCGGCTTCCTGGCCCTGAAGTTCCATGGGCGCTTGAAGTACCTCCATGGT
R F R eLL 0 N SSG F L A L K F H G R L K Y L H G
630 640 650 660 670 680 690 700
CAAAACTTTTCCAGGGACAGTGAGAGCTGTAAACGTATCCAGCTGGCTCTGTTTGCCATCGCTGTGCCTGTCCAGTCT
Q N F S R 0 S ESC K R I Q L A L F A I A V P v Q S
710 720 730 740 750 760 770 780
CCGTCAATTGTGGAGATCAGAGCCAAAATGCTCCTCTTCCAGACAAGGCACAAGCTGGACTTCACACCCACTGGCGTT
PSI V E I R A K M L L F Q T R H K L 0 F T P T G V
790 800 810 820 830 840 850
TGCAGCAGGGGGAAGATAATCCTGGGTTATTCTGAGACAGAGCTGTGTATGAAAGGCTCAGGATATCAGTTCATCCAT
C S R G K I I L G Y SET E L C M K G S G Y Q F I H
570 880 890 900 910 920
GCTGCTGACATGATGTACTGCGCTGACAACCACATCCGCATGATTAAGACCGGCGAGAGTGGCATG
A ADM M yeA 0 N H I R M I K T G E S G M
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ATTCGATTGAATTCTGCAGACAACGGTTCCGGCATGTGCAAAGCCGGATTCGCCGGAGACGACGCCCCTCGTGCTGTC
I R L N SAD N G S G M C K A G FAG D D APR A V
80 90 100 110 120 130 140 150
TTCCCATCCATCGTTGGTCGCCCAAGGCATCAGGGCGTGATGGTTGGTATGGGCCAGAAGGACAGCTATGTAGGTGAT
F PSI V G R P R H Q G V M V G M G Q K D S Y V G D
160 170 180 190 200 210 220 230
GAAGCCCAGAGCAAGAGAGGTATTCTGACCCTGAAGTACCCCATCGAGCACGGTATTGTGACCAACTGGGACGACATG
E A Q S K R GIL T L K Y PIE H G I V T N W D D M
240 250 260 270 280 290 300 310
GAGAAGATCTGGCATCACACCTTCTACAACGAGCTGAGAGTTGCCCCTGAGGAGCACCCCGTCCTGCTCACAGAGGCC
E K I W H H T F Y N E L R V APE E H P V L L TEA
320 330 340 350 360 370 380 390
CCTCTGAACCCCAAAGCCAACAGGGAGAAGATGACCCAGATCATGTTTGAGACCTTCAACACCCCCGCCATGTACGTT
P L N P K A N R E K M T Q I M F E T F N T PAM Y V
400 410 420 430 440 450 460
GCCATCCAGGCCGTGCTGTCCCTGTACGCTTCTGGTCGTACCACTGGTATCGTCATGGACTCCGGTGATGGTGTGACC
A I Q A V L SLY A S G R T T G I V M D S G D G V T
480 490 500 510 520 530 540
CACACAGTGCCCATCTATGAGGGTTACGCCCTGCCCCATGCCATCTTGCGTCTGGACTTGGCTGGCCGCGACCTCACA
H T V PlY E G Y ALP H A I L R L D LAG R D L T
550 560 570 580 590 600 610 620
GACTACCTCATGAAGATCCTGACAGAGCGTGGCTACTCCTTCACCACCACAGCTGAGAGGGAAATTGTGCGCGACATC
D Y L M K I L T ERG Y S F T T T A ERE I V R D I
630 640 650 660 670 680 690 700
AAGGAGAAGCTGTGCTATGTCGCCCTGGACTTCGAGCAGGAGATGGGTACCGCTGCCTCTTCTTCATCCCTGGAGAAG
K E K L C Y V A L D F E Q E MGT A ASS S S L E K
710 720 730 740 750 760 770 780
AGCTACGAACTCCCTGACGGACAGGTCATCACCATCGGCAATGAGAGGTTCCGTTGCCCAGAGGCCCTCTTCCAGCCT
S Y E L P D G Q V I T I G N E R F R C PEA L F Q P
790 800 810 820 830 840 850
TCCTTCCTTGGTATGGAGTCCTGCGGAATCCACGAGACCACCTACAACAGCATCATGAAGTGCGACGTTGACATCCGT
S F L G M ESC G I H E TTY N S I M K C D V D I R
870 880 890 900 910 920 930
AAAGACCTGTACGCAAACACCGTGCTGTCTGGTGGTACCACCATGTACCCTGGCATTGCTGACAGGATGCAGAAGGAG
K D L Y ANT V L S G G T T M Y P G I A D R M Q K E
940 950 960 970 980 990 1000 1010
ATCACAGCCCTGGCCCCATCCACTATGAAGATCAAGATCATTGCCCCACCAGAGCGTAAATACTCTGTCTGGATCGGA
I TAL A PST M K I K I I A P PER K Y S V WIG
1020 1030 1040 1050 1060 1070 1080 1090
GGCTCCATCCTGGCCTCCCTGTCCACCTTCCAGCAGATGTGGATCAGCAAGCAGGAGTACGATGAGTCTGGCCCCTCC
G S I LAS L S T F Q Q M W I S K Q E Y DES G P S
1100 1110 1120
ATCGTACATCGCAAGTGCTTCGGATCCTCGAATCAC
I V H R K C F G S S N H
Figure 7. RT-PCR cloning ofPLHC-1 AHR2 and J3-actin. (A) Degenerate primers
(Table 1) were used to amplify eDNA prepared from DMSO- (0.1 %) and TCDD- (2nM)
treated PLHC-1. (B) AHR2 sequence. (C) J3-actin sequence. Sequences corresponding
to the specific primers are indicated by bold face.
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Figure 8. PLHC-I AHR expression after cell cycle synchronization. (A) Cells were
synchronized with a double block of aphidicolin and sampled at subsequent times after
release. Cell cycle stages and AHR expression were assessed in sub-samples ofthe same
cells. (B) AHR mRNA expression was assessed by RT-PCR following aphidicolin
release. (C) AHR mRNA expression was normalized to ~-actin expression and
expression in randomly cycling cells harvested at the same time (CI for 0-4 hours, C2 for
6-12 hours). AHR protein expression was measured by TCDD specific binding in the
presence of InM 3H-TCDD. Specific binding was also normalized to time-matched,
randomly cycling controls. Absolute values were 50±5 finol/mg for all treatments.
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DISCUSSION
This work extends the usefulness of the PLHC-l cell line in toxicological studies,
particularly those involving HAH toxicity and cell cycle interactions. The rate of and
optimal conditions for proliferation have been established, and the abilities of several
chemicals to inhibit progression of the cell cycle have been evaluated. Interactions
between AHR signaling and cell cycle progression were investigated, and techniques for
future studies of such interactions have been developed.
Proliferation ofPLHC-l
The doubling time measured here for PLHC-l cells (22 hours) is similar to that of
commonly used mammalian cell lines of hepatocellular origin (e.g. 17 and 19 hours for
Hep2 and HEPA-lc1c7, respectively, Ma et al. 1996; Sourlingas et al. 1996), but shorter
than published values for fish cells (e.g. 44 hours for RTG-2, Ackermann and Fent 1998).
This is at least partially due to the lower temperature at which most other fish cells are
maintained (typically :0; 20°C vs. 30°C for PLHC-l), leading to slower metabolic rates.
Ackerman and Fent (1998) measured proliferation rates ofPLHC-l in different
media, and reported a doubling time of2 days in MEM with 10% FBS. However, the
cells in that study were seeded at 1.6x105/cm2, a density near which we found an
increased lag before onset of proliferation (Figure 2B). Our data at l.2x105/ cm2 in 10%
FBS predict a doubling time of2.5 days, so comparisons ofproliferative rate should
consider effects of initial seeding density as well as culture medium.
The longer lag time at low initial densities suggests that these cells release a
relatively stable autocrine factor into the medium, and that a minimum concentration of
that factor is required to support proliferation. Another possibility is that cell-cell
contacts are required for proliferation, and a few isolated areas containing a higher local
density of cells are proliferating at early time points. The ability ofFBS to support
proliferation at lower densities than calf serum supports the former hypothesis.
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TCDD inhibited proliferation in the particular sub-clone ofPLHC-1 used in the
experiments shown in Figure 6, but not in any subsequent sub-clones tested. This is
likely due to heterogeneity in the cells themselves and is similar to results obtained for
the loss ofCYPlA inducibility following serum starvation (Chapter 5). The instability of
these phenotypes suggests that the PLHC-I cell line may not be suitable for some studies
involving proliferative effects. This is a common problem with transformed cell lines,
which lack some of the controls on proliferation (e.g. tumor supressor activity) present in
vivo. Furthermore, the lack of consistent results regarding the effect of TCDD on cell
proliferation reflects the confounding state of the field as a whole, where variable and
sometimes contradictory results have been reported (Gierthy et al. 1984; Busser et al.
1987; Wolfle et al. 1988; Gottlicher et al. 1990; Lucier et al. 1991; Schrenk et al. 1992;
Fox et al. 1993; Gierthy et al. 1993; Hushka et al. 1995).
Cell Cycle and Synchronization
Lengths of the cell cycle stages were evaluated and used to determine the lengths
of incubations necessary to achieve synchrony with the inhibitors used. The plant amino
acid mimosine, the ribonucleotide reductase inhibitor hydroxyurea, and the nucleotide
analogue thymidine were all unsuccessful in inhibiting cell cycle progression. It is
possible that the structures of molecules affected by these inhibitors are sufficiently
different in fish to negate their effect. Another possibility is that the inadequacy of these
compounds is confined to PLHC-I cells. Results of attempts to synchronize other fish
cells are required to distinguish between these possibilities.
The DNA polymerase inhibitor aphidicolin produced a high degree of synchrony,
especially when a double-block strategy was used. Nocodazole, an inhibitor of
microtubule polymerization, combined with a physical shake-off did yield cells highly
synchronized in mitosis, but yields were too low to allow exponential growth following
reattachment. Nocodazole alone or after an aphidicolin block produced cell populations
less synchronous than with an aphidicolin double block. Therefore, the aphidicolin
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double block is presently the method of choice for synchronizing PLHC-l cells, although
the potential utility of several other methods has yet to be assessed.
Measurement ofCYP1A by Flow Cytometry
FACS techniques have been used to investigate variability in CYP1A inducibility
within cell populations. Miller and Whitlock (1981) measured benzo[a]pyrene (BaP)
metabolism with a flow cytometer by following disappearance of the fluorescent
substrate. This technique was used to isolate sub-populations of cells that were deficient
in CYP1A inducibility. BaP requires UV excitation, which is not always available on
cell sorters. This led to the development of ethoxyfluorescein ethyl ester (EFEE) as a
suitable diagnostic substrate (Miller 1983), and the technique has been applied to
populations ofprimary hepatocytes (Black et al. 1993).
EFEE is no longer available from the supplier (Molecular Probes), but we were
able to obtain a supply of the structurally related MFME. Structural similarity to
methoxyresorufin suggests that this may be a better substrate for CYP1A2 than CYPIAl,
but since fish CYF1A shares sequence and metabolic characteristics of both mammalian
CYP1As (Morrison et al. 1995; Woodin et a11999) we expected that MFME would be
metabolized by CYP1A in PLHC-l cells. Figure 5A demonstrates that MFME
metabolism is inducible by AHR agonists, and the small degree of overlap between the
induced and control populations suggests that this technique may prove useful for future
characterization of fish cell populations.
CYF1A immunofluorescence was less suitable for separating induced and control
populations (Figure 5B). Furthermore, analysis by immunofluorescence requires fixation
of the cells, so its applications are more limited (Mudzinski 1993; Stauber et al. 1995).
However, complications present in CYF1A activity assays (e.g. inhibition by inducing
compounds, see Chapters 3 and 4) are avoided by this technique. It may also prove
useful for analysis of samples collected under conditions where immediate analysis is
impossible.
61
AHR Cloning and Expression
AHR2 had previously been cloned from PLHC-l (preliminary results and
phylogenetic analysis in Hahn 1998a), but no AHRI isoforms were found in that effort.
Recent evidence that AHRI forms may be inducible by treatment with AHR agonists led
us to clone AHRs from TCDD-treated cells and examine a greater number of clones in an
attempt to isolate a PLHC-l AHRI. None were found in treated or control cells, and the
low expression of AHRI in Fundulus heteroclitus livers (Karchner et al. 1999) suggests
that AHRI either is not present or is expressed at extremely low levels in PLHC-l cells.
AHR cloned from teleost species other than F. heteroclitus are all AHR2 forms
(Karchner et al. 1999). For these reasons, measurement of AHR expression focused on
the cloned AHR2 form.
AHR2 mRNA expression did not vary among stages of the cell cycle (Figure 8C).
Thus, any cross-talk between the cell cycle and AHR signaling in PLHC-l cells is likely
to occur at the functional level. This is consistent with previous findings in HEPA-lclc7
and Swiss 3T3 cells (Scholler et al. 1994; Vaziri et al. 1996). In the former study,
nocodazole treatment inhibited CYP1A induction by interfering with binding of the AHR
to XREs; AHR expression was unaffected (Scholler et al. 1994). Growth arrest by serum
withdrawal led to a reduction in AHR expression, but reintroduction of serum in the
presence of a cell cycle inhibitor led to normal levels of AHR without cycle progression
(Vaziri et al. 1996), demonstrating that control of AHR expression was not coupled to the
cell cycle. In this context, it should be noted that PLHC-l AHR2, like other AHR2
forms, contains a MYCAD protein sequence at the location where AHRI forms,
including those sequenced in mammals, have an LXCXE sequence predicted to be
involved in association with pRb (Karchner et al. 1999).
These studies have established a foundation for future work investigating possible
links between AHR function and the cell cycle. Studies of controls on cell proliferation
should be performed in another system, since sub-clone heterogeneity and the
transformed phenotype of these cells reduces their utility. However, other interactions
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may be preserved, and the base of knowledge regarding ARR sequence, expression and
function in this cell line makes it the a valuable system in piscine AHR research. Future
studies should use the tools developed here to focus on possible functional interactions
between the ARR and cell cycle.
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Chapter 3: Cell Culture Serum Alters the Uptake aud Relative Potencies
of Halogenated Aromatic Hydrocarbons in PLHC-l Cells
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ABSTRACT
The effects of many chemicals on cellular processes are governed by their ability
to enter the cell, which is in tum a function ofthe composition of the cell's external
environment. To examine this relationship, the effect of serum in cell culture medium on
the bioavailability of cytochrome P450 lA (CYP1A)-inducing compounds was
determined in PLHC-l cells. The presence of 10% calf serum in the medium increased
the EC50 for induction of ethoxyresorufin O-deethylase (EROD) activity by 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) 20-fold as compared to treatment in serum-free
medium. Measurement of eHjTCDD uptake and Ah receptor binding indicated that the
apparent difference in potencies was a result of decreased bioavailability in the presence
of serum, effectively reducing the concentration of TCDD within the cells. Induction of
EROD and CYPIA protein in response to treatment with each of three coplanar
polychlorinated biphenyls (pCB congeners 77,126, and 169) was similarly affected by
serum, although the magnitude varied among inducers and assays. Relative potencies
(calculated as EC50TCDD I EC50pCB) for EROD induction by the three PCBs were
significantly higher in the absence of serum. However, serum showed no significant
effect on the relative potencies for CYPIA protein induction. These results demonstrate
that measured inducing potencies, and relative potencies for EROD induction, by
halogenated aromatic hydrocarbons are strongly dependent on the composition of culture
medium, which can lead to artificial differences in comparisons among cell types.
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INTRODUCTION
Cells in culture, both primary cultures and established cell lines, have become
important systems for investigating toxic mechanisms and evaluating the potential
toxicity ofpreviously unstudied compounds. Establishing accurate concentration-
response relationships in such systems is critical. The impact of artifacts introduced by
cultured-cell assays on the ability to compare responses among organisms, cell types, and
individual compounds is poorly understood. One potential source of error introduced in
such assays is the presence of serum in the culture medium. Serum is poorly defined,
comes from diverse donor animals, and has substantiallot-to-lot variability in
composition. In addition, cell lines have differing serum requirements, which introduce
further variability when comparing responses among cell lines. Serum factors affect the
proliferation rates of cells as well as a host of other metabolic processes.
The induction of cytochrome P450 lA (CYPIA) protein and catalytic activity in
cultured cells is being used with increasing frequency to compare the sensitivities of a
variety of organisms to the effects of halogenated aromatic hydrocarbons (HAR). Cells
from mammals (Sawyer and Safe 1982; Safe 1987; Tillitt et al. 1991), birds (Kennedy et
al. 1996a; Kennedy et al. 1996b) and fish (Clemons et al. 1996; Hahn et al. 1996b) have
been used to study the mechanisms of HAR toxicity and, in the absence of in vivo data, to
establish taxon-specific toxic equivalency factors (TEFs) for these compounds (van den
Berg et al. 1998). Comparisons of these results can reveal mechanistic differences in the
induction pathway of CYPIA among taxa. However, differences in CYPIA induction
among cell culture systems can also reflect the culture conditions of the cells.
Serum is known to impact the effects of CYPIA inducers and CYP levels in
cultured cells. For example, the presence of 10% fetal calf serum reduces the potency of
TCDD and PCB126 for inhibiting aromatase (CYPI9) activity in JEG-3 human
choriocarcinoma cells (Drenth et al. 1998). Serum and other medium components can
also alter the detectable levels of cytochromes P450 in rat hepatocytes (Turner and Pitot
1989; Hammond and Fry 1992) and HepG2 cells (Doostdar et al. 1988; Doostdar et al.
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1991). Despite these provocative findings, there has been no quantitative study of the
effect of serum on CYP1A induction by HAR. Because these compounds are very
hydrophobic and have limited aqueous solubilities, it can be expected that serum
components, such as proteins and lipids, would have a significant effect on the
bioavailability ofHAR for cell uptake. Since entry into the cell is the first step in the
toxic mechanism of these compounds, effects at this stage will be propagated (and
perhaps multiplied) through subsequent cell responses.
Following entry of an inducer into the cell, CYP1A induction is controlled by the
ligand-activated transcription factor, aryl hydrocarbon receptor (ARR). Binding ofHAR
to the ARR activates transcription ofCYPIA and mediates the toxicity of the inducer. A
compound's potency for CYPIA induction in vivo or in cultured cells is a strong
predictor of its toxicity (Safe 1984). Use of cell culture systems for rapid analysis of the
potential toxicity of individual compounds and environmental samples has increased with
refinements in CYP1A measurement techniques. Levels ofboth the CYP1A protein
(Bruschweiler et al. 1996a; Hahn et al. 1996b) and its ethoxyresorufin O-deethylase
(EROD) activity (Kennedy et al. 1993) can be measured directly in the same multi-well
plates used for growth of the cells and exposure to HAR.
The toxic equivalency approach utilizes these induction data to assess the toxic
potential of individual compounds or mixtures relative to that of2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD). The potency of a compound for eliciting a response
can be compared to the potency of TCDD for the same response by calculating the ratio
of their respective EC50s (concentration eliciting a 50% maximal effect). Such relative
potencies from several systems, including cultured cells, are then used to determine TEFs
for individual taxa (van den Berg et al. 1998).
In previous reports we have established the conditions and methods for measuring
EROD activity and CYP1A induction in PLHC-1 cells (Hahn et al. 1993; Hahn et al.
1996a; Hahn et al. 1996b), which are derived from a hepatocellular carcinoma of the
topminnow Poeciliopsis lucida (Hightower et al. 1988). Here we make use of those
findings to examine the role of serum in uptake ofHAR from the culture medium by
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cells. This represents a first step in examining the complex interaction between these
cells and their chemical milieu. The results provide compelling evidence that serum
affects the potency of AHR ligands, and likely other hydrophobic compounds, in cells in
culture.
MATERIALS AND METHODS
Chemicals and solutions
The 2,3,7,8-tetrachloro[I,6}H]dibenzo-p-dioxin ([3H]TCDD, stated purity:2:
97%, specific activity 27 Ci/mmol) was obtained from Chemsyn Science Laboratories
(Lenexa, KS). Its radiochemical purity was >91 % as determined by HPLC immediately
prior to use for uptake experiments and >96% for specific binding determination.
Unlabeled TCDD, 2,3,7,8-tetrachlorodibenzofuran (TCDF), PCB 77 (3,3',4,4'-
tetrachlorobiphenyl), PCB 126 (3,3',4,4',5- pentachlorobiphenyl) and PCB 169
(3,3',4,4',5,5'- hexachlorobiphenyl) were all obtained from Ultra Scientific (Kingstown,
RI). Resorufin, ethoxyresorufin and Amplex Red were obtained from Molecular Probes
(Eugene, OR). Peroxidase conjugated goat anti-mouse antibody was from Pierce
(Rockford,IL). All other reagents were obtained from Sigma (St. Louis, MO).
Phosphate-buffered saline (PBS) is 0.8% NaCl, 0.115% Na2HP04, 0.02% KCl,
0.02% KHZP04, pH 7.4. Phosphate buffer is 50 mM Na2HP04 with pH adjusted to 8.0
with 50 mM NaH2P04. TCDD, TCDF, and PCB solutions were prepared in dimethyl
sulfoxide (DMSO) as described previously (Hahn et al. 1996b). Concentrations of
[3H]TCDD solutions were verified by liquid scintillation counting (LSC) on a Beckman
LS5000TD.
Growth and Treatment ofCells
PLHC-l cells (Hightower et al. 1988) were grown at 30°C in minimum essential
medium (MEM) containing Earle's salts, nonessential amino acids, L-glutamine and 10%
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calf serum (Sigma C6278, lot 106H4628), as described previously (Hahn et al. 1993).
One day prior to dosing, cells were suspended to 0.5 to 1 xl 06 per ml and seeded into 48-
or 96-well plates (Costar; Cambridge, MA) at 0.5 or 0.2 ml per well, respectively. One
day later the medium was removed and replaced with fresh medium. Media used in the
experiments include MEM without serum, with 5% serum, with 10% serum, with 10%
delipidated, charcoal stripped calf serum (Sigma C1696), and with 10% fetal bovine
serum (FBS; Gibco; Grand Island, NY). Serum-free MEM supplemented with bovine
serum albumin (BSA) was also used. The cells were then treated by addition of solutions
dissolved in DMSO or DMSO alone (2.5 or 1.0 ~l/well). DMSO concentrations were s
0.5% (v/v) in all treatments. Following treatment, plates were incubated at 30°C for 24
hours unless otherwise indicated. For TCDD specific binding experiments, cells were
seeded into 24-well plates (Coming; Coming, NY) at 2x106 cells in 1 ml culture medium
per well. With the exception of the delipidated serum and FBS, all serum used was from
a single lot. None of the media or HAH treatments reduced cell viability, as assessed by
Trypan Blue exclusion.
EROD and protein assays
EROD activity was measured using a multiwell fluorescence plate reader by a
modification of the method of Kennedy et al (1995). Cells were rinsed once with 0.5 ml
room temperature PBS, and the EROD reaction was then initiated with the addition of
2~M 7-ethoxyresorufin in phosphate buffer (200 ~lIwell). The reaction was stopped after
eight minutes (resorufin production is linear with respect to time over this period; Hahn et
al. 1996b) with the addition of150 ~l ice-cold fluorescamine solution (0.15 mgiml in
acetonitrile). After a fifteen minute incubation, resorufin and fluorescamine fluorescence
were measured. Resorufin and protein concentrations were determined from standard
curves prepared in the same plate. BSA was used for the protein standard curve. In some
experiments, the EROD reaction was followed kinetically over eight minutes, as
described previously (Hahn et al. 1996b). Protein was measured using fluorescamine as
described above.
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TCDD Uptake
PLHC-1 cells were seeded in 48-well plates, grown for one day, and then fed
media as indicated in figure legends. They were treated with [3H]TCDD in DMSO as
above and incubated at 30°C. At 0.5, 1,2,7 and 24 hours post-treatment, the culture
medium was transferred from each well to a separate vial. Cells were removed by
sequential incubation with two, 0.2 ml a1iquots of 0.05% (w/v) trypsin, which were then
combined in a single vial. Cell removal was verified by microscopy. TCDD retained on
well surfaces was extracted with a single 1 ml aliquot of hexane. TCDD associated with
each fraction (medium, cells and well) was determined by LSC. Protein concentrations
were determined using fluorescamine in duplicate wells fed each medium and treated
with DMSO alone.
TCDD Binding
Specific binding of eH]TCDD in PLHC-1 cells was measured by a whole-cell
filtration assay (Dold et al. 1990). One day after seeding in 24-well plates, the cells were
fed 0.5 ml of the indicated media. Cells were treated with 0.18 nM eH]TCDD in the
presence or absence of 40 nM TCDF and incubated 2 hours at 30°C. This time was
determined to be sufficient to achieve a steady state of bound radio1igand (not shown).
Following the incubation, medium was removed, cells were rinsed with 0.5 m1 ice-cold
PBS, and then detached with 0.5 ml trypsin. The trypsin was inactivated by the addition
of 0.5 ml ice-cold culture medium (with 10% serum), and cells from each well were
collected under vacuum on a 25 mm Whatman GFIF filter that had been prewetted with
PBS. Filters were then washed four times with 2.5 ml acetone that had been precooled to
-80°C. Replicates were processed in batches of twelve on a Millipore 1225 filter
manifold. Radioactivity remaining on the filter was quantified by LSC. Specific binding
was measured in triplicate as the difference of each of three total binding (without TCDF)
replicates and the average of three nonspecific binding (with TCDF) replicates in each
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medium. Protein concentrations were determined in duplicate wells fed each medium
and treated with DMSO alone.
ELISA Assay
Enzyme-linked immunosorbence assays to detect CYPIA were performed
essentially as described (Bruschweiler et al. 1996a). One day after treatment in 96-well
plates, cells were fixed in 50% ethanol 15 minutes, in 75% ethanol 15 minutes, and in
95% ethanol 30 minutes. After washing three times with PBS, non-specific antibody
binding was blocked with 10% fetal bovine serum and 2% BSA in PBS for I hour. The
primary antibody, mouse anti-scup CYPIA monoclonal antibody 1-12-3 (10 flg/ml; Park
et al. 1986), was then added in 100 fll blocking solution for I hour. After three washing
steps with PBS, 100 fll secondary antibody, peroxidase conjugated goat anti-mouse
(1: I000 in blocking solution), was added for I hour. After another three washing steps
withPBS, 100 fll substrate solution (100 flM Amplex Red, 100 flM H202 in phosphate
buffer, pH=7.0) was added for 30 minutes. All incubations were performed at room
temperature. Resorufin formation was measured in the fluorescence plate reader. For
each treatment the background fluorescence, defined as the fluorescence detected in
untreated cells, was subtracted, and all values were normalized to the maximum response
measured. The assay was also performed on wells without cells or without the addition
of primary antibody, and these controls yielded fluorescence values nearly identical to
those in untreated cells, consistent with our earlier results detecting no CYPIA protein or
EROD activity in untreated cells (Hahn et al. 1996b).
Curve Fitting and Statistical Analysis
For determination of dose-response relationships, EROD data were fit to a
modified Gaussian function, and CYPIA induction data were fit to a logistic function.
The rationale for use of these functions has been described previously (Kennedy et al.
1993; Hahn et al. 1996b). The Gaussian function properly reflects the biphasic nature of
EROD induction, while a logistic function forms a plateau at higher inducer
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concentrations, consistent with CYP1A protein induction in these cells. Statistical
analyses were performed with the aid of Excel (Microsoft; Redmond, WA) and JMP IN
(SAS Institute, Inc.; Cary, NC) software.
RESULTS
Culture Medium Composition Affects TCDD Uptake
While investigating the effects of culture media composition on responses to
TCDD in PLHC-1 cells, we found that TCDD was more potent in eliciting an EROD
response when added to cells in serum-free medium (So) than in medium with 10% calf
serum (SI0; Figure 1). In this experiment, cells were grown in SlO that was replaced by
either So or SlO immediately prior to treatment with TCDD. CYP1A-catalyzed EROD
activity was measured 24 hours later. The dose ofTCDD required to elicit a 50%
maximal induction ofEROD was about 20-fold less in cells treated in So than in cells
treated in SlO (Table 1). A separate comparison ofEROD induction in medium
supplemented with 10% FBS showed that the EC50 was about 4-fold lower than in SlO
and 5-fold higher than in So (not shown). Consistent with earlier results (Hahn et al.
1996b), there was no basal EROD activity in any ofthe media.
Table 1. Effect of medium on dose-response relationship parameters for EROD rates in
PLHC-1 cells treated with TCDD.
Medium EC50 (nM)"
So 0.022
EC100 (nM)"
0.138
SlO 0.474 2.590
Modified Gaussian functions were fit to data from Figure 1 (So and SlO) to obtain these
values.
a: EC50 and ECIOO are nominal TCDD concentrations producing 50% and 100% of
maximal EROD induction, respectively.
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Figure 1. Effect of serum on potency ofEROD induction by TCDD. Cells were fed
culture medium with (SlO) or without (So) 10% calf serum immediately prior to treatment
with TCDD. EROD activity (pmol of resorufin formed per minute per mg of cellular
protein) was measured 24 hours later. The 0.0001 nM TCDD concentration represents
treatment with DMSO alone. Points are means ± SE of four wells. The modified
Gaussian fits to these data are plotted.
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In order to determine whether the culture medium affected partitioning ofTCDD
within the environment of a well, we measured the uptake of eH]TCDD. Four different
serum treatments were compared: So, SlO,lO% delipidated serum (SDL), and 5% calf
serum (Ss). After growth in SlO, PLHC-1 cells were treated with 1 nM eH]TCDD in
each of these media and sampled at subsequent times to determine the timing ofTCDD
uptake by the cells (Figure 2A). The TCDD associated with cells declined steadily from
an early maximum and reached steady state between 2 and 7 hours post-treatment.
TCDD was added directly to the medium overlying the cells in a DMSO solution, and the
higher density of that solution accounts for the large early values of cell-associated
TCDD in the adherent PLHC-1 cells. Once a steady state had been achieved, cell-
associated TCDD was 2-3 fold greater in cells treated in So or SDL than in Ss or SlO.
Having established the timing of TCDD uptake, it was possible to determine its
partitioning in wells at different concentrations. Using the same four media, the fraction
of total TCDD added that was associated with the cells was determined 24 hours post-
treatment for four different concentrations ofTCDD (Table 2 and Figure 2B). Again, the
fraction of TCDD associated with the cells was highest in the cells treated in So and
lowest in those treated in SlO. The fraction ofTCDD associated with cells was nearly
constant between 0.01 nM and 1 nM within each medium treatment but declined at 10
nM (Figure 2B). The fraction of TCDD in the overlying medium was similar within each
medium treatment at all concentrations ofTCDD; at 10 nM a greater fraction of TCDD
was found associated with the polystyrene walls of the wells (Table 2).
Since the delipidation process may remove several serum constituents, it was
necessary to determine which component(s) of serum was responsible for retaining
TCDD in the medium. The effect of protein concentration on TCDD uptake was
investigated. Cells were treated with 1 nM TCDD as above, except that additional
treatments consisting of So supplemented with increasing concentrations ofBSA were
added (Figure 2C). Protein at concentrations near those in SlO or SDL (5 to 8 mglml
according to the supplier) produced uptake identical to that in SDL, indicating that protein
and lipid both contribute to reduced uptake in the presence of serum.
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Table 2. Fractions of TCDD associated with culture medium, PLHC-1 cells, and well
surfaces.
Medium Nominal TCDD Fraction of total TCDD associated with
treatment concentration (nM)
Medium Cellsa Wells
So 0.01 37% 36% (1.4) 27%
0.1 33% 47% (15) 21%
1 33% 44% (160) 23%
10 28% 16% (460) 56%
SDL 0.01 72% 14% (0.75) 14%
0.1 71% 18% (5.7) 10%
1 71% 19% (78) 9%
10 59% 9% (261) 33%
Ss 0.01 74% 15% (0.67) 11%
0.1 83% 12% (3.6) 5%
1 78% 17% (61) 5%
10 74% 6% (180) 20%
SIO 0.01 79% 11% (0.56) 10%
0.1 90% 7% (2.4) 3%
I 86% 12% (45) 2%
10 79% 5% (170) 16%
PLHC-1 cells were grown in SlO for 24 hours after subculture, fed the indicated medium,
and treated with the indicated nominal concentration of [3H1TCDD. Partitioning ofthe
eH1TCDD was determined after 24 hours as described in Materials and Methods.
a: average pmol of eH1TCDD associated with the cells in a well for each medium
treatment and eH1TCDD concentration are indicated in parenthesis.
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Figure 2. Effect of serum on TCDD uptake in PLHC-l cells. Cells were fed culture
medium with no serum, 10% delipidated calf serum (SDd, 5% calf serum (Ss), 10% calf
serum, or increasing concentrations ofBSA (numbers in mg/ml). (A) Cells were treated
with 1 nM [3H1TCDD and sampled at the indicated times to determine the amount of
TCDD associated with the cells. Cell-associated TCDD was normalized to protein
content to account for differences in cell number among the treatments. Points are means
of duplicate wells. (B) Cells were treated with the indicated concentrations of eH1TCDD
and collected after 24 hours. The ordinate represents the fraction of the total amount of
TCDD recovered that was associated with the cells. * indicates significantly different
from all other medium treatments (P<0.05, ANOVA). (C) As B, except that So
supplemented with 10, 5,2.5, 1, and 0.5 mg/ml BSA were also compared, and treatment
was with 1 nM TCDD. Points are means ± SE of three wells.
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Differences in Uptake Affect TCDD Binding by the AH Receptor
The effect ofmedium composition on specific binding of TCDD by AHR in
PLHC-l cells was measured. Cells were grown in SIO, fed one of the four media, treated
with 0.18 nM [3H]TCDD in the presence or absence of 40 nM TCDF, and incubated for
two hours. This concentration ofTCDD was selected because it is near the value at
which cells treated in So or SIO showed the greatest difference in EROD response (Figure
1). Binding of TCDD to the AHR was measured by a whole-cell filtration assay (Dold et
al. 1990). The amount ofTCDD bound was 3-4 fold higher in cells treated in So, and
showed the same relationship among medium treatments as the fraction ofTCDD
associated with the cells, i.e. So» SDL> S5> SIO (Figure 3). Thus, the differences in
specific binding reflect the differing concentrations ofTCDD within the cells among the
treatments, as shown in Figure 2.
Differences in EROD Response are Due to Differences in TCDD Uptake
PLHC-l cells were fed the four media and treated with 0.01,0.1,1 or 10 nM
eH]TCDD exactly as for the uptake experiment, except that after 24 hours the levels of
CYPlA-catalyzed EROD activity were measured (Figure 4A). As expected from the
results shown in Figures 1 and 3, a greater amount of TCDD bound by the AHR in So led
to a greater induction ofEROD even though nominal TCDD concentrations were the
same. For example, at 0.1 nM TCDD, the magnitude of the EROD response among the
medium treatments showed the same rank order as the magnitude ofTCDD specific
binding. Though the use of fewer concentrations ofTCDD makes determination ofa
dose-response relationship less precise, the induction potencies in this assay were similar
to those seen in the initial experiment (Figure 1).
When the dose-response curves are expressed in terms of cell-associated TCDD
rather than nominal concentration in the medium, the points from the individual
treatments align into a single biphasic induction curve typical ofEROD induction by
TCDD in PLHC-l cells (Figure 4B). This relationship suggests that the difference in
induction potency among media used for treatment ofPLHC-l cells is due solely to
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Figure 3. Effect of serum on specific binding of TCDD in PLHC-l cells. Cells were fed
the indicated medium immediately prior to treatment with 0.18 nM [3H]TCDD in the
presence or absence of200-fold molar excess TCDF. Specific binding was determined by
the whole-cell filtration assay ofDold and Greenlee (1990). Specific binding ofTCDD is
reported as finol ofTCDD per mg of total cellular protein. Points are means ± SE ofthree
specific binding determinations.
79
A60
!--e-SO
50 i-.-SDL
Ci i--e-s5
.§ 40 :___ 510c]
<5 30
E
.5
c 200
'"UJ 10
---
0
0.001 0.01 0.1
Nominal [TeDD] (nM)
10
B
60,.- -,
50
c;
.§ 40
c
.§
~ 30.
Eo
c~ 20_
UJ
ioSO~1
I
".. SOL
.55
i. 510
10
•
100.10.01
o ~==:::::__..~._----_----_----:!"=!
0.001
pmal TCDD I mg protein
Figure 4. TCDD uptake and EROD induction. (A) EROD rates versus nominal TCDD
concentration in medium. Cells were fed and treated as in Figure 2B. EROD activity was
measured 24 hours later. The 0.001 nM nominal TCDD concentration represents
treatment with DMSO alone. Points are means ± SE of four wells. (B) The EROD rates in
(A) plotted against cell-associated TCDD determined as in Figure 2B. TCDD
concentrations are expressed as pmol of cell-associated TCDD per average mg cellular
protein for each treatrDent. Average cellular protein contents for the medium treatments
were 92,116,116 and 134 flg per well for So, SOL, Ss, and SIO, respectively. The
Gaussian fit to the data is plotted (EC50 = 0.025 pmol/mg, ECIOO = 0.135 pmol/mg).
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differential partitioning of TCDD between the media and the cells. The concentrations of
TCDD necessary to induce given EROD responses can be expressed in terms of pmol of
TCDD per mg of cellular protein for comparison across all treatments (EC50 = 0.025
pmol/mg, EC100 = 0.135 pmol/mg). Since protein content of the wells is linear with
respect to cell number (Hahn et al. 1996b), TCDD doses shown are proportional to the
dose per individual cell.
Culture Medium Composition Alters the Relative Potency ofHAH
We wished to determine if serum reduces the uptake of other HAH to the same
degree that it does TCDD. PLHC-1 cells were exposed to each of three coplanar PCBs in
medium with or without serum, and EROD activity was assayed 24 hours later (Figure 5).
The EC50 values for the responses are shown in Table 3. For each compound, the EC50
in So was lower than that in SIO. The differences ranged from about 20-fold for TCDD to
about 2000-fold for PCB 77, although there is substantial uncertainty in the latter value,
because a precise EC50 is difficult to obtain for this compound in SIO (e.g. Hahn et al.
1996b).
Since the potency ofEROD induction by PCB 77 in PLHC-1 cells is quite
variable and the efficacy ofEROD induction was much lower for both PCBs 77 and 169,
levels ofCYF1A protein were analyzed more directly using an ELISA. Cells were
treated as for the EROD assay, but were fixed and analyzed for CYP1A content using the
monoclonal antibody 1-12-3, as described in Materials and Methods (Figure 6).
As with EROD induction, EC50 values for ELISA-measured CYF1A induction
(Table 3) were consistently higher in SIO. However, the magnitudes of the increases (the
ratio in the final column of Table 3) were five- to ten-fold smaller with PCBs 77 and 169
for CYP1A protein as compared to EROD. The EC50 for induction of CYF1A protein
was greater than the EC50 for EROD induction in all treatments, in agreement with our
previous results (Hahn et al. 1996b).
The ELISA as performed provides only a relative measure of CYF1A protein content, but
the range of values produced and the pattern of induction by TCDD in SIO closely parallel
those previously obtained by Western blot (Hahn et al. 1996b). This indicates that the
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Figure 5. Effect of serum on potency for EROD induction by coplanar PCBs. Cells were
treated and assayed as in Figure I, except that treatment was with (A) PCB 77, (B) PCB
126, or (C) PCB 169. The lowest concentration in each panel represents treatment with
DMSO alone. Points are means ± SE of four wells. The modified Gaussian fits to these
data are plotted.
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response as measured in this assay can be correlated with the values from a more
quantitative approach. Furthermore, maximal levels of detected fluorescence from the
ELISA assay were similar among all the treatments, indicating that the maximally
induced level of CYPIA is similar among the four compounds, regardless of medium
used.
The EC50s for the EROD and ELISA assays were used to calculate relative
potencies for the four compounds within each medium treatment (Table 4). Relative
potencies as determined by EROD assay for the three PCBs were significantly lower in
SIO than in So. In contrast, when CYPIA induction was measured by ELISA, there were
neither consistent nor significant differences in relative potencies determined with cells in
the two media.
Table 3. Effect of serum on CYPIA induction EC50s measured by EROD and ELISA
for TCDD and three coplanar PCBs.
EROD EC50 (uM)" Ratio of ELISA EC50 (uM)" Ratio of
So SIO EC 50sb So SIO EC 50sb
TCDD 0.016±0.004 0.33±0.10 21 0.021±0.003 1.2±0.3 57
PCB 169 1.58±0.43 246±102 160 38±5 1400±I48 37
PCB 126 0.029±0.004 0.99±O.l8 35 0.24±12 4.4±2.7 19
PCB 77 0.73±0.30 1500±550 2000 13±5 2200±82 170
a: EC50s were determined from modified Gaussian functions for EROD dose-responses
and from logistic functions for ELISAs. Values are means ± SE of 3 or 4 replicate
determinations. Figures I, 5 and 6 are examples of one such replicate.
b: ratio = EC50(SIO) I EC50(So) for each compound and assay
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Figure 6. Effect of serum on potency of CYPIA induction by BAH. Cells were treated as
in Figures 1 and 5. CYPIA content was measured 24 hours later by ELISA. The
compounds used were (A) TCDD, (B) PCB 77, (C) PCB 126, or (D) PCB 169. The
lowest concentration in each panel represents treatment with DMSO alone. Points are
means ± SE of four wells. The logistic fits to these data are plotted.
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Table 4. Effect of serum on determination of induction relative potencies.
EROD Relative Potencya R . b ELISA Relative Potencya R . batlO abo
So SIO So SIO
TCDD 1 1 1 1 1 1
PCB 169 0.0075 0.0016 0.21 c 0.0016 0.00049 0.31
± 0.0018 ± 0.0010 ± 0.0008 ± 0.00009
PCB 126 0.67 0.12 0.18 c 0.031 0.075 2.4
± 0.18 ±0.02 ± 0.004 ± 0.041
PCB 77 0.017 0.00040 0.02 c 0.0016 0.00054 0.34
± 0.005 ± 0.00013 ± 0.0008 ± 0.00012
a: Relative potencies were determined for each medium treatment and assay by dividing
the EC50 for TCDD by the EC50 for each PCB. Values are means ± SE of 3 or 4
replicate determinations.
b: ratio = relative potency (SIO) I relative potency (So) for each compound and assay
c: Indicates relative potency in 10% serum is significantly lower than relative potency in
0% serum (p<0.05) by one-tailed paired t-test. Relative potencies from each experiment
were paired for the analysis.
DISCUSSION
This series of experiments demonstrates a reduction in HAH uptake by PLHC-I
cells when bovine serum is included in the culture medium. This in tum leads to
decreased occupancy of the AHR and an apparent decrease in the CYPIA induction
potency of the compounds. Furthermore, the magnitude of this decrease is not the same
among the HAH studied; this may lead to changes in relative potencies for EROD and
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CYFIA induction among the compounds. Serum will likely have a similar effect on the
uptake of other hydrophobic chemicals.
HAH Partitioning in a Multi-well Plate
Our measurements ofTCDD partitioning demonstrate that the majority of the
compound remains in the medium when serum is present. Thus, small changes in
medium composition could have significant effects on the amount of compound that
enters the cells. The fraction of the total TCDD associated with the polystyrene wells
was approximately equal to that found in the cells, suggesting that the composition of the
chamber used for treatment also could affect the amount of compound that reaches the
cells.
The percentage of total TCDD associated with the PLHC-l cells was lowest at the
highest nominal concentration of TCDD (10 nM), regardless of the medium used for
treatment (Table 2). Also, at 10 nM TCDD the fraction associated with the well walls
increased, perhaps because at this concentration the cells were saturated with TCDD, and
the compound was diffusing through the basal membrane of the cells to the floor of the
well. Reduced diffusion at low TCDD concentrations is consistent with the finding of Yu
et al (1997) that H4IIE cells apparently reduced sorption of PCB 77 to the floor of culture
plates. That same study also found that a majority ofPCB 77 (-75%) remained in the
medium, which was supplemented with 15% FBS. They found no effect of carrier
(isooctane vs. DMSO) on the fraction of the compound associated with the cells, which
was at most 5%. Uptake studies with radiolabeled PCB77 have demonstrated similarly
low levels associated with PLHC-l cells (A. Patel and M.E. Hahn, unpublished results),
suggesting that HAH partitioning is consistent between these two cell types and their
media. In contrast, Schirmer et al (1997) found that the presence of 10% FBS in culture
medium greatly altered the solubility of fluoranthene, but did not significantly change the
amount ofthat compound associated with cells from two fish lines.
AHR Occupancy and CYPIA Induction
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The magnitude of the effect of serum on AHR occupancy was nearly identical to
the difference in uptake ofTCDD by cells (compare Figure 3 and the 0.1 nM TCDD
group in Figure 2B). This supports a direct relationship between the amount of
compound associated with the cells and the amount bound by the AHR when the
concentration of TCDD is sufficiently below the amount required for receptor saturation.
The latter condition is satisfied here, since the concentration used was less than the KD
for TCDD binding to the AHR (KD=0.8 nM in So; Hestermann et aI., in preparation).
However, comparison of receptor occupancy and induction ofEROD or CYPIA
does not reveal a direct relationship like that occurring between TCDD uptake and
receptor occupancy. There was a 4-fold increase in receptor occupancy in cells in So
rather than SIO medium, but a much larger increase in CYPIA content (compare Figure 3
with the 0.1 nM nominal TCDD concentration in Figures I and 6A). This is most likely
the result of a nonlinear occupancy-response relationship (also known as "spare
receptors" or "receptor reserve"; Kenakin 1999) for TCDD and the AHR in these cells.
Under such conditions, sub-maximal receptor occupancy will produce maximal cell
response, so that small changes in occupancy would produce much larger changes in
downstream responses. We are pursuing the precise nature of this relationship in the
PLHC-I cell line.
Relative potencies of the three coplanar PCBs determined in So were significantly
higher than those determined in SIO for EROD response but not CYPIA protein
induction. This suggests that the presence of serum has an effect on CYPIA catalytic
activity that is separate from its induction via the AHR. The biphasic dose-response
relationships typical ofEROD induction are a result of the balance between CYPIA
induction and competitive inhibition of catalytic activity by the inducer at higher
concentrations (Gooch et al. 1989; Hahn et al. 1993; Petrulis and Bunce 1999).
Inhibition lowers EROD induction EC50s relative to EC50s for induction of CYPIA
protein, and thereby increases the apparent relative potency for the EROD response
(Hahn et al. 1996b). It therefore seems likely that serum influences the inhibitory effect
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of the inducing compounds. Alternatively, there may be serum components that alter
EROD activity in PLHC-1 cells by another mechanism.
Implications ofReduced Uptake
Perhaps the greatest potential for error in interpretation of in vitro bioassay data
suggested by our results is in comparison of induction EC50s and relative potencies
among cell lines. Cell lines vary widely in culture medium contents. Serum may be
absent or present at concentrations of up to 20%, and may come from a variety of animals
and different developmental stages. Based on our results, such variations in media
composition will affect cellular uptake ofHAH and thus measured CYP1A induction
potencies. Differences in potencies thus might incorrectly be attributed to mechanistic
differences in CYP1A induction among the cell types and lead to false conclusions about
relative sensitivities of the cells to the HAH in question.
One solution to this potential problem is to treat different cells in a single
medium. Serum-free medium is the best candidate, since variations in composition
among the chemically defined basal media (e.g. MEM, DMEM, RPMI-1640, F12) should
have a negligible effect on bioavailability. Using serum-free medium also allows the
greatest sensitivity in response to inducing compounds. The ability of each cell type to
respond to HAH in serum-free medium should be determined, since serum withdrawal
greatly reduces AHR content in Swiss 3T3 cells (Vaziri et al. 1996) and can abrogate
CYP1A induction in PLHC-1 cells after 48 hours (Chapter 5). As noted previously, the
presence of serum also affects the levels of cytochromes P450 in some cultured cells
(Doostdar et al. 1988; Turner et al. 1989; Doostdar et al. 1991; Hammond et al. 1992).
PLHC-1 cells have recently been adapted to long-term culture in media with
serum replacements (Ackermann et al. 1998), providing promise for their future use in a
chemically defined medium. Such media should reduce the problems with lot-to-Iot
variability that can be encountered with serum; however, the serum replacements used
still have a high protein and/or lipid content, which can be expected to reduce
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bioavailability as serum does. In addition, the ability of cells grown in these media to
respond to HAH exposure has not been detelTI1ined.
The effect of serum on bioavailability is also a concern for other assays involving
uptake of hydrophobic compounds. The reduction in specific TCDD binding in the
presence of 10% serum shown here is an example of such an assay. Serum composition
also affects bioavailability of estrogenic compounds (Arnold et al. 1996; Nagel et al.
1997). This suggests that the effect of serum is a general one, and its magnitude should
be detelTI1ined for individual compounds. Comparisons of apparently anomalous results
among assays perfolTI1ed in different laboratories or cell lines should take this factor into
account, and previous conclusions regarding extrapolation from cultured cells may
require reexamination.
This report continues our work of establishing the utility and optimal conditions
for use ofPLHC-l cells in studying the mechanisms ofHAH action. It also establishes a
framework for measuring other effects of culture medium composition on AHR signal
transduction in these cells. Through continued use of this model we hope to gain a better
understanding of the molecular mechanisms that ultimately result in HAH toxicity. By
comparing the shared and distinct features of AHR signal transduction in a variety of taxa
we can also better approach questions of AHR function and evolution.
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Chapter 4: Stimulus-Response Relationships Demonstrate the Contributions of
Affinity and Intrinsic Efficacy to Aryl Hydrocarbon Receptor Ligands Potency
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ABSTRACT
Pharmacological models of receptor action have power for describing properties of
ligand-receptor interaction and are necessary for mechanism-based risk assessment of
receptor-mediated toxic effects. In order to build such a model for the aryl hydrocarbon
receptor (AHR), binding affinities and CYPIA induction potencies were measured in
PLBC-l cells for ten halogenated aromatic hydrocarbons (BAH): 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD), 2,3,7,8-tetrachlorodibenzofuran (TCDF), and
polychlorinated biphenyl (PCB) congeners 77,81, 105, 118, 126, 128, 156 and 169.
From these data an operational model of AHR action was used to determine intrinsic
efficacies of these ligands. TCDD, TCDF, and non-artha-substituted PCBs 77,81, 126
and 169 behaved as full agonists and displayed high intrinsic efficacy. In contrast, the
mono- and di-artha substituted PCBs bound to the AHR but displayed lower or no
intrinsic efficacy. PCB 156 was a full agonist, but with an intrinsic efficacy 10- to 50-
fold lower than non-artha-substituted PCBs. PCB 118 was a very weak partial agonist.
PCBs 105 and 128 were shown to be competitive antagonists in this system. When
induction ofCYP1A by mixtures of PCB 126, 128 or 156 with TCDD was measured,
both PCB 156 (a low intrinsic-efficacy agonist) and PCB 128 (a competitive antagonist)
inhibited the response to TCDD. The stimulus-response model predicts that only 1-2% of
the receptors in the cell need be occupied to achieve 50% ofmaximal CYP1A induction
by one of the high intrinsic efficacy agonists, demonstrating the existence of "spare"
receptors in this system. These data show that the insensitivity ofPLBC-l cells to artha-
substituted PCBs is due to both reduced affinity and reduced intrinsic efficacy as
compared to non-ortho-subsituted PCBs. More generally, separation of AHR ligand
action into the properties of affinity and intrinsic efficacy allows for improved prediction
of the behavior of complex mixtures of ligands, as well as mechanistic comparisons
across species and toxic endpoints.
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INTRODUCTION
The aryl hydrocarbon receptor (ARR) is a cytosolic receptor that mediates the
toxicity of a variety of compounds, most notably 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD) and structurally related halogenated aromatic hydrocarbons (HAR). The
relationships among chemical structures and biological potencies of ARR ligands have
been studied for decades in order to predict their toxicity both individually and in
mixtures. As the mechanisms of action for the ARR have been elucidated, the need for
application ofpharmacological principles to describe these phenomena has become clear
(Poland 1991; Poland 1996). A "Receptor Biology Roundtable" has called for
quantitative assessment of ligand-receptor interactions to aid in mechanism-based risk
assessment of environmental toxicants (Limbird and Taylor 1998). These quantitative
pharmacological models have broad applicability, including extrapolation from model
organisms to humans and expansion to other receptor-mediated toxicants, such as
hormonally active compounds.
Downstream responses to receptor binding must be evaluated to categorize a
ligand as a full agonist, partial agonist or antagonist l . The potency of the ligand for
eliciting a response (i.e. the dose-response relationship) depends on the properties of
affinity and efficacy. Affinity is the strength of the interaction, or binding, to the
receptor, and efficacy is the ability of that ligand-receptor complex (or stimulus) to
produce a response (Ariens 1954; Stephenson 1956). Affinity is a property of the ligand
and receptor, while both ligand- and tissue-specific properties affect efficacy. Tissue-
specific properties (often collectively termed "coupling") include the concentrations of
receptors and other molecules required for transduction of the signal initiated by the
ligand-receptor complex. Intrinsic efficacy of a ligand is the ability of that ligand to
convert one receptor to an active form, and is independent of tissue coupling (Furchgott
1 I have followed the definitions of these and other terms related to receptor
pharmacology as outlined in reference (Jenkinson et al. 1995).
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1966i. Thus, individual ligands can be characterized by their affinity for the receptor
and by the intrinsic efficacy with which they activate the receptor.
The best-studied and most frequently used measure of response to AHR agonists
is AHR-mediated cytochrome P4501A (CYP1A) induction. Following agonist binding,
the AHR trans10cates to the nucleus, forms a heterodimer with ARNT, and interacts with
enhancer elements (XREs) and transcriptional co-factors to activate transcription of
several genes, including CYPIA1 (for review see Hankinson 1995; Schmidt et al. 1996).
Levels of this enzyme may be quantified by immunoassay or by its ethoxyresorufin-O-
deethylase (BROD) activity.
The properties of several AHR ligands have been evaluated by measuring
response (typically CYP1A induction) following co-treatment with a known agonist
(usually TCDD) and the compound of interest. These include partial agonists, such as 6-
methy1-1,3,8-trichlorodibenzo-p-dioxin and a-naphthoflavone (Blank et al. 1987; Astroff
et al. 1988; Merchant et al. 1992; Santostefano et al. 1992), and antagonists, including
several substituted flavones (Lu et al. 1995; Reiners et al. 1998; Ciolino et al. 1999;
Henry et al. 1999) and di-artha substituted polychlorinated biphenyls (PCBs) (Biegel et
al. 1989; Aarts et al. 1995). In some instances AHR binding affinities and/or response
inhibition IC50s were determined, but intrinsic efficacies of these ligands were not
considered.
Here we report the characterization of AHR ligands in a system where stimulus
(AHR binding) and response (CYP1A induction) were measured in whole-cell assays,
2 It is important to note that a tissue with sufficient receptors and other required
molecules will still produce a maximal response after treatment with a ligand that has
comparatively low intrinsic efficacy. Thus, due to differential coupling the same
compound can be a full agonist, partial agonist, or antagonist in different tissues in the
same organism (Kenakin 1999). Here I will refer to high-intrinsic efficacy and low-
intrinsic efficacy agonists to indicate properties of the ligand-receptor interaction that are
independent of tissue. The terms full and partial agonist are used to describe agonists that
are capable or incapable, respectively, of inducing the maximal tissue response.
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and these data were used to build a stimulus-response model for the cells of interest. The
primary use of this model was to develop a pharmacological approach to distinguish the
contributions of affinity and intrinsic efficacy to AHR ligand potency. The utility of this
approach was demonstrated by using these data to detennine the molecular basis for the
relative insensitivity offish to ortho-substituted PCBs. The reduced potency ofthese
compounds was first suggested by in vivo studies of CYPIA induciblity (Gooch et aL
1989) and later supported by embryotoxicity (Walker et at 1991). We chose the PLHC-l
cell line, derived from a hepatocellular carcinoma of the teleost Poeciliopsis lucida
(Hightower et al. 1988), because these cells express AHR (Hahn et at 1993; Hestermann
et al. in press) and an inducible CYPIA (Hahn et al. 1993; Hahn et al. 1996a; Hahn et al.
1996b; Hestennann et al. in press). Ten HAH, including a representative dioxin (TCDD),
furan (2,3,7,8-tetrachlorodibenzofuran; TCDF), and non-ortho-, mono-ortho-, and di-
ortho-substituted PCBs were chosen to include known agonists as well as suspected
partial agonists and antagonists. Stimulus-response relationships detennined for these
HAH broaden our understanding of the activities of these compounds and provide a
framework for future studies of other organisms, tissues, AHR ligands and response
endpoints.
MATERIALS AND METHODS
Chemicals and solutions
The 2,3,7,8-tetrachloro[I,6-3H]dibenzo-p-dioxin ([3H]TCDD, purity 2 97%,
specific activity 27 Ci/mmol) was obtained from Chemsyn Science Laboratories (Lenexa,
KS). TCDD, 2,3,7,8-tetrachlorodibenzofuran (TCDF) and all PCBs (purity >98% for all)
were obtained from Ultra Scientific (Kingston, RI). Resorufin, ethoxyresorufin and
Amplex Red were from Molecular Probes (Eugene, OR). Peroxidase conjugated goat
anti-molise antibody was from Pierce (Rockford, IL). All other reagents were obtained
from Sigma (St. Louis, MO).
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Phosphate-buffered saline (PBS) is 0.8% NaC!, 0.115% Na2HP04, 0.02% KCl,
0.02% KH2P04, pH 7.4. Phosphate buffer is 50 mM Na2HP04 with pH adjusted to 8.0
using 50 mM NaH2P04. TCDD, TCDF and PCB solutions were prepared in dimethyl
sulfoxide (DMSO) as described previously (Hahn et al. 1996b). Concentrations of
eH]TCDD solutions were verified by liquid scintillation counting (LSC) on a Beckman
LS5000TD.
Growth and Treatment ofCells
PLHC-l cells (Hightower et al. 1988) were grown at 30°C in minimum essential
medium (MEM) containing Earle's salts, nonessential amino acids, L-glutamine and 10%
calf serum, as described previously (Hahn et al. 1993). These cells express a single
CYPlA isoform, which has no detectable constitutive expression (Hahn et al. 1996b).
These cells also express only one AHR, an AHR2 form (Hahn 1998a; Chapter 2). For
EROD and CYPlA ELISA assays, cells were seeded into 96-well plates (Costar;
Cambridge, MA) at 2xl05 cells in 0.2 ml culture medium per well. One day later the
medium was removed and replaced with 0.2 ml serum-free MEM. The cells were then
treated by addition of solutions dissolved in DMSO or DMSO alone (1 flVwell). DMSO
concentrations were S; 0.5% (v/v) in all treatments, and did not affect cell viability.
Following treatment, plates were incubated at 30°C for 24 hours. For TCDD specific
binding experiments, eH]TCDD and competitors were dissolved at twice the desired
concentration in 0.75 ml serum-free MEM in glass tubes. Cells were trypsinized and
resuspended at 2 to 4xl06 cells per ml in serum-free medium, and 0.75 ml cell suspension
was added to each tube. Aliquots of cell suspension were reserved for protein
determination.
EROD and protein assays
EROD activity was measured using a multiwell fluorescence plate reader by a
modification of the method of Kennedy et al (1995). Cells were rinsed once with 0.2 ml
room temperature PBS, and the EROD reaction was then initiated with the addition of
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2}lM 7-ethoxyresorufin in phosphate buffer (100 Ill/well). The reaction was stopped after
eight minutes (resorufin production is linear with respect to time over this period; Hahn et
al. 1996b) with the addition of75 }ll ice-cold fluorescamine solution (0.15 mg/ml in
acetonitrile). After a fifteen-minute incubation, resorufin and fluorescamine fluorescence
were measured. Resorufin and protein concentrations were determined from standard
curves prepared on the same plate. BSA was used for the protein standard.
For the TCDD binding experiments, cell protein was measured by the
bincinchinoic acid method of Smith (1985), using BSA as the standard and MEM as the
blank.
ELISA Assay
Enzyme-linked immunosorbence assays to detect CYPIA were performed
essentially as described by Briischweiler et al (1996a). One day after treatment in 96-well
plates, cells were fixed in 50% ethanol 15 minutes, in 75% ethanol 15 minutes, and in
95% ethanol 30 minutes. After washing with PBS, non-specific antibody binding was
blocked with 10% fetal bovine serum and 2% BSA in PBS for I hour. The primary
antibody, mouse anti-scup CYPIA monoclonal antibody 1-12-3 (10 }lg/ml; Park et al.
1986), was then added in 100 }ll blocking solution for 1 hour. After three washing steps
with PBS, 100 }ll secondary antibody, peroxidase conjugated goat anti-mouse (1: I000 in
blocking solution), was added for I hour. After another three washing steps with PBS,
100 }ll substrate solution (100 }lM Amplex Red, 100 }lM Hz0 2 in phosphate buffer,
pH=7.0) was added for 30 minutes. All incubations were performed at room temperature.
Resorufin formation was measured in the fluorescence plate reader. For each
treatment the background fluorescence, defined as the fluorescence detected in untreated
cells, was subtracted, and all values were normalized to the maximum response
measured. The assay was also performed on wells without cells or without the addition
of primary antibody, and these controls yielded fluorescence values nearly identical to
those in untreated cells, consistent with our earlier results detecting no CYP IA protein or
EROD activity in untreated cells (Hahn et al. 1996b).
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TCDD and Competitor Binding to the AHR
Specific binding of [3H1TCDD in PLHC-I cells was measured by a modification
of the whole-cell filtration assay of Dold and Greenlee (1990). For detennination of the
equilibrium dissociation constant (Ko) ofTCDD binding to the AHR and the receptor
content (RT) ofPLHC-I, cells were treated with increasing concentrations ofeH1TCDD
in the presence or absence of200-fold molar excess of unlabeled TCDF and incubated 2
hours at 30°C. This time was detennined to be sufficient to achieve a steady state of
bound radioligand (Appendix B). For detennination ofbinding inhibition constants (K;),
0.5 to I nM [3H1TCDD and increasing concentrations of competitors (or a 200-fold
excess TCDF treatment to measure non-specific binding) were dissolved in MEM. Cells
suspended in MEM were subsequently added to ensure true competition, since off rates
for AHR ligands can be extremely slow (Farrell and Safe 1987). Cell densities were
equal among experiments in order to minimize protein concentration effects on binding
(Bradfield et al. 1988a). Following the incubation, tubes were vortexed briefly to assure
even distribution of cells, and a 0.1 ml aliquot was removed to detennine final eH1TCDD
concentration. Three, 0.45 ml aliquots of cell suspension from each tube were then
collected under vacuum on prewetted 25 mm Whatman GF/F filters. In some cases cell
aliquots were pelleted (200g, 10 minutes) and resuspended in PBS prior to application to
filters. Filters were then washed three times with 2.5 ml acetone that had been precooled
to -80°C. The number of washes was detennined empirically as that necessary to remove
the free eH1TCDD remaining on the filters. Replicates were processed in batches of
twelve on a Millipore 1225 filter manifold. Radioactivity remaining on the filter was
quantified by LSC.
Data Analysis and Theoretical Models
EROD data were fit to a modified Gaussian function for detennination of dose-
response relationships, as described previously (Kennedy et al. 1993; Hahn et al. 1996b).
CYPIA induction data were fit to the Hill response function:
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[CYl1 A] = _-"-[A-,,-]_
[CYl1Am,,] [A] + EC50
(1)
where CYPlA and CYPlAmax are the amount of CYPIA content measured at inducer
concentration [A] and with 10 nM TCDD, respectively, and EC50 is the concentration of
inducer required to elicit half-maximal CYPIA expression. A modified version of this
equation that included a tenn allowing for non-zero background expression was used to
fit data from the co-treatment experiment (Figure 6).
For AHR binding, total binding (without TCDF) and nonspecific binding (with
TCDF) were measured as the average of three replicates at each eH]TCDD
concentration. Because the eH]TCDD concentrations in the total and nonspecific
binding treatments were not exactly equal, specific binding is shown as the difference of
the total binding at a given concentration and the nonspecific binding at the same
concentration as detennined from a linear regression of the nonspecific binding data
collected. These specific binding values were calculated for illustrative purposes only,
and were not used for detennination ofK.J and Rr . Those values were determined by
simultaneous fitting of the data collected to equations describing total and nonspecific
binding:
TB = [A]x[RT ] +m[A]
[A] +K d
NSB = m[A]
(2)
(3)
where TB is total binding, [A] is the concentration ofradioligand, NSB is nonspecific
binding, and m is the slope of the nonspecific binding curve. This method has significant
advantages over others, such as Scatchard plots, which can place undue emphasis on a
few points of the binding curve (Kenakin 1999). Specific binding curves were plotted
using the Hill-Langmuir isothenn:
[A.R] = [A]x[RT ]
[A]+Kd
(4)
where [A R] is the concentration of ligand-receptor complex (i.e. specifically bound
ligand). The data were also fit to equations that did not assume a Hill coefficient of I
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(i.e. a lack of cooperative binding), but these showed no statistical improvement, and the
Hill coefficients were not significantly different from 1.
Binding inhibition constants (Ki) were detennined by fitting inhibition data from
at least three experiments to the Gaddum equation (Gaddum 1937):
(5)
where SB is specific binding and [1] is the concentration of competitor. Competitive
inhibition of [3H]TCDD binding by PCB 105 and antagonism ofCYP1A induction by
PCB 128 were shown by Schild analysis according to the following regression
(Arun1akshana and Schild 1959):
10g(~~i -1) =10g[I] -logKi (6)
where [A '] is the concentration of ligand required to achieve the same amount of specific
binding (or response) in the presence of competitor [1] that would be achieved by [A] in
the absence of competitor. The ratio [A']/[A] is called the concentration ratio, and is also
represented by r. A linear regression oflog (r-1) on log [1] was perfonned. The
regression supports (but does not prove) a mechanism of competitive antagonism if the
slope=l, and in this case alone the intercept provides an estimate ofKi.
Stimulus-response coupling for individual AHR agonists was modeled using the
operational model of Black and Leff(Black et al. 1983). This assumes a hyperbolic
relationship between the amount ofligand-receptor complex and the observed response:
= ----=-[A_·_R-=-]_
KE+[A-R] (7)
where Ea is the response observed at agonist concentration [A], Em the maximal response,
and KE the concentration of ligand-receptor complex that gives half-maximal response.
Combining equations 4 and 7 yields:
(8)
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CYPIA induction (i.e. response) data for individual agonists were fit to equation 8 using
experimentally dete=ined values for RT and Ki (assuming K i = Ki) in order to dete=ine
the value ofKE.
Fitting and statistical analyses were perfo=ed with SigmaPlot (Jandel Scientific)
and Jmp In (SAS Institute) software.
RESULTS
cyp1A Response to HAH Exposure
Induction ofCYPIA by HAH was quantified by its EROD activity and by
ELISA. Responses to TCDD, TCDF and eight PCBs (four non-ortho-, three mono-
ortho-, and one di-ortho-substituted) were measured. CYPIA induction by TCDD and
three of the non-ortho PCBs (TIJPAC numbers 77,126 and 169) has been measured and
reported previously (Heste=ann et al. in press). Those data are shown here in Figures
IA and 2A, with hyperbolic curves fitted for CYPIA protein induction. Representative
induction curves for the other compounds are shown (Figures 1B and 2B), and the EC50s
of induction for all ten compounds are in Table I. TCDD, TCDF, all four non-ortho
PCBs and one mono-ortho PCB (156) induced CYPIA protein and catalytic activity,
while two other mono-ortho PCBs (lOS and 118) and the one di-ortho PCB (128)
induced little or no measurable CYPIA.
AHR Binding Affinities
Binding affinities for the ten compounds were measured by inhibition of
[3H]TCDD binding to the AHR (Figure 3). Specific binding of [3H]TCDD was measured
by a whole-cell filtration method (Dold et al. 1990). The total, nonspecific and specific
TCDD binding measured in the absence of competitor are shown in Figure 3A.
Inhibition curves in Figure 3 B and C are shown as a fraction ofbinding in the absence of
competitor. K i values for each compound (Table I) were dete=ined by simultaneous
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Figure 1. EROD induction by AHR agonists. Cells were treated with the indicated
concentrations of inducer and EROD activity (pmo1 of resorufin formed per minute per
mg of cellular protein) was assayed 24 hours later. For each compound, the lowest
concentration represents treatment with DMSO alone. Points are means ± SE of three
wells. The modified Gaussian fits to these data are plotted. (A) TCDD, PCB 77, PCB
126 and PCB 169 (B) TCDF, PCB 81 and PCB 156. PCBs 105, 118 and 128 were all
inactive in inducing EROD.
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Figure 2. CYF1A induction by AHR agonists. Cells were treated as in Figure 1. ELISA-
detected CYF1A protein content was assayed 24 hours later. For each compound, the
lowest concentration represents treatment with DMSO alone. Points are means ± SE of
three wells. Values are normalized to induction with 10 nM TCDD. The hyperbolic fits
to these data are plotted. (A) TCDD, PCB 77, PCB 126 and PCB 169 (B) TCDF, PCB 81
and PCB 156. PCBs 105, 118 and 128 were all nearly or totally inactive in inducing
CYF1A.
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Figure 3. Inhibition of [3H]TCDD binding by AHR ligands. Cells were treated with
CH]TCDD in the presence or absence of increasing concentrations of competitors,
including a 200-fold excess TCDF treatment to measure non-specific binding. Specific
binding of CH]TCDD was measured by a whole-cell filtration assay (Dold et al. 1990).
(A) Binding curves for [3H]TCDD in the absence of competitors. The plot through the
specific binding points is from equation 4, with RT=103 frnol/mg and KJ=0.14 nM. Inset
shows specific binding on a semi~logaritlunic plot. Inhibition curves are shown for (B)
full agonists and (C) partial agonist and antagonists. Values are fractions of specific
[3H]TCDD binding measured in the absence of competitor. Points are means ± SE of
three replicates.
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fitting of3-4 such curves from independent experiments, as described in the Methods. Ki
values for the agonists showed the same rank order potency as EROD and CYPIA EC50s
(Table 1).
Table 1. Parameters for CYP1A and EROD activity induction and AHR binding for
selected HAH.
Compound ERODEC50 CYP1AEC50 Ki
(uM) (uM) (uM)
TCDD 0.016 0.015 0.76
TCDF 0.014 0.032 1.5
PCB 126 0.029 0.12 16
PCB 81 0.063 0.19 29
PCB 77 0.73 14 860
PCB 169 1.6 18 2200
PCB 156 230 1900 2500
PCB 118 >50000a >50000 a 2900
PCB 105 NDb ND 4600
PCB 128 ND ND 6600
EROD induction EC50s for TCDD, PCB 126, PCB 77 and PCB 169 are from
(Hestermann et al. in press). EROD and CYP1A EC50s are means of at least three
separate determinations, with one such determination shown in Figures 1 and 2. K i
values are likewise determined from at least three separate binding inhibition experiments
such as that shown in Figure 3.
a: minimal induction detected, but insufficient data for determining an EC50
b: ND = no induction detected
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Two compounds, PCBs 105 and 128, inhibited TCDD specific binding but failed
to induce EROD or CYPlA, suggesting that they are antagonists in PLHC-l cells over
the range ofconcentrations used. In order to determine if antagonism by PCB 105 is
competitive, binding inhibition was measured at three concentrations of TCDD (Figure
4A). The resulting Schild plot is shown in Figure 4B. The slope ofthe plot is not
significantly different from unity, supporting the identification of PCB 105 as a
competitive antagonist. The Ki determined from the intercept of the plot with slope
constrained to 1 (2200 nM) is not significantly different from that determined from the
data in Figure 3C (4600 nM).
Stimulus-Response Coupling
The logarithms ofEC50 values are plotted against logarithms ofKi values in
Figure 5A, such that each point represents a single compound. The figure shows that
EC50s for CYPlA protein induction increase in a 1: 1 relationship with increases in
binding affinities, with EC50s approximately 100-fold lower than KiS for each
compound. This relationship does not hold for EC50s for EROD activity induction,
where the slope ofthe line is significantly less than l. This is in agreement with our
previous results with a more limited set of compounds showing that EC50s based on
EROD induction overestimate relative potencies as compared to CYPlA protein
induction in the same cells (Hahn et al. I996b; Hestermann et al. in press).
The artho-substituted PCBs do not follow the trends seen with the other
compounds. Figure 5A shows that the EC50s for CYPlA induction by PCB 156 are
much higher than predicted from its Ki and the relationships observed for the other
compounds. Minimum EC50 values of 50 J.lM for PCB 118 place it even farther from the
observed relationships. The findings suggest that these compounds are less efficient at
eliciting a response following receptor binding.
Since AHR binding (stimulus) and CYPlA induction (response) were measured
in the same whole-cell system, it is possible to determine relationships between the two.
This was done using an operational model (Black et al. 1983), as described in the
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Table 1.
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Table 2. Stimulus-response coupling for AHR agonists.
Compound KE (finol/mg)a R50(%i R95 (%)b
TCDD 2.0 1.9 27
TCDF 2.5 2.2 30
PCB 126 1.0 0.75 13
PCB 81 0.70 0.65 11
PCB 77 3.1 1.7 24
PCB 169 0.88 0.78 13
PCB 156 39 45 94
a: KE represents the amount ofreceptor-ligand complex required for half-maximal
response. These values were determined from CYP1A induction data as described in the
Methods (Equation 8).
b: Rso and R9S are the fraction ofreceptors (expressed as a percentage) that must be
occupied by the indicated compound for 50% and 95% CYP1A induction, respectively.
Methods. The model assumed a hyperbolic stimulus-response relationship, which is
consistent with data from other receptor systems and the mechanism of CYP1A
induction. Fitted KE values for the agonists, as well as calculated R so and R95 values, are
shown in Table 2. KE represents the amount of receptor-ligand complex required for
half-maximal response. These values are on the unit order of magnitude for all
compounds except PCB 156, for which the KE is -10- to 50-fold higher. The Rso and R9S
values are the fraction of receptors that must be occupied to elicit a 50% and 95%
response, respectively. Lower values indicate that fewer occupied receptors are
necessary for response. Thus, fewer than 30% of the receptors need be occupied for a
95% response to TCDD, while about 94% must be occupied for the same response to
PCB 156.
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The stimulus-response relationship is shown graphically in Figure 5B, where the
fitted constants were used to draw theoretical stimulus-response curves for each agonist.
Collectively, the stimulus-response relationships represented in Table 2 and Figure 5B
demonstrate quantitatively what was earlier shown qualitatively, that PCB 156 is much
less efficient in eliciting a response after binding to the AHR than the other compounds
tested. Thus TCDD, TCDF, and the non-ortho-substituted PCBs are high-intrinsic
efficacy agonists, and PCB 156 is a low-intrinsic efficacy agonist for the PLHC-l AHR.
Note that all are full agonists, as determined by maximal response, in this system.
Demonstrating Ligand Character in a Mixture
These data demonstrate that the compounds tested include representatives of three
classes ofreceptor ligands: high-intrinsic efficacy agonists (TCDD, TCDF, PCBs 77, 81,
126 and 169), low-intrinsic efficacy agonists (PCB 156 and likely PCB 118) and
antagonists (PCBs 105 and 128). Each class of compound should display unique
properties when response is measured after co-treatment with a high-intrinsic efficacy
agonist such as TCDD (Goldstein et al. 1974). A mixture of two high-intrinsic efficacy
ligands should produce additive response. An antagonist should inhibit the response
produced by the high-intrinsic efficacy ligand alone. Since a low-intrinsic efficacy
agonist has properties of both an agonist and antagonist, it should exhibit concentration-
dependent additive and inhibitory effects on the high-intrinsic efficacy ligand.
This co-treatment was done with PCBs 126, 128 and 156 as representatives of
each class of ligand (Figure 6). Cells were treated with TCDD in the presence of
increasing concentrations of each PCB, and the EC50 for CYPIA induction by TCDD
was measured. For each of the three mixtures, Schild regressions were produced using
the fitted EC50s for TCDD at each concentration ofPCB (Figure 7). In such a plot, a
high-intrinsic efficacy agonist would be expected to show a slope of 0, a competitive
antagonist a slope of 1, and a low-intrinsic efficacy agonist a slope between these two
values.
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Figure 7. Schild regression for co-treatments. The EC50 values from the curves in Figure
6 were used for regressions. The EC50 value determined in the presence of the highest
concentration of each PCB was excluded due to high baseline induction (PCBs 126 and
156) and/or limited solubility (PCBs 128 and 156). The slope of the PCB 126 regression
is not significantly different from 0, nor the slope ofthe PCB 128 regression significantly
different from 1, while the slope of the PCB 156 regression is significantly greater than 0
and less than 1 (p<O.Ol for all).
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PCB 126 alone induced CYP1A, and in co-treatment caused only a slight increase
in EC50s for CYPIA induction by TCDD (Figures 6A and 7). PCB 128 did not induce
CYPIA, but did cause a progressive increase in EC50s for CYP1A induction by TCDD
(Figures 6B and 7). PCB 156 induced CYPIA and increased EC50s for TCDD in co-
treatment, although not to the same degree as PCB 128 (Figures 6C and 7). As predicted,
the Schild regression indicates that PCB 126 is a high-intrinsic efficacy agonist (slope not
significantly different from 0), PCB 156 is a low-intrinsic efficacy agonist (slope
significantly different from both 0 and I), and PCB 128 is a competitive antagonist (slope
not significantly different from I). The y-intercept for the PCB 128 regression predicts a
K i that is not significantly different from that determined by ligand binding.
DISCUSSION
This set of experiments represents the first quantitative determination of stimulus-
response relationships for AHR ligands, in any system. Structure-activity relationships
for both stimulus (receptor binding) and response (CYPIA induction) were determined in
intact cells. From such assays, affinities and intrinsic efficacies ofligands can be
evaluated, and the structural parameters that determine agonism can be determined
separately for each of these properties of the ligand-receptor interaction. These data were
also used to construct an operational model for AHR-ligand interactions, which has
application for risk assessment as well as predicting effects of perturbations to the
signaling pathway.
Interpreting CYPlA Induction and Competitive Binding Affinities
The data presented here demonstrate clearly a relationship between AHR binding
affinities and CYPIA protein induction potencies. The regression shown in Figure 5a
reveals that these values increase in a I: I relationship for the agonists studied. The
114
correlation exists because TCDD, TCDF, and the non-ortho-substituted PCBs have
similar intrinsic efficacies (Table 2), so that differences in AHR binding affinities
account for the differences in CYP IA induction potencies among these compounds.
Thus, knowledge of either the EC50 for induction of CYPIA or the Kj for a high-intrinsic
efficacy agonist allows for close estimation of the other value. However, this method
would overestimate Kjs for lower intrinsic efficacy ligands such as PCBs 156 and 118.
There was also a strong correlation between binding affinities and EC50s for
CYPIA-catalyzed EROD induction, which is consistent with earlier studies comparing
binding in rat hepatic cytosol and EROD response in vivo and in H4IIE cells (Safe 1990).
However, the 1:1 relationship found here between EC50s for induction ofCYPIA protein
does not hold true with EC50s for EROD induction, which would underestimate the true
value of the Kj for less potent agonists. This almost certainly is due to inhibition of the
enzyme activity by the inducing compounds (Gooch et al. 1989; Hahn et al. 1993), which
lowers EC50s for EROD induction relative to EC50s for CYPIA protein induction (Hahn
et al. 1996b). For this reason, subsequent analyses and conclusions were drawn from
data for induction ofCYPIA protein, rather than activity.
Agonistic activity is a de facto demonstration ofbinding to a particular receptor
site, but what of antagonists? Competitive inhibition of TCDD binding to the AHR was
shown here for the two antagonists, PCBs 105 and 128. Inhibition curves like those
shown in Figure 3 are often mistakenly held to be evidence ofbinding competition, but
they cannot distinguish true competitive inhibition from other types (e.g. allosteric
inhibition or irreversible inactivation). Demonstrating competitive binding inhibition
requires the measurement of binding or response with several concentrations ofligand
and inhibitor, followed by analysis by Schild regression, as was done here, or by double-
reciprocal plots analogous to those used in enzyme inhibition studies.
Understanding the Mechanistic Basis ofStructure-Activity Relationships
Previous studies have shown that in fish, ortho-substituted PCBs are inactive or
nearly so in terms of both CYPIA induction (Gooch et al. 1989; Newsted et al. 1995;
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Hahn et al. 1996a) and toxicity (Walker et al. 1991; Zabel et al. 1995). This has led to
differences in recommended toxic equivalency factors (TEFs) for these compounds in
fish and mammals (van den Berg et al. 1998). The data here indicate that the insensitivity
of fish to artha-substituted PCBs is a result of both reduced affinity and reduced intrinsic
efficacy ofthese compounds. Receptor binding Kjs were 10-100 fold greater for the
artha-substituted PCBs than for their structurally related non-artha-substituted
counterparts (i.e. PCB 126 vs. 156,81 vs. 118 and 77 vs. 105). Comparing EC50s for
CYP1A induction among PCBs with similar binding affinities (PCBs 118, 156 and 169)
reveals the reduced intrinsic efficacy of the artha-substituted congeners. Our data
provide a mechanistic explanation for previous studies that have noted less than additive
interactions for CYP1A induction by mixtures ofTCDD and artha-substituted PCBs both
in viva (Newsted et al. 1995) and in cultured cells (Clemons et al. 1998).
The results of this work also have general applicability. Properties of ligand-
receptor interactions and tissue coupling have a large effect on measured relative
potencies. Potency depends on both affinity and efficacy, and the TEF concept as
currently used does not allow for differences in intrinsic efficacy among compounds.
Low-intrinsic efficacy compounds will yield less than additive responses in mixtures with
high intrinsic efficacy agonists (Figure 6). Furthermore, relative potencies from different
endpoints and tissues have been used to determine TEFs. Coupling between the receptor
and response can be different for these endpoints and tissues, leading to variability among
measured responses. A partial agonist for one response or tissue could be a full agonist
or an antagonist for another. Therefore, relative potencies are tissue- and endpoint-
specific.
Intrinsic efficacy spans a continuum between full agonism and full antagonism.
Ligands with intrinsic efficacies spanning this range were found in the set of compounds
studied here. PCBs 118, 156, and 169 have similar AHR binding affinities (Table 1), but
produce very different responses. Although there was insufficient response to PCB 118
in this cell type to quantify a stimulus-response relationship, it is clear that the intrinsic
efficacy of PCB 118 is less than that of PCB 156, which in tum has a lower intrinsic
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efficacy than PCB 169. Given that PCBs 105 and 128 have even lower binding affinities,
it is possible that they are partial agonists rather than true antagonists, and that solubility
limitations obscure their nature. However, given that limitation, in this cell type PCBs
105 and 128 are antagonists in practice, ifnot in theory.
Stimulus-response Modeling for the Ah Receptor
AHR binding assays traditionally have been performed using isolated cytosol, a
system that preserves only a few ofthe subsequent signaling events. Two previous
studies have approached the question of AHR ligand intrinsic efficacy using such in vitro
systems. AHR binding and XRE mobility shift in isolated cytosol both were measured in
a recent study of substituted flavones (Henry et al. 1999). This system allowed the
authors to characterize the compounds' agonistic and/or antagonistic properties for events
up to and including XRE binding, and thereby determine properties of ligand structure
that affect those steps. Similarly, a study of several dioxin and furan congeners revealed
a lO-fold range in receptor binding affinities, but a lOa-fold range in EC50 values for
XRE mobility shift, suggesting differences in intrinsic efficacy among those compounds
(Santostefano et al. 1992).
While useful for characterizing ligand-receptor interactions, such in vitro systems
lack a full assessment of stimulus-response relationships and coupling in a particular
tissue (see below). Cultured cell assays are ideal for addressing molecular mechanisms
of AHR signal transduction in a system that retains several aspects of biological
relevance. A combination of AHR binding affinities measured in vitro and responses
measured in vivo or in cultured cells could potentially be used to classify a compound as
an agonist, partial agonist, or antagonist. However, since the concentrations ofligand,
receptor, and signaling cofactors vary among the assays, a quantitative stimulus-response
model for the tissue cannot be constructed. Our use of whole-cell binding and response
assays obviates these complications and thus allows for construction of such a model.
An operational stimulus-response model (Black et al. 1983) was chosen for this
study because the value KE has a definition that is easily related to the mechanism of
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AHR signaling. It should be noted that KE includes both compound- and tissue-specific
properties (as well as species-specific properties, for cross-species comparisons). It is a
combination of the intrinsic efficacy of the ligand (the ability to activate the receptor to a
fonn that induces a response) and the coupling properties of the cell. In the case of the
AHR, the latter could include a host of factors, including ARNT concentration, affinity of
ARNT for the AHR-ligand complex, affinity ofthe AHR-ARNT dimer for the XRE,
concentration and affinities of transcriptional cofactors, etc. The intrinsic efficacies of
the ligands do not change among tissues within an organism, but the tissue-specific
properties can, and therefore so will KE values. This is an important consideration in
future efforts to expand modeling to the level of the organism. In this study the
compounds were compared in the same cell type, so tissue-specific properties were
constant and differences in KE values are due solely to differences in the intrinsic
efficacies ofthe ligands.
AHR Expression and Tissue Response
The value ofthe operational model lies in its power to predict the effect of
perturbations to thetissue. For example, severaHreatments have been reported to affect
expression of the AHR, including phenobarbital (Okey and Vella 1984), PCB 153
(Denomme et al. 1986), TCDD (Sloop and Lucier 1987), TGF-~ (Dohr et al. 1997b),
serum withdrawal (Vaziri et al. 1996), and loss ofa transcriptional regulator (Zhang et al.
1996). The effect of the changes on tissue response to AHR agonists has been
detennined in some of these cases, but not all. A stimulus-response model for the tissue
in question should be able to accurately predict the effect of such changes, since receptor
concentration, RT, is an element in the model (see equation 8 in Methods).
This model also reveals important aspects of signaling in the absence of
perturbation, including the presence of spare receptors. The potential for "spare" or
"reserve" AHR has been proposed, beginning with the finding that only a small fraction
of the agonist-occupied AHR accumulates in the nucleus (Greenlee and Poland 1979).
The -1 OO-fold difference between EC50 and Kj for high-intrinsic efficacy ligands
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demonstrates the presence of spare receptors in this system. Our finding that only 1-2%
ofthe AHR molecules need be occupied by high-intrinsic efficacy agonists for 50%
CYPIA induction (Table 2) shows that PLHC-1 cells have spare receptors for this
response. Even after a 3-fold reduction in receptor content, these compounds could still
induce the same maximal level of CYP1A (R95 values are less than 33%; Table 2),
although higher agonist concentrations would be required. Conversely, there is no
receptor reserve for a 95% maximal response to PCB 156, and thus any reduction in AHR
content would make this compound a partial agonist. Similarly, differences in coupling
could change the fraction of occupied receptors required for another response,
eliminating receptor reserve even for high-intrinsic efficacy agonists. The magnitude of
receptor reserve is therefore dependent on the agonist, tissue and response of interest.
In summary, the potency of AHR ligands to induce a response was separated into
the properties of affinity and intrinsic efficacy, and the resulting values were used to
build a stimulus-response model for AHR signal transduction in PLHC-1 cells. This
work represents the first time that intrinsic efficacies of AHR ligands have been
quantitatively determined. Stimulus-response models provide useful insights for HAH
risk assessment and mechanisms of toxicity across the many endpoints currently under
investigation. Expansion of these analyses to other species, tissues and responses should
prove fruitful in studying AHR function and evolution.
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ABSTRACT
Changes in expression of the aryl hydrocarbon receptor (AHR) have been
documented in several systems and in response to a variety of treatments. Due to a
relative lack of data regarding the effect of such changes on response to AHR ligands, the
significance of these findings is unclear. We tested the ability of changes in serum used
in cell culture medium to alter expression of the AHR and the subsequent induction of
cytochrome P450lA (CYPIA) in PLHC-I teleost hepatoma cells. Growth in serum-free
medium for two days led to a loss ofCYPIA inducibility by 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD). In contrast, growth in 10% delipidated calf serum increased levels of
both CYPIA protein and enzymatic activity relative to controls grown in 10% complete
calf serum. These effects were consistent between 8 and 24 hours post-treatment,
indicating that the kinetics of induction were unaffected. Measurement of induction of
CYPIA in cells grown in serum-free medium for I and 2 days demonstrated a
progressive loss of inducibility. This loss ofresponse was paralleled a time-dependent
loss of AHR protein, as measured by specific binding of 3H-TCDD. Using an operational
model for AHR action in PLHC-I cells, the measured reduction in AHR could be shown
to account for the changes in induction of CYPIA. Expression of AHR protein was
unaffected by growth in 10% delipidated serum. These phenotypes were found in only a
limited subset ofPLHC-1 cells, and only in early-passage cells. Expression of AHR
protein in late-passage cells was unaffected by serum withdrawal and matched that in
early-passage cells grown in 10% serum. Comparison of early- and late-passage cells
revealed a 2-fold greater rate of proliferation in the latter, suggesting a growth advantage
is coincident with loss of serum-dependent expression of AHR. These results provide a
quantitative link between changes in receptor expression and a downstream response,
pointing the way for future studies of receptor expression and sensitivity to toxic
responses in vitro and in vivo.
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INTRODUCTION
The aryl hydrocarbon receptor (ARR) mediates the toxicity of2,3,7,8-
tetrachlorodibenzo-p-dioxin and structurally related compounds. Several treatments have
been reported to affect expression of the AHR, including phenobarbital (Okey et al.
1984), ortho-substituted PCBs (Denomme et al. 1986;[Landers, 1991 #436]), TCDD
(Sloop et al. 1987), TGF-[3 (Dohr et al. 1997b), serum withdrawal (Vaziri et al. 1996),
and loss of a transcriptional regulator (Zhang et al. 1996). The effect of changes in AHR
expression on tissue response to AHR agonists has been determined in only a few of
these cases, and in some is complicated by effects on the response that are not connected
to AHR expression (Dohr and Abel I 997a). Determining factors affecting AHR
expression is important, but alone such analyses are incomplete. The in vivo significance
of altered AHR expression will ultimately depend on how responses, and thus the toxicity
of AHR agonists, are impacted.
Serum withdrawal reduces AHR expression 4 to IO-fold in Swiss 3T3 murine
fibroblasts (Vaziri et al. 1996), apparently by down-regulation of a tyrosine kinase. We
wished to determine if such regulation of AHR expression was present in other cell types
and to measure the impact of a decline in receptor on a downstream response. Induction
of cytochrome P450lA (CYPIA) is a response to AHR agonists that is both well
characterized and common throughout most of the vertebrate subphylum (Stegeman and
Hahn 1994; Whitlock 1999), making it the logical choice for study.
In this study, receptor expression and induction ofCYPIA were measured in
PLHC-I cells, derived from a hepatocellular carcinoma of the teleostPoeciliposis lucida
(Hightower et al. 1988). Binding of TCDD to the AHR and induction ofCYPIA have
been measured in this cell line (Chapters 3 and 4), and a mathematical model of the
stimulus-response relationship for this system has been developed. This allows receptor
expression and consequent response to be modeled quantitatively, facilitating testing of
hypotheses.
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We have also previously reported that serum in cell culture medium alters the
uptake and apparent potencies of AHR ligands (Hestermann et ai, in press). Another goal
ofthis study was to determine the effects oflonger-term growth in those serum
treatments, and to separate the effect of serum on ligand uptake from effects on cell
physiology. Therefore, in these experiments cells were grown in media containing
different serum treatments but treated with ligands in a common medium in order to
remove effects of serum on uptake.
We report that growth ofPLHC-1 in serum-free medium results in a progressive
decline ofboth AHR expression and CYP1A inducibility. In contrast, growth in medium
containing 10% delipidated serum increased maximal levels ofCYP1A without changing
the potency of induction by TCDD. This increase was not correlated with a change in
AHR expression. Both of these phenotypes were variable with regard to sub-clone and
time in culture ofthe PLHC-1 cell line.
MATERIALS AND METHODS
Chemicals and solutions
The 2,3,7,8-tetrachloro[1,6}Hldibenzo-p-dioxin (eH1TCDD, purity 2: 97%,
specific activity 27 Ci/mmol) was obtained from Chemsyn Science Laboratories (Lenexa,
KS). TCDD and 2,3,7,8-tetrachlorodibenzofuran (TCDF) were obtained from Ultra
Scientific (Kingston, Rl). Peroxidase conjugated goat anti-mouse IgG was from
Schelicher and Schuell (Keene, NH). Luminescent peroxidase substrate was from Tropix
(Bedford, MA). Resorufin and ethoxyresorufin were from Molecular Probes (Eugene,
OR). All other reagents were obtained from Sigma (S1. Louis, MO).
Phosphate-buffered saline (PBS) is 0.8% NaCI, 0.115% NazHP04, 0.02% KCI,
0.02% KHZP04, pH 7.4. Phosphate buffer is 50 mM NazHP04 with pH adjusted to 8.0
with 50 mM NaHzP04 • Sample treatment buffer is 0.25 M Tris-HCL, pH 6.8, 40% (v/v)
glycerol, 4% (w/v) sodium lauryl sulfate, 0.008% (w/v) bromphenol blue, and 5% (v/v)
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2-mercaptoethanol. TCDD, TCDF, and PCB solutions were prepared in dimethyl
sulfoxide (DMSO) as described previously (Hahn et al. 1996b). Concentrations of
[3H]TCDD solutions were verified by liquid scintillation counting (LSC) on a Beckman
LS5000TD.
Growth and Treatment ofCells
PLHC-l cells (Hightower et al. 1988) were grown at 30°C in minimum essential
medium (MEM) containing Earle's salts, nonessential amino acids, L-glutamine and 10%
calf serum (Sigma C6278, lot 106H4628), as described previously (Hahn et al. 1993).
One day prior to dosing, cells were suspended to 0.5 to 1 xl06 per ml and seeded into 48-
or 96-well plates (Costar; Cambridge, MA) at 0.5 or 0.2 ml per well, respectively. For
TCDD specific binding experiments, cells were seeded into 24-well plates (Coming;
Coming, NY) at 2xl 06 cells in 1 ml culture medium per well. One day later the medium
was removed and replaced with fresh medium. Media used in the experiments include
MEM without serum, with 10% serum, with 10% delipidated, charcoal stripped calf
serum (Sigma CI696), and with 10% fetal bovine serum (FBS; Gibco; Grand Island,
NY). After 2 days, the medium was changed to MEM +10% calf serum and the cells
were treated with TCDD dissolved in DMSO or DMSO alone (2.5 or 1.0 fll/well).
DMSO concentrations were ::s: 0.5% (v/v) in all treatments. Following treatment, plates
were incubated at 30°C for 24 hours unless otherwise indicated. With the exception of the
delipidated serum and FBS, all serum used was from a single lot. None of the treatments
reduced cell viability, as assessed by Trypan Blue exclusion.
EROD andprotein assays
EROD activity was measured using a multiwell fluorescence plate reader by a
modification of the method of Kennedy et al (1995). Volumes given are for 48-well
lates; halve for assays in 96-well plates. Cells were rinsed once with room temperature
PBS and the EROD reaction was then initiated with the addition of2flM 7-
ethoxyresorufin in phosphate buffer (200 fll/well). The reaction was stopped after eight
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minutes (resorufin production is linear with respect to time over this period; Hahn et al.
1996b) with the addition of 150 fil ice-cold fluorescamine solution (0.15 mg/ml in
acetonitrile). After a fifteen minute incubation, resorufin and fluorescamine fluorescence
were measured. Resorufin and protein concentrations were determined from standard
curves prepared in the same plate. BSA was used for the protein standard curve. In some
experiments, the EROD reaction was followed kinetically over eight minutes, as
described previously (Hahn et al. 1996b). Protein was measured using fluorescamine as
described above.
Measurement ofCYPlA Protein
CYPIA protein was measured by immunblotting of whole celllysates, essentially
as described (Hahn et al. 1996b). Cells grown and treated in 48-well plates were
solubilized at 4°C for 15 minutes in 100 fil sample treatment buffer, with gentle agitation.
Lysates were transferred to tubes and boiled 5 minutes to complete solubilization and
inactivate proteases.
Samples and CYPIA standards (purified CYPIA from scup, Stenotomus
chrysops) were analyzed by denaturing gel electrophoresis on 8-12% acrylamide gradient
minigels (Novex, San Diego, CAl. 25 fil of each sample (equivalent to 15J..1.g protein)
was used. Proteins were electrophoretically transferred onto 0.2 fim nitrocellulose and
incubated sequentially with blocking solution (Schleicher and Schuell), monoclonal
antibody 1-12-3 (anti-scup CYPIA, Park et al. 1986) at I fig/ml, and alkaline
phosphatase conjugated goat anti-mouse IgG at 1:5000 dilution. Following each
antibody incubation, membranes were 3 times each with tris-buffered saline and water.
Color was developed by enhanced chemiluminescence as directed by the supplier
(Tropix) using Kodak X-AR film. Images were acquired with a Kodak DCS200 digital
camera and Adobe Photoshop, and band intensities were quantified by densitometry
using NIH Image software. Values for CYPIA equivalents were determined from a
standard curve using the scup CYPIA.
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TCDD Binding
Specific binding of [3H]TCDD in PLHC-1 cells was measured by a whole-cell
filtration assay (Do1d et al. 1990). One day after seeding in 24-well plates, the cells were
fed I ml of the indicated media. Two days later the medium was changed to 0.5 ml of
MEM+10% calf serum, and cells were treated with 1 nM eH]TCDD in the presence or
absence of200 nM TCDF and incubated 2 hours at 30°C. This time was determined to
be sufficient to achieve a steady state ofbound radioligand (Appendix B). Following the
incubation, medium was removed, cells were rinsed with 0.5 ml ice-cold PBS, and then
detached with 0.5 ml trypsin. The trypsin was inactivated by the addition of 0.5 ml ice-
cold culture medium (with 10% serum), and cells from each well were collected under
vacuum on a 25 mm Whatman GF/F filter that had been prewetted with PBS. Filters
were then washed four times with 2.5 ml acetone that had been precooled to -80°C.
Replicates were processed in batches of twelve on a Millipore 1225 filter manifold.
Radioactivity remaining on the filter was quantified by LSC. Specific binding was
measured in triplicate as the difference of each of three total binding (without TCDF)
replicates and the average of three nonspecific binding (with TCDF) replicates in each
medium. Protein concentrations were determined in duplicate wells fed each medium
and treated with DMSO alone.
RESULTS
Effect ofGrowth Medium on CYPIA Inducibility
PLHC-1 cells were grown for two days in one of three media: serum-free MEM
(So), MEM with 10% calf serum (SIO), or MEM with 10% delipidated calf serum (SDd·
Then the medium was changed to SIO (to insure equal kinetics ofTCDD uptake
Hestermann et al. in press) and the cells were treated with TCDD. EROD activity was
assayed 24 hours later (Figure 1). Growth in So abolished induction ofEROD by TCDD,
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Figure I. Effect of growth medium on EROD inducibility by TCDD. PLHC-I were
seeded in 48-well plates and grown for two days in tbe medium indicated in the legend.
The medium was then changed to SlO, and cells were treated with TCDD. EROD activity
was assayed 24 hours later. Points are means ± standard error of triplicate wells.
A B
TCDD (nM)
3 10 30
So
S,0
SOL
.05 .1 .2
-- i
10 100
TCDD (nM)
Figure 2. Effect of growth medium on CYFIA protein induction. Cells were grown and
treated as in Figure I. Celllysates were harvested 24 hours after treatment with TCDD
and analyzed by SDS-PAGE and immunoblotting with mAb 1-12-3. (A) Digital image
of blot with medium and TCDD treatments indicated. The bottom row shows scup
CYPIA standards with pmol amounts indicated. (B) Integrated densities of individual
bands were converted to CYPIA equivalents. Points are mean ± standard error of
duplicate samples.
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and growth in SOL led to a significant increase in induction relative to SIO. Growth in
10% FBS led to similar increases over the activity seen in 10% calf serum (not shown).
These results were confirmed at the level of CYPIA protein expression by
imrnunoblot (Figure 2). At doses of TCDD below I nM the levels of CYPIA were
undetectable by this method. At higher doses of TCDD the trend follows the results with
EROD activity, i.e. greater induction with cells grown in SOL than in SIO, and little or no
induction with cells grown in So.
In order to determine if the different media were having an effect on the timing of
CYPIA induction, EROD was measured from 8 to 24 hours after treatment (Figure 3).
Induction ofEROD was measurable by 8 hours in cells previously grown in SIO or SOL,
and rates continued to increase until 16-20 hours after treatment. Rates decreased slightly
from this maximum at 24 hours. In contrast, no induction was measured in cells grown in
So at any point up to 24 hours post-treatment.
Timing and Mechanism ofLoss ofInducibility
Cells were grown in S10, So, or SOL for I or 2 days, changed to S10, and treated
with TCDD. EROD activity was measured 20 hours later (Figure 4). After a single days'
growth in So, the EC50 for induction ofEROD had increased about 10-fold as compared
to cells in SIO, but the maximum level of induction was unchanged (Figue 4A). After two
days, the EC50 increased further, and the maximal level of induction was lower than that
observed after one day in So. In contrast to previous results (Figure I), a small amount of
induction was observed after two days of growth in So (Figure 4B). Subsequent
experiments showed similar subtle variability in the kinetics ofloss of inducibility.
The progressive decline in inducibility could be due to a time-dependent loss of
AHR protein or function. Levels of AHR protein were measured by specific binding of
3H_TCDD in PLHC-I cells grown in the different media for I or 2 days (Figure 5). After
two days, the amount of AHR in cells grown in So showed a significant decrease as
compared to cells grown in SIO or SOL (Figure 5A). The decrease was time-dependent; a
significant reduction was already present after one day of growth in So. After two days,
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Figure 3. Time course of induction ofEROD activity. PLHC-1 cells were grown and
treated as in Figure 1, and EROD activity was assayed at the indicated times after TCDD
treatment. Points are means ± standard error of triplicate wells. Cells were grown in (A)
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Figure 5. Effect of growth medium and time on AHR expression. PLHC-1 were grown
in the indicated media, changed to SlO, and incubated with 1 nM 3H_TCDD in the
presence or absence of200 nM TCDF for two hours. 3H-TCDD binding was measured by
a whole-cell filtration assay (Dold et al. 1990). Specific binding is shown as the average
+ standard error of three replicates. * indicates significantly less specific binding than
cells in SIO (p<O.Ol; t-test). (A) Cells were grown in the indicated media for two days
prior to assay. (B) Cells were grown for one or two days.
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Figure 6. Response of early (IS) and late (44) passage cells to growth medium. Cells
were grown, treated and assayed as in Figure 1. (A) Late-passage cells. (B) Early
passage cells.
Days
Figure 7. Proliferation in early- and late-passage cells. Early (IS) and late (44) passage
PLHC-I cells were seeded in 25 cm2 flasks at 2.4xI05/cm2 and grown in 8 10 . Cells were
counted at daily intervals with a hemacytometer. Counts were normalized to the value on
day 0, and are means ± standard error for triplicate flasks. Exponential fits are shown
(proliferation had stopped in late-passage cells by day 3), and the predicted doubling
times are 30 and 50 hours for late- and early-passage cells, respectively.
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specific binding was barely detectable (Figure 5B). Interestingly, there was no difference
between AHR content in cells grown in SIO and SDL (Figure 5A).
Passage and Sub-clone Effects
The phenomena of AHR down-regulation and loss of inducibility were detectable
only in a limited set ofPLHC-l sub-clones, and did not persist beyond 30 passages.
Later-passage cells treated and assayed with early-passage cells revealed no significant
differences in induction ofEROD, regardless of growth medium (Figure 6). The
transition between the phenotypes depicted in Figure 6 (termed "early" and "late"
passage) was abrupt; typically, only three passages separated the responses shown in the
same sub-clone of cells. In order to address a possible mechanism for this change, rates
of proliferation for early- and late-passage cells were determined (Figure 7). Late-
passage cells proliferated at nearly twice the rate of early-passage cells.
DISCUSSION
This report explores the connection between AHR expression and cellular
responses to AHR agonists. We have demonstrated a loss of inducibility ofCYPlA in
early-passage PLHC-l grown in serum-free medium for two days. Cells grown in
medium with 10% delipidated serum showed an increase in maximal level of induction
over cells grown in the typical 10% calf serum. Neither the loss in So nor the increase in
SDL was due to a change in the kinetics of induction. The loss of inducibility paralleled a
loss of AHR over the same period. These effects were witnessed in early- but not late-
passage PLHC-l.
The results presented also demonstrate that the effect of serum on ligand uptake
(Hestermann et ai, in press) can be separated from other effects on induction ofCYPlA.
Cells grown in So or SDL and returned to SIO for short-terms (:5: 24 hours) ofligand
exposure exhibited induction properties different from those of cells grown in SIO. This
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suggests that the mechanisms of the observed effects involve changes in protein
expression or another relatively slow (i.e. several hours to days) response, rather than
changes in ion flux, enzyme activity, or similarly quick (i.e. minutes to hours) response.
Loss ofCYP1A Inducibility and Receptor Expression
The loss of inducibility ofEROD after two days in So was complete, but a small
amount of CYPIA protein expression was still seen in cells treated with large doses of
TCDD (<: 10 nM; Figures I and 2). At high concentrations, the inducing compound will
also act as an inhibitor ofEROD (Gooch et al. 1989; Hahn et al. 1993; Petrulis et al.
1999), so the enzymatic activity of the small amount ofCYPIA present would not be
evident. Thus, it is possible that in other experiments (e.g. Figure 4B) greater amounts of
CYPIA are present in the cells treated with high concentrations ofTCDD than is
apparent from the measured EROD activity. However, since the overall effect of
inhibition is to decrease apparent EC50s relative to CYPIA protein induction, small
losses in inducibility (which increase EC50; Figure 4) could be masked by inhibition.
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Figure 8. Influence ofreceptor number on induction ofCYPIA. EROD data from
Figure 4 (points) are shown with induction curves (lines) predicted at various levels of
AHR expression. Predicted responses were calculated from the following equation, with
RT = 110 finol/mg at 100% AHR, KD = 15 nM and KE = 2 finol/mg:
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The decline in inducibility of CYPIA protein and activity paralleled a decline in
specific binding of 3H_TCDD, and presumably AHR protein expression. With the
operational model of AHR function developed in the previous chapter, it is possible to
predict the effects of changes in receptor content on measured responses. Figure 8 shows
the EROD induction data from Figure 4 superimposed on predicted curves for different
levels of AHR expression. The EROD activities have been normalized to the maximal
values in cells grown in SIO for each day. The AHR content in cells grown in So was 33%
of that in cells grown in SIO after one day, and 15% after two days (Figure 5).
Induction curves predicted by the model for full AHR expression and for a 3-fold
reduction in AHR fit the induction data from SIO and one day in So very well. However, a
-30-fold decline in AHR is necessary to bring the predicted curve in alignment with the
induction data from day 2. Because the receptor content measured after two days in So is
near the limit of detection, a 30-fold reduction is not significantly different from the
measured value. Again, inhibition ofEROD activity could also account for some ofthe
difference seen between the actual induction and that predicted for 15% of normal AHR
expressIOn.
Another possibility is that a fraction of the AHR present is able to bind ligand but
not competent to induce CYPIA. In this context, correlation of loss of inducibility with
reduced AHR expression suggests a mechanism for the lack of induction of CYP lA, but
does not exclude regulation after ligand binding. Nuclear translocation, ARNT
dimerization, XRE binding, and recruitment of transcriptional co-activators remain as
possible sites ofregulation. Given this caveat, the most parsimonious explanation for the
observed data remains a direct effect of loss of receptor protein on downstream
responses.
This analysis provides a link between measured changes in AHR expression and
function. Similar differences in response have been noted between wild type and reduced
AHR mutants ofHEPA-1 cells (Karenlampi et al. 1988; Zhang et al. 1996), where
reductions in AHR content were correlated with increases in EC50 and reduced maximal
induction of CYPIAI. The phenotype of one of the mutants was unstable (Karenlampi et
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al. 1988), and CYP1A1 inducibility increased over time in culture, which is also similar
to the results seen here. The source ofreduced AHR expression in that system was
selection for mutants deficient in CYP1A1 inducibility rather than a transient treatment
like that used here, so the mechanisms ofreduced expression and changes in phenotype
are likely different.
We have previously demonstrated the existence of"spare" receptors for induction
ofCYPIA by TCDD in PLHC-I cells (Chapter 4). The presence of spare receptors
implies that a small reduction in receptor content will increase the EC50 for the response,
but not significantly decrease the maximal level of induction. A larger decrease in
receptors will further increase the EC50 and reduce maximal response (Appendix C).
This had not been demonstrated experimentally before the results presented here.
Increased CYP1A Induction in PLHC-l Cells Grown in Delipidated Serum
No change in receptor expression was seen after growth in SOL as opposed to SIO
(Figure 5), and increases in receptor content would not be expected to increase the
maximal level of response (Appendix C). Thus, the increased induction ofCYP1A
protein and activity after growth in SOL must be the result of another mechanism. Since
the EC50 of induction was not changed by growth in SOL, any proposed mechanism must
affect signaling following binding ofligand to the AHR.
The increased induction of CYP IA observed here in cells grown in SOL is
reminiscent of the potentiation of induction previously observed upon co-treatment of
PLHC-1 cells with AHR agonists and glucocorticoid receptor (GR) agonists (Celander et
al. 1996; Celander et al. 1997). The former study found increased expression ofCYP1A
when cells were treated with dexamethasone and TCDD versus TCDD alone.
Potentiation was also observed with the hormonal GR agonists cortisol and prednisone,
and was inhibited by GR antagonists. The potentiation of induction ranged from 2-20
fold, depending on doses of each compound used, and showed variability between
experiments, as was seen here (compare maximal EROD rates for cells grown in SOL in
Figures 1 and 3). Such potentiation has been shown to involve increased rate of CYP1A
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mRNA transcription, and has been hypothesized to involve binding ofthe GR to response
elements in the CYF1A promoter (Mathis et al. 1989).
Another possible mechanism is the loss of transcriptional "squelching" in cells
grown in SDL. Squelching is the process in which activated receptors compete for a
limited supply of co-activators (Prywes and Zhu 1992; Cahill et al. 1994), and is well
established for steroid hormone receptors. According to the supplier (Sigma), their
process for removal oflipids from serum does remove cholesterol, and likely steroid
hormones as well. Thus, removal of steroid hormones would reduce activation of their
receptors, leading to an increase in co-activators available for the AHR. The switch from
SDL to SIO for AHR agonist exposure complicates this hypothesis, since steroid hormones
would be reintroduced at the time ofTCDD treatment. Thus, this hypothesis depends on
the kinetics of activation of the various receptors.
Effects ofPassage Number and Sub-Clone
The phenomena reported here did not occur in all ofthe sub-clones ofPLHC-1 we
studied, and did not persist beyond 30 passages in the sub-clones where they were
present. Figure 7 shows that the late-passage cells have a growth advantage over early-
passage cells. Whether this is a transition that the entire population of cells makes or an
increase in the relative numbers of a sub-population is unclear. If the latter hypothesis is
true then this provides another link between cell proliferation and AHR function, because
a sub-population of cells with faster proliferation also shows the loss of a control on AHR
expressIOn.
The lack of differences in inducibility seen in some sub-clones even at very early
passages (e.g. passage 10) suggests that heterogeneity may have existed in the parent line.
The term sub-clone is even somewhat misleading for this cell line, because PLHC-I cells
do not proliferate at low densities, so no population is truly clonal. The apparent
heterogeneity is consistent with earlier results (Chapter 2) showing differences in the
effects ofTCDD on cell proliferation.
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In sunnnary, a lack of inducibility ofCYPlA in cells grown in serum-free
medium has been connected to a concurrent loss of ARR. The operational model of
ARR signaling developed previously has been used to show that responses measured at
intermediate points of ARR expression are consistent with our understanding of the
relationship between receptor levels and downstream responses. Future work should
focus on comparing several different responses to determine how changes in receptor
expression and tissue coupling may influence sensitivity to ARR ligands.
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Chapter 6: Conclusions and Future Directions
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This work demonstrates the power and utility ofPLHC-l cells for addressing
questions of Ah receptor function. Several methods and tools have been developed for
use in future studies, enabling the reported studies to unlock the potential of these cells.
Cross-talk between AHR and other signaling pathways previously demonstrated in
mammals were extended to a new class of organisms, and aspects of AHR function that
were previously unexplored in any system have been elucidated. In this chapter those
individual results will be placed into a wider context, and future work toward which they
point will be proposed.
Interactions between AHR Signaling and Cell Proliferation
The early goals ofthis research revolved around exploring interactions among
signal transduction pathways involving the AHR, progression through the cell cycle, and
cell proliferation. As was discussed in the Introduction, there are several provocative
hints indicating that interactions among these pathways occur at the molecular level, but a
clear understanding is lacking. Ifthese interactions are a crucial aspect of AHR function,
then it can be expected that they have been maintained through much, if not all, of the
evolutionary history of this receptor. By comparing the shared and distinct features of
such interactions among organisms, it will be possible to formulate hypotheses regarding
that history.
PLHC-l cells were evaluated as a teleost model for exploring such interactions.
Several pieces of information necessary for these studies initially were lacking, including
knowledge of the proliferation rate and cell cycle characteristics, optimum growth
density, response to serum withdrawal and cell cycle inhibitors, and characteristics of
AHR(s) expressed in the cells. After addressing these deficiencies, it was possible to ask
what effect(s) AHR ligands have on cell proliferation, and in tum how proliferation and
cell cycle progression influence AHR function.
Following several reports of inhibition of proliferation by TCDD in cells of
hepatic origin, this possible effect was measured in PLHC-l cells. Dose- and time-
dependent inhibition ofproliferation was observed in a sub-clone ofthese cells, but not in
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any of several others examined. The EC50 for this effect, 60 pM, is consistent with the
potency of TCDD for producing other responses via the AHR (e.g. EC50 for CYFIA
activity induction is 330 pM in that medium). The inhibition was also transitory; TCDD-
treated cells resumed proliferation 4-5 days following treatment. This effect was
reminiscent of the lag before proliferation when PLHC-I cells were seeded at lower
densities, suggesting that perhaps TCDD interferes with the mechanism for committing to
proliferation.
The inability to replicate this finding in other sub-clones implies heterogeneity
within the PLHC-I cell line. This is a very real possibility, since these cells have not
been established from a single clone at any point in their history in culture. Furthermore,
a loss of the ability of TCDD to inhibit proliferation suggests that some control on this
process has been lost in most of the PLHC-I cells. This is consistent with the
observation in Chapter 5 that late-passage cells proliferate at a greater rate and have lost a
serum-dependent control on AHR expression. Whether these two phenomena (i.e. TCDD
inhibition of proliferation and serum-dependent AHR expression) are connected remains
unclear.
Expression of AHR mRNA and protein was found to remain constant throughout
the cell cycle. However, serum withdrawal, a treatment known to block cell cycle
progression at the GO/GI transition, led to a decrease in AHR protein. PLHC-I cells do
proliferate in serum-free medium for at least a week (not shown), so the absence of serum
is not blocking the cell cycle. This effect of serum on AHR expression independently of
changes in cell cycle progression is consistent with findings in 3T3 fibroblasts (Vaziri et
al. 1996), and suggests a control on AHR expression that has been conserved throughout
much of vertebrate evolution.
Whereas these effects were measured successfully in PLHC-I cells, heterogeneity
of response makes this cell line less than perfect as a model for studying such
interactions. A great deal of time and effort was expended in studies of cells that turned
out to be non-responsive for the types of effects described above. A survey to determine
responses of other piscine cell lines to such treatments is warranted, as a more
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appropriate model may exist. Such a survey will benefit from the knowledge and
techniques developed here. However, until a better model is found the PLHC-l cells
remain the only piscine model capable of supporting further research in interactions
among the AHR and other signal transduction pathways.
AHR Ligand Treatment and Response
The other major thrust ofthis thesis was to improve our understanding of AHR
signal transduction and responses to AHR ligands. The sort of scheme shown in Figure 2
of the Introduction is common in the field of AHR research, but what is lacking in large
part are numbers associated with the arrows. Equilibrium conditions of some of the steps
are known, but a thorough understanding requires rates of each step to be determined. In
addition, since much of the previous work has been performed in a number of different
systems, differences between them must be considered when building a comprehensive
model.
Toward an Accurate Assessment ofLigand Concentration
The effect of serum on potencies of induction detailed in Chapter 3 was first
observed as a complicating factor in the experiments shown in Chapter 5. PLHC-l cells
were grown and treated in medium with or without serum, and differences in both ligand
potency (i.e. EC50) and efficacy (i.e. maximal response) were observed. The effect on
potency grew from a nuisance to an interesting study of its own when a survey of the
literature revealed the expanding use of cultured cells in risk assessment for AHR
ligands. Such studies are attractive to regulatory agencies because of their relative ease
of use and lower cost when compared with in vivo tests. Our results demonstrated the
potential for increased sensitivity within a cell system and confounding results when
comparing among systems.
Entry of compound into the cell and subsequent availability for binding is a step
in the pathway to toxicity that has been under-appreciated in this field. Toxicokinetic
studies in an organism typically end at the level of concentration in a tissue, and
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mechanistic studies in cells pick up with binding of ligand to the AHR. Some recent
work has begun to address the routes and kinetics ofHAH entry into cells (Dulfer et al.
1996; Dulfer 1998), but this step remains perhaps the subject of the least understanding
and greatest number of assumptions in the pathway ofHAH toxicity. The relationship
between the amount of compound applied to cells and the concentration available for
binding is largely a mystery.
The results in Chapter 3 address one component of this issue by examining factors
controlling the fraction of compound that is associated with the cell. This fraction is
dependent on time, external environment, and dose. Subsequent collaborative work has
shown that even two laboratories ostensibly following the same protocol for treatment of
cells will measure widely different results simply based on these controllable factors.
Given the number and magnitude ofdecisions that are being made on the basis of data
collected in cell bioassays, such discrepancies should be addressed as early as possible.
One question not addressed by the studies in Chapter 3 is the location ofHAH
within the cell after it enters from the medium. The extremely hydrophobic nature of
these compounds suggests that much of it will associate with lipid membranes and
perhaps hydrophobic interiors oflipid or protein aggregates. The concentration ofligand
in the cytosol and available for receptor binding depends on such factors. In fact, it has
been suggested that the difference in AHR binding affinities among some PCBs (e.g.
PCBs 77 and 169) is not due to an actual difference in affinity, but rather to differences in
their cytosolic concentration that result from differences in hydrophobicity (P. Sinclair,
personal communication). Studies of binding affinity in increasingly purified
preparations ofAHR suggest that such miscalculation of the "free" concentration of
ligand can lead to an -1000-fold difference in measured Kos (Bradfield et al. 1988b).
However, whether such a mechanism accounts for apparent differences in affinity among
compounds is not known.
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Stimulus-Response Relationships
Our understanding of events subsequent to ligand binding also suffers from a lack
of quantitative measurement of the kinetics and controlling factors for receptor
transformation. Although the existence of AHR partial agonists and antagonists has been
recognized for a decade, a simplistic model of binding leading to transformation, which
in tum leads to response, continues to pervade much of the published literature. The
separation of ligand potency into the properties of affinity and intrinsic efficacy, reported
in Chapter 5, begins to move in the direction of considering differences in ligand
properties other than binding affinities. Together with recent efforts to explore the
structural bases for ligand intrinsic efficacy (Henry et al. 1999), hopefully these studies
will gamer a larger appreciation for the myriad factors linking binding and response.
One current limitation of the analysis performed in Chapter 5 is the restriction to
cultured cell systems. This analysis requires measurements of binding and response too
numerous to perform in vivo, and only recently possible in cultured cells. Reliable
protocols for rapid, large-scale analysis ofbinding to the AHR and induction of CYPlA
protein and activity were adapted to the PLHC-l cell system. Transfer of such assays to
other cell lines to analyze species- and tissue-specific effects should be relatively
straightforward. However, expansion to the level ofthe organism will require carefully
targeted studies to assess factors upstream ofligand entry into the cell and downstream of
cellular response.
Moving down in level of organization, assays performed using isolated cell
fractions lose the ability to analyze several of the relevant steps leading to response.
However, such assays are valuable for careful analysis ofthe steps that are retained (e.g.
ligand binding, interactions with ARNT and other proteins, DNA binding, and possibly
initiation of transcription). The number of events falling under the term "efficacy" is
large, and no assessment has been made ofwhich are constant within a tissue (i.e. tissue
coupling) and which are in some part variable, depending on the identity of the ligand.
For example, recent studies of estrogen receptor structure suggest that antagonists induce
a different receptor conformation than agonists, and that the antagonist occupied estrogen
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receptor does not interact with transcriptional coactivators (Brzozowski et al. 1997;
Norris et al. 1998). Such confonnational changes could effect steps in the AHR signal
transduction pathway that involve interactions with other molecules (e.g. ARNT, DNA,
co-activators; Lees and Whitelaw 1999).
The separation of ligand action into the tenns affinity and efficacy is just a first
step in developing this understanding. Further separation of efficacy into ligand- and
tissue-specific properties may obscure the likelihood that some processes are dependent
on both. We now have the tools to detennine the molecular mechanisms of differences in
efficacy. This should allow a conjunction of classical phannacology and molecular
endocrinology to approach a compelete understanding ofligand-receptor interactions.
Even with the limitations discussed above, I am excited about the prospects of this
understanding of AHR action for driving future research. The sort of analysis performed
in Chapter 5 can be applied to a wide variety ofligands, cell types and responses to build
a more complete model of AHR function. Several candidates for endogenous AHR
ligands have been proposed, and it will be interesting to see how their affinities and
intrinsic efficacies compare to xenobiotics.
Another immediate application lies in the area of interspecies extrapolation.
Rodent toxicity data is often used to estimate human health risks, and knowledge of the
differences in affinities and intrinsic efficacies for binding to the human and rodent
AHRs will improve such estimates. Furthermore, tissue coupling will vary among
organisms for various responses, and detennination of these values will aid our
understanding of why some organisms show resistance to certain toxic endpoints but not
others (Birnbaum 1991).
Obviously, similar arguments apply to wildlife toxicity. As model organisms are
developed and used for different taxa it will be important to know how responses in the
model organisms differ from others of interest. Some of this work already is being done
in measuring potencies of induction of CYPIA and, in more limited cases, AHR binding
affinities for compounds of interest. However, collection and analysis of such data will
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be most effective when it is driven by a need to understand mechanistic differences and
to construct valid stimulus-response models.
The need to work within a pharmacologically sound framework is pointed out by
the limitations of the currently used TEF approach. As was discussed in Chapter 4, AHR
ligands in mixtures are assumed to have solely additive interactions, which does not take
into account ligands with lower intrinsic efficacies. Thus, TEF-derived toxic potencies
are almost certain to be overestimates when the contributions of individual compounds
are sununed. Working from known concentrations of compounds toward estimating
toxic effects will require adjustment for low-intrinsic efficacy compounds.
Conversely, bioassay-derived potencies will tend to underestimate the
concentrations of AHR ligands. CYFIA activity, a common bioassay, is inhibited by
many of the inducing compounds themselves, further complicating its use in such
analyses. Despite these complications, the concept of using bioassays to predict toxicity
ofHAH mixtures is extremely useful. Bioassay-derived potencies do correlate well with
a variety of toxic endpoints. However, this approach has been applied when the
underlying correlations are not well established.
Finally, it is satisfYing to be able to build quantitative models and predict
outcomes that can be tested by experiment. As more numbers are added to the arrows in
that general AHR signal transduction scheme, these models will become more pervasive,
more accurate, and more useful. The few interactions quantified here are simply a start.
Science is useful primarily because it improves our ability to predict future outcomes.
This field is moving into a stage where that promise will be fulfilled.
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Appendix A: A Primer on Radio-Ligand Binding Assays
following Kenakin, T. (1999) Pharmacologic Analysis ofDrug-Receptor Interaction,
3rd ed. Raven Press.
The goal of any ligand binding assay is twofold. First, free ligand must be
separated from bound ligand. Second, ligand bound with a relatively higher affinity must
be separated from that bound with a relatively lower affinity. Several assays have been
devised to achieve the first goal. To achieve the second goal, radio-ligand binding assays
assume that lower affinity binding is unsaturable in the range of ligand concentrations
used. Thus, labeled ligand can be displaced from higher affinity, but not lower affinity,
binding sites by an excess ofunlabeled ligand. Therefore the definition of high-affinity
binding sites is binding sites which are saturable within the concentrations of ligand used.
High-affinity binding is determined by subtracting the amount of ligand bound in the
presence of competitor from the amount of ligand bound in the absence of competitor.
Therefore, actual data collected from an experiment consists of two binding
curves, a "total binding" curve measuring binding at several ligand concentrations in the
absence of competitor, and a "non-specific binding" curve determined in the presence of
competitor. The "specific binding" curve is simply the difference between these two. It
is important to note that specific binding is not a directly determined value, but a derived
one. Nevertheless, the total amount and affinity of specific binding are the values of
interest, so we begin by considering the interaction between receptor and ligand.
The specific interaction of a ligand and its receptor is reversible, with rate
constants for the association and dissociation of the ligand with the receptor:
[A]+[R~[AR]
k2
(I)
Where [A], [R], and [AR] are the concentrations ofligand, receptor and ligand-receptor
complex, respectively, and k1 and k2 are the association and dissociation rate constants.
At equilibrium, association and dissociation occur at an equal rate, and
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(2)
The amount of receptor competent to bind ligand is divided into two pools, with
and without ligand bound:
(3)
Where RT is the total receptor pool. Substituting this relationship into equation 2 and
rearranging produces:
[A]x([RT]-[AR]) = k, [AR] (4)
k,
And now if a single equilibrium dissociation constant, KD is defined to replace the rate
constants:
(5)
and this is substituted in equation 4, we arrive at the following expression relating ligand
concentration and the fraction of receptor that is occupied by ligand:
[AR] =---"[_A]'------
[RT ] [A]+KD
(6)
This relationship is known as the Langmuir binding isotherm.
Equation 6 relates binding to free ligand concentration; if total ligand
concentration is measured, the amount bound must be subtracted. In addition, the
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relationship expressed by equation 6 involves several assumptions about the nature of the
association. The most important ones to remember are:
1) The system must have reached equilibrium, i.e. association and dissociation
are occurring at equal rates when binding is measured.
2) Binding of one ligand molecule does not effect binding of another, which
includes two major components:
A) Removal of a ligand molecule from the available pool by binding does not
alter the concentration of free ligand, i.e. the fraction of total ligand that is
bound to the receptor is relatively small.
B) Binding is not cooperative.
Deviation from any of these assumptions requires modification of equation 6 in order for
it to be useful. For example, cooperative binding can be modeled by adding an exponent
(the Hill coefficient) to the free ligand concentrations:
[AR] [Aj" X [Rr ]= [Aj" + K n
(7)
Possessing both a method to determine specific binding and a theoretical
relationship to describe it, it should be possible to fit data to the relationship. By
measuring the amount ofreceptor occupied at several different free ligand concentrations,
the values ofRT and KD can be determined.
First it is necessary to determine whether sufficient data have been collected to
perform a proper binding analysis. The data should include several points at
concentrations of free ligand above the KD• This can be assessed visually by plotting
specific binding versus free ligand concentration on a semi-log plot, but not with a linear
scale of free ligand, which can be misleading. The figures below show an idealized
specific binding curve. The data on the left are plotted with a linear x axis and seem to
indicate that the last few points are beyond the inflection point (i.e. the KD) of the curve,
and that a saturating ligand concentration is being approached. However, the semi-log
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plot on the right reveals that the inflection point has not been reached, and RT and KD
(hereafter collectively called the binding constants) cannot be estimated properly (Klotz
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Figure 1. Linear and semi-log plots of binding.
Once sufficient data have been collected, the binding constants can be
determined. The classic method for estimating these values, and one still in use, is the
Scatchard plot. Since equation 6 describes a nonlinear function of ligand concentration, a
transformation that yields a linear relationship would be both visually satisfying and
simpler to fit. By cross multiplying the terms of equation 6 and dividing throughout by
[A]*KD such a linear relationship is established:
[AR] [AR] [RT ]
--=---+--[A] K D K D
(8)
A plot of bound ligand (or receptor) concentration divided by free ligand
concentration on the ordinate and bound ligand concentration on the abscissa yields a line
with a slope of -I/KD and an x-intercept ofRT. An obviously nonlinear relationship for
data plotted in this fashion is a sign that one of the assumptions listed for equation 6 is
false.
While the Scatchard plot is a useful tool for visually assessing the nature of the
binding interaction and easily computing RT and K D, it does have its drawbacks. The
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transformation necessary to achieve the linear relationship includes both independent
(ligand concentration) and dependent (binding) variables in the y axis. Therefore data
points from different ligand concentrations are weighted unequally, with points at the
highest and lowest ligand concentrations receiving greater relative weight in the
determination of the binding constants. This typically leads to overestimation ofboth RT
andKD•
With the advent of computer software for performing nonlinear curve fits, it is
possible to fit data directly to the Langmuir isotherm without transformation. This
produces more accurate estimates of the binding constants. However, the specific
binding values are not calculated from primary data, so this approach is still somewhat
removed from the ideal of determining binding directly from measured quantities.
Since "non-specific binding" is by definition unsaturable within the range of
ligand concentrations used, it increases as a linear function ofligand concentration:
NSB=m[A] (9)
and total binding should simply be the sum ofthe specific and non-specific binding:
TB = [A]x [Ry] + m[A]
[A]+K D
(10)
Therefore the data collected for the total binding curve can be fit to equation lOin order
to determine the binding constants and the slope of the non-specific binding line.
Theoretically, even more accurate estimates of the binding constants can be achieved by
simultaneously fitting the total binding data to equation 10 and the non-specific binding
data to equation 9; however, if the quality of the total binding data is good, then the two
estimates should be identical.
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Example
What follows is an example comparing methods for determining binding. The
data is 3H_TCDD binding in PLHC-I cells; where free ligand has been separated from
bound by a filtration assay. The total, specific and non-specific binding numbers and free
ligand concentrations are listed below, with free TCDD concentrations in nM and binding
in frnol/mg protein.
Table I. Binding data for 3H_TCDD in PLHC-I cells.
[TCDD] Total Specific
0.092 7.27 3.61
0.101 15.21 14.29
0.145 18.04 16.77
0.174 19.10 16.45
0.237 13.73 9.02
0.355 22.32 17.55
0.439 20.24 14.33
0.580 31.79 24.06
0.817 47.93 38.85
0.972 31.36 19.70
1.172 57.85 42.35
1.519 60.20 43.96
2.236 97.95 68.17
3.352 54.42 48.29
4.559 109.01 69.09
4.870 122.24 55.10
[TCDD]
0.077
0.080
0.102
0.187
0.192
0.318
0.324
0.503
0.673
0.793
0.987
1.459
1.876
2.876
4.061
4.174
NS
3.39
8.31
14.33
7.42
8.78
9.73
13.74
11.46
25.97
17.96
33.88
47.58
42.31
24.08
81.34
60.20
Since free ligand concentrations for the total and non-specific binding
determinations don't match, specific binding was determined by fitting a line to the non-
specific binding and using that regression to determine non-specific binding at the free
ligand concentrations present in the total binding determinations:
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Figure 2. Non-specific binding.
Therefore specific binding is: TB - 17.517*[TCDD]
First the specific binding values were transformed and plotted by the method of
Scatchard:
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Figure 3. Scatchard plot.
This yields values of 1.22 nM (1/0.8909) and 84 (75.269/0.8909) fInol/mg for K..J and RT,
respectively.
Next specific binding was fit to the Langmuir isotherm. Since the linear fit of
these points in the Scatchard plot wasn't very good, the possibility that some form of
cooperative binding was taking place was investigated. The data were fit to both
equations 6 and 7 to see how much better equation 7 fit the data. The coefficients
determined by these fits are shown in Table 2.
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Figure 4. Varying Hill coefficient and binding data fit.
Table 2. Binding coefficients.
Coefficient Langmuir Varying Hill
n I 0.913
KD (uM) 0.954 1.11
RT (fmolJmg) 76.53 81.69
The values for KD and RT are similar for the two methods, n is not significantly different
from 1 in the second fit, and that equation does not provide a significantly better fit of the
points by F-test (not shown), so a Hill coefficient of 1 will be used from here on.
Next the total binding was fit to equation 10:
5432 6 ,
i
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---------~--~-~
150
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'0 100t:
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Figure 5. Total binding determination.
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The values ofKD and Ry deteTIllined by this method were 0.80 nM and 65.8 fmoVmg.
The specific binding curve using these values is shown below.
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Figure 6. Fit of curve predicted from total binding.
Finally, non-specific and total binding data were fit simultaneonsly to equations 9
and 10.
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Figure 7. Simnltaneous fitting of specific and non-specific binding.
This yields binding constants ofKD= 0.50 nM and R y=53 frnol/mg. The corresponding
specific binding curve is also shown in the figure above.
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Shown in the table below are the constants determined for the various curve fits.
Table 3. Binding constants for different fitting methods.
N Ko m
Scatchard
Varying Hill
Langmuir
Total
Simultaneous
I
0.913
I
1
1
1.22
1.11
0.95
0.8
0.5
84
82
77
66
53
14
15
Notice that as the theoretical appropriateness of the fits increases (moving down the
table), the KD and RT decrease. Overestimation ofthe RT is common when a few points
with higher specific binding skew the fit, as the two points near 70 finol/mg of specific
binding do in these data. The fits determined with the last four methods are plotted
against specific binding below. The fitted lines have been extrapolated beyond the data
to demonstrate the leveling ofthe curves.
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Figure 8. Fits to specific binding using various methods.
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Appendix B: Development of an AHR Binding Assay for PLHC-l Cells
I recognized at the beginning of this thesis project that a dependable, high-
throughput assay for measuring binding of ligands to the AHR was required to complete
the objectives. This has proven true; every data chapter includes at least one ligand
binding assay. The lack of an antibody that reliably detects fish AHRs has increased this
assay's value, because it can be used to measure AHR expression as well as ligand
binding affinities.
Previous, mostly unpublished, work by Mark Hahn had attempted to refine
previously described assays used with isolated cytosol to measure binding to the PLHC-I
AHR. This was greatly complicated by the fact that fish AHRs are generally less stable
and therefore more difficult to isolate than their mammalian counterparts (Denison et al.
1986; Heilmann et al. 1988; Lorenzen et al. 1990). Furthermore, charcoal-coated
dextran, which is commonly used to remove excess unbound ligand, also strips ligand
from the AHR (Lorenzen et al. 1990). Nevertheless, some success was obtained with
sucrose-density gradient (not a high-throughput assay), protamine sulfate (Denison et al.
1984) and hydroxylapatite (Gasiewicz and Neal 1982) assays (summarized in Hahn
1998a).
I decided to focus on the whole-cell filtration assay (Dold et al. 1990) for several
reasons:
I. It is rapid, with time investment relative to results equal to other batch assays.
2. It had been developed for use with cultured hepatoma cells (HEPA-I).
3. Exposure to ligands takes place in intact cells. The importance ofthis in regard to
comparison with response data is highlighted in Chapter 4, but another advantage is
that this avoids degradation of AHR during isolation of cytosol (Swanson and
Perdew 1991).
Initial efforts focused on finding the best combination of equipment and
conditions, and the published protocol was followed exactly. One study showed a
modest, but reproducible, increase in specific binding when GFIF filters were used
157
250
1120
1100
I l'\.80.~ 60 '\.40 r-...'-... T
20
r\\T 0 0 1 2 3 4,
~~~ -'
~"~ T
..... ::::t
200
Ci
..§ 150(5
§.
Cl
c 100
'0
c
iii
50
o
o 1 2
Washes
3 4
-+--- Talai A
-lI- NS A I
-.- Specific A
~TolalF
-a-NS F
--6- Specific F
Figure 1. Binding measured by filtration on GF/A or GF/F filters. HEPA-l were
exposed to 0.5 nM 3H_TCDD with or without 200 nM TCDF for two hours. The assay
was performed as described in Chapter 2. Total, non-specific (NS) and specific binding
are shown using GF/A (A) or GF/F (F) filters. The x-axis is the number of acetone
washes. The inset shows specific binding alone. Error bars are SE of three replicates.
instead of GF/A (Figure 1). The GF/F filters have smaller pore size and faster flow rate,
so cells should be retained better but the acetone flows through faster.
Another change to the published protocol involved exposure in suspended, rather
than attached cells. This adjustment was made because of high variability in cell number
and thus protein content among replicate wells in the 24-well plates originally used. The
protocol using attached cells was employed for binding assays in Chapters 2, 3, and 5, but
they required several attempts before reproducible results were obtained. By suspending
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Figure 2. Binding measured after exposure in suspended cells. The incubation
conditions are as in Figure 1, except that PLRC-l cells have been exposed to 3R_TCDD
and TCDF in suspension in MEM + 10% calf serum. The inset shows only the last three
washes on a smaller scale for comparison.
the cells prior to incubation, even distribution of cell aliquots to replicate binding tubes
was assured. This method also makes simultaneous addition of competitors easier. One
disadvantage is that the cells are not washed before being applied to the filter, so a much
larger amount of unbound TCDD must be removed. This requires a greater number of
washes (Figure 2), and prohibits use of the assay at 3R·TCDD concentrations exceeding 5
nM.
Fortunately, PLRC-1 cells do not attach to glass substrates during the two hour
incubation. In addition, they do show equal amounts of receptor content whether the
incubation is performed in medium with or without serum. Limited experiments with
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H4IIE and HEPA-l cells revealed a tendency to clump in serum free medium and attach
in medium with serum. The former problem made removal of free TCDD difficult, and
the latter removed the advantage gained over assays with adherent cells.
The kinetics of binding were followed to insure that the two hour incubation was
sufficient to achieve equilibrium (Figure 3). Specific binding was not significantly
different between 90 minutes and 4 hours, so 2 hours is sufficient. Binding was also
measured at several protein concentrations to insure that binding to individual sites (ARR
and others) was independent (i.e. [free TCDD]»[bound TCDD]) across the protein
amounts used in the several studies (Figure 4). The linear relationship shown
demonstrates that TCDD concentration is not limiting binding at these protein
concentrations, but the positive V-intercept indicates that free TCDD may not be totally
removed from filters. This will not affect specific binding values, since TCDD will
remain on filters used to determine non-specific binding as well.
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Figure 3. Time course of binding in PLHC-l cells. Cells were incubated with 1 nM 3H_
TCDD with or without 200 nM TCDF as in Figure 2, except that exposure was in serum-
free medium, and aliquots were removed from the tubes at the indicated times for
analysis.
160
16
14
12
"C 10
~
:> 80
.c
"0 6
.§
4
2
------.~
--~
~
•
o
o 50 100
Protein (ug)
150 200
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to JH-TCDD as in Figure 3 for 2 hours. Total binding was measured.
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Appendix C: Modeling the Effects of Changes in AHR Expression on Responses
This appendix will present mathematical modeling of the effects that changes in
receptor expression have on response in PLHC-I cells as well as some primary data
showing a lack of AHR induction by compounds shown to induce in other systems. As
was noted in Chapters 4 and 5, several factors affecting AHR expression have been
reported, leaving open the question ofwhat effect such changes would have on
downstream responses. The models presented here attempt to address this issue.
Neither TCDD nor PB Induce AHR in PLHC-I
PLHC-l cells were treated with TCDD and phenobarbital, two compounds
reported to induce expression of AHR in other systems (Okey et al. 1979; Sloop et al.
1987). Cells were exposed for 24 hours before harvesting RNA and performing semi-
quantitative RT-PCR, according to the method in Chapter 2 (Figure I). Neither of these
compounds induced expression of AHR mRNA in PLHC-I cells, although a slight, dose-
dependent decline may have occurred with PE. Therefore, it was not possible to show
CYFIA induction data from cells with increased receptor content.
Predicting Effects ofChanges in AHR Expression
In Chapter 5, Equation 4 from the Introduction was used to predict the effects of
progressive reductions in receptor content on CYFIA expression. A more complete set
of such curves is shown in Figure 2A. The EC50s and maximal responses are shown in
Table I. A reduction in receptor expression as great as lO-fold would still allow near-
maximal induction ofCYFIA by TCDD, albeit with a 9-fold increase in the EC50.
Greater reductions in receptor content lead to steady declines in maximal level of
induction, but even with a 500-fold lower level ofreceptor, induction would still be
measurable.
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Figure I. Effect ofTCDD and PB on AHR expression. PLHC-I cells were treated with
TCDD or PB at the indicated concentrations for 24 hours and then harvested. RNA was
isolated and used to amplifY AHR and ~-actin products by RT-PCR as detailed in the
Methods section of Chapter 2. AHR expression was normalized to actin expression for
each treatment and then normalized to the DMSO control. A value of 1 indicates an
AHR/actin ratio equal to that in the control.
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Predicted effects of increases in AHR expression are shown in Figure 2B, with
EC50 and maximal induction values in Table 1. A series of2-fold increases in receptor
expression lead to no change in maximal induction, but do produce 2-fold decreases in
EC50s. Thus, a doubling of receptor content (which is the magnitude of many of the
reported induction values) should halve the EC50 for response. This small change is not
likely to be resolved using even sensitive and precise measurement techniques.
Note that these predicted curves use KD, KE and Rr values from CYP1A induction
by TCDD in PLHC-1 cells. This response has a large receptor reserve (Chapter 4). It is
possible that another response with less efficient tissue coupling (and thus a greater KE)
would show a more pronounced effect ofreduction in receptor number on response.
Equivalently, the effect ofreducing AHR content on CYPIA response to a low-intrinsic
efficacy agonist would be greater. As stated in Chapter 4, decreases in AHR content
would render PCB 156 a partial agonist for induction ofCYP1A, since there is no reserve
for that ligand and response.
Since an increase in KE or decrease in Rr have the same effect on the dose-
response curve (see equations for Table I), such conditions can be pictured by using the
curves in Figures 2A, but assuming a different starting concentration ofreceptors. For
example, if these were curves for a response with 10-fold greater KE, the 10-fold lower
Rr curve in Figure 1 represents response at 100% receptor expression. A 5-fold decrease
in receptor content (to the 50-fold reduction curve) would cause a 30% decline in
maximal response and a 3-fold increase in EC50. In contrast, for induction ofCYP1A,
such a decline in AHR (from I to 5-fold reduction) would result in a 5-fold increase in
EC50, with only a slight reduction in maximal response. Ifour hypothetical response
with the higher KE were lethality or incidence of tumors, the potential significance of the
change in receptor content becomes much greater.
These calculations reveal the importance of determining intrinsic efficacies for
different ligands and tissue coupling for the various responses of interest. Biomarkers
such as CYP1A induction will be most useful when the differences in tissue coupling
164
among responses are known. Without such knowledge, the impact of perturbations to the
signaling pathway is impossible to predict.
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Figure 2. Effect of receptor number on response. Curves were generated using Equation
4 from the Introduction, using KD = 1, KE = 2, and an initial Rr = 110. These numbers
are consistent with induction ofCYP1A by TCDD in PLHC-1 cells. (A) Effect of
reduction in receptor number. The numbers in the legend indicate fold reduction in
receptor. (B) Effect of increase in receptor number. The numbers in the legend indicate
fold increase in receptor.
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Table I. Effect of receptor number on EC50 and maximum response.
Fold Induction EC50 Maximal
or (Reduction) response
(500) 0.90 0.10
(100) 0.65 0.35
(50) 0.48 0.52
(10) 0.15 0.85
(5) 0.083 0.92
1 0.018 0.98
2 0.0090 0.99
4 0.0045 1.00
8 0.0023 1.00
16 0.0011 1.00
32 0.00057 1.00
Values calculated as follows:
RTI
IKEMaximal response = ---'-----"-~
1+(Rj{J
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Appendix D: Predicting AHR Ligand Intrinsic Efficacy in H4IIE
AHR binding affinities and CYF1A induction potencies have been detennined in
a variety of systems, but not under conditions that allow direct comparison of the
resulting KDS and EC50s as appears in Chapter 4. Therefore, intrinsic efficacies cannot
be calculated for those compounds. However, it is possible to calculate relative
efficacies by normalizing results to a standard compound, such as TCDD, and then
comparing KDs and EC50s.
This analysis was performed for 5 HAH in H4IIE rat hepatoma cells (Table 1).
AHR binding affinities in rat cytosol (Bandiera et al. 1982) were normalized to the
affinity of TCDD, and relative potencies of induction ofCYP1A activity (AHR or
EROD) were calculated from both new data and published results (Sawyer et al. 1982;
Tillitt et al. 1991). Induction relative potencies were divided by relative affinities in
order to express relative efficacies of the compounds (RE, column 5 of Table 1). RE
determined from induction data here were compared to those calculated from two
previous studies (Columns 5-7 of Table 1).
The results from the three studies are somewhat different, but a few trends
emerge. PCBs 77, 105 and 156 consistently have lower efficacy than TCDD in H4IIE
cells, whereas the efficacy ofPCB 126 is similar to that for TCDD. Since CYF1A
activity assays were used, inhibition obscures determination of maximal response levels,
and thus characterization of these ligands as full or partial agonists. If any of the lower-
intrinsic efficacy PCBs are full agonists, then that implies a receptor reserve for CYF1A
induction in this cell type.
The preliminary assignment of PCB 77 (a non-artha-substituted congener) as a
low-intrinsic efficacy agonist in H4IIE suggests that structure-efficacy, and thus
structure-activity, relationships vary among species. Relative efficacies were calculated
for PLHC-l from data in Chapter 4 (final column of Table 1). PCB 77 has lower relative
efficacy in H4IIE than in PLHC-1, while the values between the two cell types are similar
for the two artha-substituted PCBs, 105 and 156.
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The striking differences between potencies for artha- and non-artha-substituted
PCBs observed in fish is not seen in mammals, although most of the comparisons
perfonned use PCBs 77 and 105 as representatives of those two classes of compounds.
Relative efficacies of these two compounds were quite similar to one another in data from
the two published studies (although there are large differences between the studies),
indicating that the difference in affinities between them accounts for differences in
response potencies. The reduced relative efficacy of PCB 77 in H4IIE suggests that not
all non-artha-subsituted PCBs are high-intrinsic efficacy ligands as in PLHC-I,
narrowing the gap between intrinsic efficacies of artha- and non-artha-substituted PCBs
in the mammalian system. Careful analyses of the sort performed in Chapter 4 are
required in more systems in order to test this hypothesis.
Table I. Calculating relative efficacies in the rat from relative receptor affinities
measured in rat cytosol and induction potencies measured in H4IIE cells.
Relative REinH4IIE REin
Compound KD (uM)" Affinity Potency This study Tillitt SawyerC PLHC-I
TCDD 10 1 I 1 I 1 I
PCB 126 130 0.077 0.13 1.7 0.28 4.2 0.43
PCB 77 710 0.014 0.0022 0.15 0.0013 0.064 1.2
PCB 105 4300 0.0023 0 0 0.0033 0.29 0
PCB 156 7100 0.0014 0.000081 0.057 0.039 0.063 0.02
Published binding affinities were normalized to that for TCDD (Column 3). Relative
potencies ofCYPIA induction measured here (Column 4) were then divided by
nonnalized binding affinities to detennine relative efficacies (RE, Column 5). For
comparison, similar calculations were performed from published induction EC50s
(Columns 6 and 7).
a: Binding affinities from (Bandiera et al. 1982)
b: Calculated from EC50s for induction ofCYPIA from (Tillitt et al. 1991)
c: Calculated from EC50s for induction of CYPIA from (Sawyer et al. 1982)
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